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Summary 
 
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are 
common partners with common problems.  Both are chronic systemic disorders 
incurring significant morbidity and mortality.  Although around one third of patients 
with HF have concurrent COPD,
1 remarkably few reports have addressed this often 
ignored combination.  The systematic review presented within this thesis defines the 
diagnostic challenges, prevalence and prognostic implications of HF with coexistent 
COPD.  I then critically appraise the twin controversies of β-blockade in COPD and 
β-agonists in HF.  The two are inextricably linked, each therapy exerting the reverse 
pharmacologic activity of the other.  The evidence for symptomatic or prognostic 
benefit  from either therapy is limited, and in the case of β-agonists adverse 
consequences appear more likely. 
A  Cochrane  meta-analysis concluded that long term cardioselective β-
blockade is safe and well tolerated in patients with moderate to severe or reversible 
COPD.
2  Although often cited,
3 these conclusions are simply not true.  Of the 20 
randomised controlled trials included in the meta-analysis, 11 involved single doses 
and only one lasted longer than a month.  The 9 ‘long term’ studies (defined as more 
than a single treatment dose) involved 147 young, predominantly male patients with 
moderate airways obstruction (mean forced expiratory volume in 1 second (FEV1) 
1.8 litres).  The effect on health status has never been assessed in any cohort with 
COPD.  The long term impact of β-blockade on pulmonary function, symptoms and 
quality of life is therefore largely unknown.  Most importantly, no study has included 
patients with HF.   20 
I randomised 27 patients with HF and coexistent moderate or severe COPD to 
receive bisoprolol or placebo, titrated to maximum tolerated dose over 4 months.  
Patients were elderly and predominantly male.  Cardiovascular comorbidity, smoking 
history and pulmonary function were similar in each group (mean FEV1 1.37L vs 
1.26L).  There were several key findings.  A reduction in FEV1 occurred after 4 
months following treatment with bisoprolol compared with placebo (–70 ml vs +120 
ml, p=0.01).  Reversibility following inhaled β2-agonist and static lung volumes were 
not impaired by bisoprolol.  All measures of health status exhibited a consistent non-
significant improvement, including the Short Form 36 physical and mental 
component scores, Minnesota Living with Heart Failure Questionnaire, and Chronic 
Respiratory Questionnaire.  The mean number of COPD exacerbations was similar in 
the bisoprolol and placebo groups.  Although recruitment was limited, the results 
pose crucial questions and provide direction for larger randomised controlled trials. 
I analysed cross-sectional data from 61 primary care practices (377,439 
patients) participating in the Scottish Continuous Morbidity Recording scheme.  The 
prevalence of COPD in patients with HF increased year on year from 19.8% in 1999 
to 23.8% in 2004.  These changes may previously have been attributed to an ageing 
population or increasing age of presentation.  However, the trend remained 
significant after age standardisation.  A clear socioeconomic gradient was observed, 
with prevalence greatest in the most deprived.  Consultation rates for HF or COPD in 
those with both conditions were greater than disease specific contact rates in patients 
with either condition alone.  Cardiovascular comorbidity was similar in HF patients 
with and without COPD, despite differences in smoking history (respectively 76% vs 
47%, p<0.001).  This is concerning and suggests that common cardiovascular   21 
conditions are being under diagnosed (and likely under treated) in patients with HF 
and COPD. 
Although overall β-blocker prescribing increased over time, the adjusted odds 
of β-blocker prescription in patients with COPD was low (odds ratio 0.30 [95% CI 
0.28–0.32], p<0.001).  Whether the gap between patients with and without COPD is 
improving  was previously unknown.  Despite the overall improvement  in beta-
blocker prescribing, the relative difference in prescribing between those with and 
without COPD remained unchanged.  By 2004, only 18% of individuals with HF and 
COPD were prescribed β-blockers. 
COPD  is  consistently an independent predictor of death and HF 
hospitalisation in patients with HF.  However, the causes of increased mortality were 
unclear.  I examined the relationship between COPD and cardiovascular outcomes in 
patients with myocardial infarction (MI) complicated by heart failure, left ventricular 
systolic dysfunction (LVSD), or both enrolled in the Valsartan in Acute Myocardial 
Infarction  (VALIANT) trial.  COPD was an independent predictor of mortality, 
largely due to increased non-cardiovascular (HR 1.86 [1.43–2.42]) and sudden death 
(HR 1.26 [1.03–1.53]).  However, after multivariate adjustment COPD was not an 
independent predictor of atherosclerotic events (MI or stroke: HR 0.98 [0.77–1.23]).  
This is an important finding, as atherosclerotic consequences of chronic systemic 
inflammation in COPD have been postulated.  These appear of limited clinical 
significance, at least during intermediate follow-up. 
  Part of the adverse risk associated with COPD may be attributable to 
bronchodilators.  The prognosis of patients with HF prescribed bronchodilators is 
however ill defined.  I examined the prognostic implications of bronchodilator use in   22 
patients with HF enrolled in the Candesartan in Heart failure Assessment of 
Reduction in Mortality and morbidity (CHARM) programme.  The diversity and 
magnitude of adverse outcomes associated with bronchodilator therapy was 
surprising.  Bronchodilator use was associated with increased all cause mortality (HR 
1.26 [1.09–1.45]), cardiovascular death (HR 1.21 [1.03-1.42]),  death due to HF 
progression (HR 1.40 [1.07-1.82]) and HF hospitalisation (HR 1.49 [1.29-1.72]).  
Although association is not causation, it is possible that bronchodilators compound 
maladaptive remodeling and further depress myocardial function. 
Finally, β-blockers were independently associated with better survival in both 
VALIANT and CHARM.  No significant interaction was observed between either 
COPD or bronchodilators and β-blockade with respect to mortality.  Furthermore, β-
blocker use was not associated adversely with any pre-specified outcome in patients 
with COPD  or those prescribed bronchodilators, including non-cardiovascular 
mortality.  Although recruitment bias and the absence of spirometry limit inference 
to patients with severe or reversible airflow obstruction, the results should encourage 
β-blockade in patients with COPD. 
In summary, the studies presented in this thesis extend our understanding of 
HF with concurrent COPD.  Only large randomised controlled trials will solve the 
quandary of β-blockers and β-agonists.  Justification for these trials evolves from 
observational data and smaller prospective studies such as my own.  In the meantime, 
I  hope the evidence presented will stimulate physicians to re-evaluate the 
management of patients with HF and COPD.   23 
 
Chapter 1 
 
Introduction 
 
   24 
1.1  The questions that interest physicians 
 
Heart failure and chronic obstructive pulmonary disease are global epidemics, 
each affecting in excess of ten million patients.
4,5  Both conditions incur significant 
morbidity and mortality, and present major challenges to healthcare providers.
5  
Around one third of patients with HF have concurrent COPD.
1  Few reports have 
addressed this often ignored combination, and fewer still the simple questions of 
interest to physicians.  What are the pitfalls of diagnosing HF in patients with COPD, 
and vice-versa?  How frequent a comorbidity is COPD?  What are the clinical 
consequences of both conditions co-existing?   
The cornerstones of therapy are β-blockers and β-agonists respectively.  The 
short and long term effects of β-blockade are diametrically opposed: acute negative 
inotropy precedes improved left ventricular  systolic  function.    β-blockers confer 
protection from chronically elevated catecholamines and lead to up-regulation of β-
receptors.  Reverse remodeling follows.  β-agonists exert the reverse pharmacologic 
effects of β-blockers.  Exposure induces down-regulation and desensitization of β-
receptors.
6  However, whether acute positive inotropy gives way to longer term left 
ventricular systolic dysfunction is uncertain.  Further questions arise.  Does ‘severe’ 
or  ‘reversible’  airflow  obstruction  preclude  β1-selective blockade?  Is 
bronchoconstriction lessened by using a β-blocker with α1-antagonist activity?  Do β-
blockers improve the prognosis of patients with both conditions?  How safe are oral 
and inhaled β-agonists in patients with HF? 
This  introduction  examines  the diagnostic problems posed by the two 
conditions, before reviewing the prevalence and prognostic implications of COPD in   25 
patients with HF.  Finally, the controversial issues of β-blockers and β-agonists in 
patients with HF and COPD are critically appraised. 
 
1.2  Problems diagnosing HF in patients with COPD 
 
1.2.1  Clinical features 
HF is a complex syndrome without a simple objective definition.  Diagnosis 
requires both typical clinical features and objective evidence of cardiac dysfunction.
4  
Pulmonary disease may produce or obscure every symptom and sign defined by 
Framingham criteria.
7  Exertional breathlessness, nocturnal cough and paroxysmal 
nocturnal dyspnoea are common to both conditions.  No qualitative features of 
dyspnoea are unique to HF.
8  Stigmata of right ventricular failure may also be 
misleading, including jugular venous distention, ankle oedema and hepatomegaly.  
Lung hyperinflation with hepatic displacement mimics the latter, while hindering 
palpation of cardiomegaly and auscultation of rales or a third heart sound.  The 
difficulty in differentiating between HF and COPD symptoms and signs is illustrated 
in a single cohort study comparing the Framingham and Cardiovascular Health Study 
criteria for HF.  The prevalence of concurrent COPD was twice as great in patients 
fulfilling only Framingham as opposed to only Cardiovascular Health Study criteria 
(13% vs 6%).
9 
 
1.2.2  Radiology 
Radiological evidence of HF is likewise influenced by the presence of 
COPD.
10,11  Chest hyperinflation spuriously reduces the cardiothoracic ratio.    26 
Pulmonary vascular remodeling and radiolucent lung fields mask the typical alveolar 
shadowing of pulmonary oedema.
11,12  Asymmetric, regional, and reticular patterns 
of pulmonary oedema are commonplace in those with concurrent COPD.
10,11,13  
Emphysematous vascular bed loss causes upper lobe venous diversion, mimicking 
HF.
13  Isolated right heart failure is also said to cause pleural effusions through 
impaired pleural lymphatic drainage secondary to elevated systemic venous 
pressure.
14  However, in clinical practice pleural effusions are rarely due to right 
heart failure alone.
15,16 
 
1.2.3  Echocardiography 
Transthoracic echocardiography may be impeded by poor acoustic windows 
caused by the pathological changes associated with COPD.
17  Inadequate 
visualisation may relate to air trapping.  In a recent primary care study 
echocardiographic images were unsatisfactory in 10.4% of patients with COPD.
18  
This proportion increases to 35% in patients with severe COPD,
19 and 50% in those 
with very severe airflow obstruction.
20  Although studies have assessed contrast 
echocardiography in patients with poor endocardial definition, those with pulmonary 
disease were often excluded.
21,22  In lung transplant candidates, Doppler estimation 
of pulmonary artery pressure was less frequently possible in patients with a residual 
volume exceeding 150% predicted (40% versus 56%, p=0.007).
23  Studies would be 
welcome comparing the accuracy of left ventricular ejection fraction (LVEF) 
measured by contrast echocardiography against cardiac magnetic resonance imaging 
(CMR) in patients with COPD. 
   27 
1.2.4  Cardiac magnetic resonance imaging 
  CMR is the accepted reference standard for  measuring LV volumes and 
ejection fraction.
24  Results are accurate, reproducible and extensively validated.
24,25  
CMR allows precise quantification of right ventricular  volumes, function and 
transvalvular flow, while avoiding ionising radiation.
26  Tissue characterisation 
additionally identifies myocardial fibrosis which may predict risk of arrhythmias.
27  
Professional imaging societies recommend CMR to evaluate LV function in heart 
failure patients with technically limited echocardiogram images.
28 
 
1.2.5  Natriuretic peptides 
Both B-type natriuretic peptide (BNP) and N-terminal pro-BNP are useful for 
excluding HF in subjects with acute dyspnoea.
29-31  The diagnostic accuracy of BNP 
in patients with concurrent COPD is less certain.  Subgroup analysis of 417 patients 
with COPD or asthma in the Breathing Not Properly study reported a mean BNP for 
those with and without HF of 587 ± 426 pg/ml and 109 ± 221 pg/ml respectively 
(p<0.0001).
32  In a Californian study of 321 patients presenting with acute dyspnoea, 
mean BNP was significantly higher in patients with HF compared to those with 
COPD  (759 ± 798 pg/ml vs 54 ± 71 pg/ml, p<0.001).
33  Both studies have two major 
limitations.  Firstly, the diagnosis of HF was adjudicated retrospectively by two 
cardiologists based on clinical criteria and subsequent investigations; in the 
Breathing Not Properly subgroup only 29% of patients had echocardiography.
32  
Secondly, right heart failure from cor pulmonale was possibly misdiagnosed or even 
specifically classified as HF.
33  This falsely magnifies the apparent accuracy of BNP   28 
while neglecting the question of interest to clinicians, for whom diagnosing HF due 
to left ventricular dysfunction is paramount in guiding future therapy. 
Plasma BNP is elevated in both primary pulmonary hypertension and right 
heart failure secondary to chronic respiratory disease.
34-37  Levels of BNP correlate 
with pulmonary artery pressure and independently predict mortality.
34-37  However, 
few studies have assessed BNP specifically in patients with COPD.
36,38  Only one has 
examined the ability to identify HF in these patients.
39  Four natriuretic peptide 
assays produced comparable results in 200 stable elderly patients with a clinical 
diagnosis of COPD.  Each test excluded HF with reasonable accuracy (all negative 
predictive values above 0.85).  However, the positive predictive value and overall 
diagnostic accuracy was lower than observed in patients with acute dyspnoea.
30,31  
The explanation is twofold.  Stable patients exhibit lower BNP levels than those with 
acute volume overload and raised intracardiac pressures.  Secondly, BNP levels are 
increased in patients with COPD.
36,39  Both factors lessen the diagnostic accuracy in 
these patients.  The BNP Consensus Panel guidelines state that cor pulmonale is 
associated with an intermediate elevation of BNP, typically ranging from 100 to 500 
pg/ml.
29  Levels below 100 pg/ml and above 500 pg/ml have high negative and 
positive predictive values respectively for HF.  Between these thresholds a Bayesian 
approach is warranted, using BNP to corroborate the clinical evaluation. 
 
1.2.6  Heart failure with preserved ejection fraction 
  Defining and identifying HF with preserved ejection fraction (HF-PEF) is 
controversial and problematic in any population.  These difficulties are magnified in 
patients with COPD.  BNP levels are moderately elevated in both HF-PEF and cor   29 
pulmonale.
40-42  One small study compared 17 patients with COPD against 9 patients 
with HF-PEF, defined by clinical and radiological pulmonary oedema responding to 
treatment, sinus rhythm and preserved LV ejection fraction.  BNP levels were 
significantly higher in those with HF-PEF (224 vs 14 pg/ml, p<0.0001).
38  However, 
BNP was below 100 pg/ml in 4 of the 9 patients with HF-PEF, while few patients 
with COPD had significant pulmonary hypertension (mean systolic pulmonary artery 
pressure was 36 mmHg).  More robust studies are required to determine the 
diagnostic accuracy of BNP for HF in patients with COPD and varying levels of 
pulmonary hypertension. 
 
1.3  Problems diagnosing COPD in patients with HF 
 
1.3.1  Definition of obstruction and restriction 
Patients with HF exhibit both obstructive and restrictive ventilatory defects, 
which may compound or conceal the characteristic airflow limitation of COPD.   
Spirometry defines three standard indices: forced expiratory volume in one second 
(FEV1); forced vital capacity (FVC), the total volume delivered during forced 
expiration from a maximum inspiration; FEV1/FVC ratio, the proportion of the total 
volume expired in the first second.
43  Obstruction is defined by a reduced FEV1/FVC 
ratio below 70% in the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) and American Thoracic Society / European Respiratory Society 
guidelines.
5,44  Restriction is characterised by reduced lung volumes.  Both FEV1 and 
FVC are decreased with a normal or raised FEV1/FVC ratio.  Since this pattern also   30 
occurs in severe obstruction with air trapping, the diagnosis of restriction 
additionally requires detection of reduced total lung capacity by plethysmography.
43 
 
1.3.2  Obstructive pulmonary function tests 
Airflow obstruction is common in patients with decompensated HF,
45,46 
contrasting with restrictive defects when HF is stable.  Interstitial and alveolar 
oedema cause compression and obstruction of the airways, compounded by bronchial 
hyperresponsiveness.
47,48  Both misdiagnosis and overestimation of COPD severity 
may result.  With diuresis, mean FEV1 improves by up to 35% and often returns to 
normal.
45-47  Pulmonary function tests are therefore most informative when patients 
are clinically euvolaemic. 
  A mild obstructive ventilatory pattern may be observed even when not fluid 
overloaded.  A comparison dichotomising patients around a peak oxygen 
consumption of 14 ml/min/kg noted a lower FEV1/FVC ratio in severe HF (70% vs 
75%, p=0.008).
49  The ratio also declines with age in the general population, reaching 
70% in those over 75 years of age.
50  COPD may thus be over diagnosed in elderly 
patients with HF.
51 
 
1.3.3  Restrictive pulmonary function tests 
Restrictive ventilatory defects predominate in patients with stable HF.
52  
FEV1 and FVC were normal or proportionately reduced in a multicentre study of 130 
patients.
53  Contributory factors include interstitial fibrosis,
54  respiratory muscle 
weakness,
49,55,56 cardiomegaly and pulmonary congestion.
57  FEV1 and FVC may 
also be proportionately reduced with a normal ratio in patients with severe COPD   31 
and gas trapping.  Usually in such cases increased total lung capacity and residual 
volume help diagnose obstruction.
43  However, restricted lung volumes mask 
hyperinflation and thus the diagnosis of COPD in patients with concurrent HF.
10 
 
1.3.4  Performing spirometry 
  Objective evidence of airflow obstruction is mandatory for diagnosing 
COPD.
5  Approximately one third of patients labelled with COPD do not fulfil the 
GOLD criteria (Table 1.1).
39,58  Despite this, many physicians fail to confirm or 
refute the clinical diagnosis using spirometry.  A recent US study revealed significant 
disparities in confirmatory testing practices.
58  Among 219 patients discharged from 
a tertiary centre with both HF and COPD, 82% received echocardiography as 
opposed to 36% pulmonary function testing.  This lack of adherence to guidelines 
must be addressed, as both inhaled therapy and β-blockade are dictated by the degree 
of airflow obstruction. 
 
Table 1.1  GOLD classification of COPD severity based on post-bronchodilator 
FEV1 
 
Stage  FEV1/FVC  Post-bronchodilator FEV1 predicted 
I:   Mild  < 0.70  FEV1 ≥ 80% 
II:  Moderate  < 0.70  50% ≤ FEV1 < 80% 
III: Severe  < 0.70  30% ≤ FEV1 < 50% 
IV: Very Severe  < 0.70  FEV1 < 30% or 
FEV1 < 50% plus chronic respiratory failure 
 
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; Respiratory failure: 
arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without arterial partial 
pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level. 
 
1.4  Epidemiology of HF and COPD   32 
 
1.4.1  Prevalence of COPD in patients with HF 
Estimates of COPD prevalence vary according to the population studied, 
diagnostic criteria applied, measurement tools and surveillance systems.
59  
Geographical variations largely relate to differences in population age structure and 
risk factor exposure, most notably smoking.
5,59  The prevalence of COPD was greater 
in patients with HF than the general population in the Cardiovascular Health Study 
(20% vs 13%, p=0.001).
60  This may reflect both clustering of aetiological factors 
and misdiagnosis.   No study has systematically examined pulmonary function in 
patients with stable HF.
61  How many have severe, reversible, or misdiagnosed 
airflow obstruction is unknown. 
  The reported prevalence of COPD ranges from 11% to 52% in North 
American patients with HF, and from 9% to 41% in European cohorts (Table 1.2).  
Half the studies originate in the United States.  The prevalence of COPD is greater in 
more recent studies (Table 1.2).  Four studies examining trends in HF epidemiology 
confirm the increasing prevalence.
62-65  This may represent greater awareness of 
COPD, an ageing population or increasing age at onset of HF.  A consistent non-
linear relationship is apparent between age and frequency of concurrent COPD in 
patients with HF.
66-69  The prevalence increases until around 75 years of age, and 
declines thereafter.  Possibly the presence of COPD reduces survival beyond this 
age.  Alternatively, less intensive investigations in the elderly may under-diagnose 
comorbidity. 
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Table 1.2  Prevalence of COPD in patients with HF 
   
Reference  Prevalence 
COPD 
(%) 
Country  Data 
Collection 
n  Population  Data Source 
Rich.
70  11  U.S.  1983-
1986 
410  HF 
hospitalisation 
Washington University 
Hospital 
Bangdiwala.
71  15  U.S. Canada  1988-
1989 
6273  HF 
hospitalisation 
SOLVD Registry 
Auerbach.
72  19  U.S.  1989-
1994 
1298  HF 
hospitalisation 
SUPPORT Study 
Barker.
62  18  U.S.  1990-
1994 
393  HF 
hospitalisation 
Kaiser Permanente Centre 
Health Research 
Wang.
73  12  U.S.  1989-
1995 
231  HF 
hospitalisation 
Philadelphia Geriatric Centre 
Mathew.
74  19  U.S.  1992-
1995 
301  Mixed  Cook County Hospital 
Harjai.
75  18  U.S.  1994-
1995 
434  HF 
hospitalisation 
Ochsner Foundation 
Hospital 
Kitzman.
60  20  U.S.  1994-
1995 
425  Outpatient  Cardiovascular Health Study 
Vaccarino.
76  27  U.S.  1994-
1995 
2445  HF 
hospitalisation 
Connecticut Peer Review 
Organisation 
Gambassi.
67  19  U.S.  1992-
1996 
86094  Outpatient  SAGE Database 
Polanczyk.
65  24  U.S.  1994-
1996 
1896  HF 
hospitalisation 
Massachusetts General 
Hospital 
Baker.
64  25  U.S.  1991-
1997 
23505  HF 
hospitalisation 
Cleveland Health Quality 
Choice Program 
Ansari.
77  26  U.S.  1996-
1997 
403  Outpatient  Kaiser Permanente Medical 
Care Program 
Braunstein.
78 
 
26  U.S.  1999  122630  Outpatient  Medicare 
Kosiborod.
63  33  U.S.  1992-
1999 
3957520  HF 
hospitalisation 
Medicare 
Havranek.
68  33  U.S.  1998-
1999 
34587  HF 
hospitalisation 
National Heart Failure 
Project 
Rathore.
79  33  U.S.  1998-
1999 
30996  HF 
hospitalisation 
National Heart Failure 
Project 
Kamalesh.
80  52  U.S.  1999-
2000 
495  Outpatient  Indianapolis Veterans 
Affairs Medical Centre 
Goldberg.
81  34  U.S.  2000  2445  HF 
hospitalisation 
Worcester Metropolitan 
Hospitals 
Laramee.
82  22  U.S.  1999-
2001 
287  HF 
hospitalisation 
Fletcher Allen Medical 
Centre, Vermont 
Rector.
83  24  U.S.  1999-
2003 
769  HF 
hospitalisation 
Minneapolis Veterans 
Affairs Medical Centre 
Ezekowitz.
84  32  Canada  1993-
2001 
12065  HF 
hospitalisation 
Alberta Health Care 
Insurance Registry 
Lee.
85  21  Canada  1999-
2001 
2624  HF 
hospitalisation 
EFFECT Study 
Nieminen.
86  19  Europe  2004-
2005 
3580  HF 
hospitalisation 
EuroHeart Failure Survey II 
Brown.
87  12  Scotland  1995  27477  HF 
hospitalisation 
Scottish Morbidity Record 
Murphy.
88  15  Scotland  1999-
2000 
973  Community   Primary Care Records 
Newton.
89  9  England  1998-
2001 
528  HF 
hospitalisation 
Leicestershire Health 
Authority 
van Jaarsveld.
90  9  Netherlands  1993-
1998 
293  Community  Groningen Longitudinal 
Aging Study 
Bouvy.
91  19  Netherlands  -  152  Mixed  Trial of Pharmacist   34 
Intervention 
van der Wel.
69  25  Netherlands  1999-
2003 
269  Community  Nijmegen Practice-Based 
Research Network 
Taubert.
92  11  Germany  1997-
1998 
266  HF 
hospitalisation 
Ludwigshafen Heart Failure 
Registry 
Jost.
93  20  Germany  1995-
2004 
675  Mixed  Ludwigshafen Heart Failure 
Registry 
Martinez-
Selles.
94 
30  Spain  1996  1065  HF 
hospitalisation 
Heart failure Observation of 
Local Admissions 
Di Lenarda.
95   41  Italy  2000  2127  HF 
hospitalisation 
TEMISTOCLE Study 
Senni.
96  17  Italy  2003  807  Mixed  Italian College of General 
Practitioners 
Macchia.
97  24  Italy  2003  1020  HF 
hospitalisation 
Northern Italian Local 
Health Authorities 
Tavazzi.
98  30  Italy  2004  2807  HF 
hospitalisation 
Italian survey on Acute 
Heart Failure 
Siirila-Waris.
99  13  Finland  2004  620  HF 
hospitalisation 
Finnish Acute Heart Failure 
Study 
Gustafsson.
100  22  Denmark  1993-
1996 
5491  HF 
hospitalisation 
DIAMOND-CHF Registry 
Galatius.
101  8  Denmark  1999-
2001 
283  Community  Frederiksberg University 
Hospital 
Rohde.
102  21  Brazil  2000-
2004 
779  HF 
hospitalisation 
Hospital de Clinicas de Porto 
Alegre 
Wright.
103  19  New 
Zealand 
1996-
1997 
197  HF 
hospitalisation 
Auckland Heart Failure 
Management Program 
Chong.
104  12  Malaysia  -  97  HF 
hospitalisation 
Kuala Lumpur General 
Hospital 
 
COPD, chronic obstructive pulmonary disease; HF, heart failure. 
 
COPD is more common in male compared with female HF 
patients,
69,76,94,97,100,105  and in urban compared with rural areas.
92  The prevalence is 
notably lower (by 6–11%) in those managed by cardiologists as opposed to general 
physicians.
72,77,106,107  Non-cardiac comorbidity is a well recognised barrier to 
specialty referral.
108  Alternatively, cardiologists perhaps fail to recognise airways 
disease.  In patients with preserved ejection fraction the reported prevalence is 
generally higher (Table 1.3).
109-119  A degree of misdiagnosis undoubtedly exists.
120  
Finally, remarkably few clinical trials report the presence of COPD (Table 1.4).  In 
these, the lower prevalence of 7% to 13% in stable outpatients suggests significant 
recruitment bias. 
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Table 1.3  Prevalence of COPD in patients with HF and reduced or preserved left 
ventricular ejection fraction 
 
Reference  Ejection 
Fraction 
Prevalence 
COPD 
(%) 
P value 
Preserved 
vs Reduced 
n  Population  Country 
Masoudi.
109  Preserved  34  p<0.001  6754  HF 
hospitalisation 
U.S. 
Reduced  31  12956 
Ansari.
110  Preserved  30  p=0.075  147  Community  U.S. 
Reduced  21  191 
Dauterman.
111  Preserved  33  p=0.32  430  HF 
hospitalisation 
U.S. 
Reduced  29  352 
Gustafsson.
112   Preserved  26  p<0.001  2218  HF 
hospitalisation 
Denmark 
Reduced  19  3022 
Bursi.
113  Preserved  38  p=0.06  308  Community  U.S. 
Reduced  30  248 
Bhatia.
114  Preserved  18  p=0.002  880  HF 
hospitalisation 
Canada 
Reduced  13  1570 
McDermott.
115  Preserved  21  p=0.80  92  HF 
hospitalisation 
U.S. 
Reduced  19  206 
Liao.
116  Preserved  21  p=0.02  186  Community  U.S. 
Reduced  11  166 
Ilksoy.
117  Preserved  41  p=0.72  26  HF 
hospitalisation 
U.S. 
Reduced  36  63 
Kjaergaard.
118 
 
Preserved  27  p=0.15  96  HF 
hospitalisation 
Denmark 
Reduced  20  276 
Agoston.
119  Preserved  38  -  121  HF 
hospitalisation 
U.S. 
Reduced  28  327 
Ahmed.
121  Preserved  24  p=1  238  HF 
hospitalisation 
U.S. 
Reduced  24  200 
Tribouilloy.
122  Preserved  20  p=0.91  368  HF 
hospitalisation 
France 
Reduced  21  294 
Diller.
123  Preserved  44  p=NS  54  Community  U.S. 
Reduced  48  82 
Berry.
124   Preserved  7  p=0.16  130  HF 
hospitalisation 
Scotland 
Reduced  11  315 
Varadarajan.
125  
(VA Hospital) 
Preserved  4  p<0.0001  963  HF 
hospitalisation 
U.S. 
Reduced  9  1295 
 
 
Table 1.4  Prevalence of COPD in HF trials 
 
 
Reference  n  Prevalence 
COPD (%) 
LVEF 
(%) 
Trial  Population 
Parker.
126  6797  7  ≤ 35  SOLVD  Community 
Sharma.
127   3044  9  ≤ 40  ELITE II  Community 
Staszewsky. 
128  5010  13  < 40  Val-HeFT  Community 
Massie.
129  1587  8  ≤ 35  WATCH  Community 
Grancelli.
130  1518  9  Any  DIAL  Community 
NETWORK Investigators.
131  1532  7  -  NETWORK  Mixed 
Gheorghiade.
132  319  10  ≤ 40  ACTIV-CHF  HF hospitalisation 
Cuffe.
133  949  23  < 40  OPTIME-CHF  HF hospitalisation 
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Measurement of ejection fraction inherently changes the estimated 
prevalence.  In the Olmsted County study,
134  23% of patients with HF had 
‘restrictive/chronic obstructive pulmonary disease’.  However, the prevalence was 
lower (15%) among those undergoing echocardiographic assessment.  An incorrect 
diagnosis of COPD may be removed once LVSD is confirmed.  Additionally, fewer 
patients with COPD are referred for echocardiography.  Across 417 Italian centres, 
COPD independently predicted failure to assess LV function during hospitalisation 
(OR 1.25 [95% CI 1.02-1.53]).
95 
 
1.4.2  Prevalence of HF in patients with COPD 
Cigarette smoking, the commonest cause of COPD, is associated with a 50% 
increased risk of HF.
112,135,136  Two studies have diagnosed HF using standardised 
criteria in patients with COPD.
32,137  Both examined the prevalence of unrecognised 
HF, excluding patients with an existing diagnosis.  The prevalence of HF was 20.9% 
in a highly selected cohort with COPD or asthma presenting to the emergency 
department with acute dyspnoea.
32  However, the diagnosis was adjudicated 
retrospectively by two cardiologists, with echocardiography performed in only 29% 
of participants.  The prevalence of unrecognised HF was the same (20.5%) in a 
comprehensive community study of 405 elderly patients with stable COPD.
137  Heart 
failure was diagnosed by an expert panel following chest radiography, 
electrocardiography, echocardiography and pulmonary function tests.  Not one 
patient had echocardiographic evidence of isolated right heart failure.  This 
corroborates reports estimating the prevalence of cor pulmonale in COPD to be 
approximately 0.2%.
138  There is a simple clinical message.  Patients with COPD and   37 
suspected heart failure must be considered to have left ventricular dysfunction until 
proven otherwise. 
 
1.4.3  Prevalence of LVSD in patients with COPD 
A recent systematic review identified 18 reports quantifying LVEF among 
COPD patients, most with small numbers of participants (n=10 to 120).
61  The 
prevalence of LVSD varied considerably, ranging from 10% to 46% in unselected 
patients with stable COPD.  Studies excluding patients with coronary disease 
observed a lower prevalence of 0% to 32%. 
 
1.4.4  Relationship between COPD and HF 
  COPD is characterised by low grade systemic inflammation, which may 
contribute to the progression of atherosclerosis and adverse cardiovascular events.
139-
141  Myocardial dysfunction may ensue.  In the NHANES III survey moderate to 
severe airflow obstruction was associated with elevated inflammatory markers and 
electrocardiographic ischaemia.
139  Reduced FEV1  independently predicts 
cardiovascular mortality in population studies after adjusting for age, cigarette 
smoking, hypertension, cholesterol, and obesity.
142  A meta-analysis demonstrated an 
increased relative risk of 1.75 (1.54-2.01) when comparing worst and best FEV1 
quintiles.
143  However, the multivariable models were often limited, notably lacking 
adjustment for co-existing diabetes and cardiovascular disease. 
Inflammation is itself implicated in the pathogenesis of HF.  Incidence of HF 
was greater in Framingham subjects with elevated C-reactive protein (CRP) and 
cytokine levels, independent of established risk factors (hazard ratio 4.07 [95% CI   38 
1.34-12.37], p=0.01).
144  However, two population studies found no evidence of a 
relationship between COPD and incidence of HF.  The Cardiovascular Health Study 
prospectively examined 5888 elderly subjects over a mean of 5.5 years.  Elevated 
CRP and reduced FEV1, but not a history of COPD, were significant factors during 
stepwise selection of variables in this study.
145  Likewise, COPD was not an 
independent predictor of LVSD in the Copenhagen study.
146  Both studies relied 
upon self reported medical history.  Such methods are particularly limited when 
examining conditions with diagnostic difficulties and overlapping symptoms. 
 
1.4.5  Prognostic implications of COPD in patients with HF 
Few studies focused on the prognosis of patients with HF and concomitant 
COPD.
97,128  However, COPD was consistently an independent predictor of death 
and HF hospitalisation when reported in multivariable models (Table 1.5).  In many 
models the prognostic significance approached or exceeded that of traditional factors 
including male gender, diabetes, hypertension, NYHA class, and anaemia.  As in all 
multivariable analyses, the risk relates in part to the number and type of variables 
adjusted for in the model.  Only one study has explored the causes of increased 
mortality.
128  The outcomes of patients with COPD enrolled in the Valsartan Heart 
Failure Trial (Val-HeFT) trial were examined using multivariate models including 
demographic, clinical, biohumoral and treatment variables.  COPD strongly 
predicted non-cardiovascular mortality (HR 2.50 [1.58-3.96], p<0.0001) and 
hospitalisations (HR 1.71 [1.43-2.06], p<0.0001), but not cardiovascular death or 
hospitalisations.  The relationship between COPD and ischaemic or arrhythmic 
events has never been reported in patients with HF.   39 
Table 1.5  Prognostic implications of COPD in patients with HF 
 
Reference  n  COPD 
(%) 
LVEF 
(%) 
Outcome  Follow Up  Univariable 
Analysis 
(±95% CI) 
Multivariable 
Analysis 
(±95% CI) 
Gustafsson. 
112  
5491  22  Any  Death  1 year  -  RR 1.36 (1.25-1.47) 
Sharma. 
127 
3044  9  ≤ 40  Death  -  RR 1.49 (1.15-
1.95) p=0.0049 
RR 1.34 (1.02-1.75) 
p=0.0354 
Lee. 
85 
2624  21  Any  Death  1 year  OR 1.30 (1.07-
1.58) p=0.009 
OR 1.41 (1.13-1.75) 
p=0.003 
Goldberg. 
81 
2445  34  Any  Death  1 year  -  OR 1.39 (1.15-1.69) 
Braunstein. 
78 
122630 26  Any  Death  1 year  RR 1.31 (1.27-
1.34) 
RR 1.12 (1.09-1.16) 
Alexander. 
147 
90316  -  Any  Death  1 year  -  RR 1.19 (1.15-1.22) 
Jong. 
148 
38702  -  Any  Death  1 year  -  OR 1.13 (1.07-1.19) 
p<0.001 
Krumholz. 
149 
222424 -  Any  Death  30 days  -  OR 1.15 (1.12-1.18) 
Martinez- 
Selles.
94 
1065  30  Any  Death  median 
19 months 
-  HR 1.6 (1.2-2.0) 
p=0.001 
Tribouilloy. 
122 
294  21  < 50  Death  5 year  -  HR 1.49 (1.04-1.95) 
p=0.05 
Tribouilloy. 
122 
368  20  ≥ 50  Death  5 year  -  HR 1.61 (1.13-2.28) 
p=0.008 
Senni. 
96 
292  15  Any  Death  1 year  -  OR 1.41 (0.99-2.35) 
p=0.005 
Agoston. 
119 
448  31  Any  Death  -  -  HR 1.45 (1.10-1.92) 
p=0.01 
Kjaergaard. 
118 
388  22  Any  Death  -  -  HR 2.67 (1.98-3.59) 
p<0.0001 
Kamalesh. 
80 
495  52  < 50  Death  -  OR 1.59 (1.15-
2.19) p=0.0048 
OR 1.34 (0.95-1.90) 
p=0.095 
Newton. 
89 
528  9  Any  Death  mean 
1257 days 
HR 1.49 (1.00-
2.20) p=0.049 
- 
p=NS 
Siirila 
Waris.
99 
620  13  Any  Death  1 year  HR 1.2 (0.80-1.87) 
p=0.4 
- 
p=NS 
Macchia. 
97 
1020  24  Any  Death  mean 
287 days 
HR 1.46 (1.12-
1.92) p=0.005 
HR 1.42 (1.09-1.86) 
p=0.010 
Macchia. 
97  
1020  24  Any  HF hospitalisation, 
MI, or stroke 
mean 
244 days 
-  HR 1.26 (1.01-1.58) 
p=0.04 
Ansari. 
77 
403  26  Any  Death or 
CV hospitalisation 
mean 
22 months 
HR 1.32 (0.9-1.9) 
p=0.14 
HR 1.39 (0.9-2.1) 
p=0.11 
Berry. 
124 
315  11  ≤ 40  Death or HF 
hospitalisation 
-  -  HF 1.61 (0.98-2.64) 
p=0.061 
Parker. 
126 
6797  7  ≤ 35  Death or 
HF hospitalisation 
-  -  OR 1.43 (1.16-1.76) 
p=0.0008 
Braunstein. 
78 
122630 26  Any  HF hospitalisation  1 year  RR 1.49 (1.45-
1.53) 
RR 1.40 (1.36-1.44) 
Harjai. 
75 
434  18  Any  HF hospitalisation  30 days  -  OR 2.2   (1.1-4.5) 
 
 
 
CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV, 
cardiovascular; LVEF, left ventricular ejection fraction (‘Any’ denotes inclusion of 
all patients with heart failure); HF, heart failure; HR; hazard ratio; MI, myocardial 
infarction; OR, odds ratio; RR, risk ratio. 
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The increased risk of HF hospitalisation is unsurprising.  Respiratory 
infections are  associated with decompensation in 10-16% of admissions.
86,150-154  
Concomitant COPD prolongs inpatient stay,
87,103  increases risk of 
readmission,
75,78,155 and independently predicts greater financial costs.
156  Respiratory 
disease, and in particular COPD, is a more frequently recorded comorbidity in 
winter.
157  The ACC/AHA guidelines advocate influenza and pneumococcal 
immunisation to reduce this risk.
158  Administering influenza A vaccine to elderly 
patients with HF during the 1991–1992 influenza epidemic reduced the rate of HF 
hospitalisation by 37%, and associated costs by 43%.
159 
 
1.5  β-blockers in COPD 
 
1.5.1  Guidelines regarding β-blocker utilisation in HF and COPD 
The ACC/AHA guidelines for the management of HF advocate ‘great 
caution’  when  using  β-blockers in patients with symptomatic ‘reactive airways 
disease’.
158,160  No definition of ‘reactive airways disease’ is provided.  Concerns 
stem from reports of acute bronchospasm in asthmatic patients given non-
cardioselective β-blockers.
161-163  The guidelines also state that ‘most patients’ with 
COPD  ‘remain  reasonable  candidates  for  β-blockade’.  More precise advice is 
lacking.  By contrast, the ESC guidelines clearly state that COPD ‘is not a 
contraindication’.
4  Low dose initiation and gradual up-titration is recommended.   
Furthermore, the guidance indicates that ‘mild deterioration in pulmonary function 
and symptoms should not lead to prompt discontinuation’. 
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1.5.2  How many patients with HF and COPD are prescribed β-blockers? 
Surprisingly few studies report the prevalence of β-blocker use in patients 
with HF and concomitant COPD (Table 1.6).  
 
Table 1.6  Prevalence of β-blocker use in patients with heart failure and chronic 
obstructive pulmonary disease 
 
Reference  Prevalence 
β-blockade 
(%) 
Population  n  LVEF 
(%) 
Country  Data Source 
Shah.
164  24  Community  916  Any  U.K.  UK DIN-LINK 
database 
Iversen.
165  27  HF 
hospitalisation 
182  Any  Denmark  ECHOS Study Group 
Macchia.
97  16  HF 
hospitalisation 
241  Any  Italy  Hospital discharge 
records 
Sin.
166  6  HF 
hospitalisation 
3834  Any  Canada  Alberta Statistics 
Registry 
Rusinaru.
167  6  HF 
hospitalisation 
156  Any  France  Hospital discharge 
records 
Patel.
168  80  HF 
hospitalisation 
57  ≤ 40  U.S.  Veterans Affairs 
Medical Centre 
Krum.
169  85  Heart failure 
clinic 
89  LVSD  Australia  Clinic 
Kotlyar.
170  84  Heart failure 
clinic 
31  LVSD  Australia  Clinic 
Mascarenhas.
171  86  Heart failure 
clinic 
73  LVSD  Portugal  Clinic 
Shelton.
172  81  Heart failure 
clinic 
124  ≤ 40  U.K.  Clinic 
Staszewsky.
128 
 
22  Clinical trial  628  < 40  Multinational  Val-HeFT 
 
HF, heart failure; LVEF, left ventricular ejection fraction (‘Any’ denotes inclusion of all patients with 
heart failure); LVSD, left ventricular systolic dysfunction 
 
 
Analysis from 152 UK general practices indicated that 24% of primary care 
patients with both conditions were prescribed β-blockers.
164  Italian and Danish 
studies observed comparable prescription levels on admission to hospital with 
worsening HF in 241 and 182 patients with concurrent COPD (respectively 16% and 
27%).
97,165  Similarly, 22% of patients with HF and COPD enrolled in the Valsartan 
Heart Failure Trial received β-blockers.
128  However, four specialised  HF clinics   42 
report consistently higher use of β-blockers in patients with LVSD and COPD.
169-172  
Between 81% and 86% of outpatients with COPD tolerated β-blockers.  Selection 
bias undoubtedly contributes (i.e. patients with less severe COPD are referred to 
specialist clinics).  In the Euro Heart Failure Survey ‘pulmonary disease’ was the 
most powerful independent predictor of β-blocker underutilisation (odds ratio 0.35 
[95% CI 0.30 - 0.40]).
173  An Australian analysis revealed similar underuse of β-
blockers at hospital discharge in patients with HF and airways disease (odds ratio 
0.35).
174  I next examine whether such fears are justified. 
 
1.5.3  Properties of β-blockers approved for the treatment of HF 
Greater  β1-receptor  affinity  provides  a  wider  division  between  β1  and  β2-
adrenoceptor blockade, the latter mediating bronchoconstriction.  Estimates of β1-
affinity (so called ‘cardioselectivity’) vary according to methodology.  In vitro, β1/β2 
selectivity ratios have been derived from receptor binding studies in a wide range of 
tissues using different response measures, agonists and antagonists.  β1-selectivity is 
demonstrated in vivo through antagonism of biochemical (serum potassium, glucose 
and insulin) and haemodynamic (heart rate and blood pressure) responses  to  β2-
stimuli such as terbutaline or isoprenaline.
175  Table 1.7 outlines the properties of β-
blockers approved for the treatment of HF. 
 
 
 
 
 
 
 
 
 
   43 
Table 1.7  Properties of β-blockers approved for the treatment of HF 
 
β-blocker  β1-
selectivity 
α-
antagonism 
Intrinsic 
sympathomimetic 
activity 
Lipid 
solubility 
Route of 
elimination 
Half life 
(hours) 
Carvedilol
176  1  +  -  moderate  hepatic  7-10 
Metoprolol
177  40  -  -  moderate  hepatic  3-7 
Bisoprolol
178  75  -  -  low  hepatic / 
renal 
10-12 
Nebivolol
179  >300  -  -  high  hepatic  12-19 
 
1.5.4  Randomised trials of cardioselective β-blockade in COPD 
  No study has prospectively examined β-blockade in patients with both HF 
and COPD.  The evidence in those with COPD alone informs our daily decisions.  
Any review of ‘COPD and HF’ must therefore objectively appraise β-blockade in 
‘COPD without HF’.  A Cochrane Library meta-analysis concluded that long term 
cardioselective  β-blockade is safe and well tolerated in COPD.
2,180  This  meta-
analysis evaluated pulmonary function in 20 randomised, controlled, cross-over trials 
of cardioselective β1-blockers in patients with COPD (Table 1.8).
181-200  No study 
included any patients with HF. 
The evidence has many limitations.  Only two studies involved more than 20 
patients,
192,198 some were single rather than double-blinded,
196,197 and others lacked a 
placebo control.
182,192,193,196  Eleven trials involved a single treatment dose and only 
one lasted longer than a month.
192  The effect of long term β-blockade is therefore 
unknown.  The 9 ‘long term’ studies (defined as more than a single treatment dose) 
involved 147 young, predominantly male patients with moderate airways obstruction 
(mean FEV1 1.8 litres).  Extrapolation to elderly or female patients with HF therefore 
requires caution.   44 
Table 1.8  Randomised controlled trials of cardioselective β-blockers in patients with COPD 
 
Reference  n  Duration  Severe 
 
Reversibility  Placebo 
Control 
Double 
Blind 
Mean FEV1 
(l) 
Mean FEV1 
(% Pred) 
β-blocker  Route  Dose 
(mg) 
Reduction 
FEV1 (l) (%) 
Anderson.
181  9  single 
dose 
-  -  Yes  Yes  -  -  metoprolol  
propranolol 
PO  100 
80 
- 
Beil.
200  
 
20  single 
dose 
-  -  Yes  Yes  -  -  atenolol 
propranolol 
PO  100 
80 
- 
Sorbini.
182  8  single dose  -  -  -  Yes  1.9  -  metoprolol  PO  50, 100, 150, 200  10% 
Schaanning.
183  20  single dose  -  -  Yes  Yes  1.9  -  practolol  IV  15  6% 
Perks.
189 
 
10  single 
dose 
-  -  Yes  Yes  1.9  -  atenolol 
oxprenolol 
PO  50, 100 
80 
- 
Lammers.
184  8  4 weeks  -  -  Yes  Yes  2.4  -  metoprolol 
pindolol 
PO  100 bd 
10 bd 
0.25 
0.20 
Tivenius.
185  12  2 days  -  -  Yes  Yes  1.7  50  metoprolol 
propranolol 
PO  50 tds 
40 tds 
0.14 
0.41 
van der Woude.
199   15  4 days  -  -  Yes  Yes  2.4  72  propranolol 
metoprolol 
celiprolol 
PO  80 
100 
200 
0.33 
0.25 
0.09 
Ranchod.
186  15  3 weeks  -  -  Yes  Yes  2.3  -  atenolol 
propranolol 
PO  100 od 
40 qds 
0.13 
0.12 
Adam.
187 
 
10  single 
dose 
-  Yes  Yes  Yes  1.7  -  metoprolol  
atenolol  
labetolol  
propranolol 
PO  100 
100 
200 
80 
0.09 
0.15 
0.01 
0.23 
von Wichert.
188 
 
12  single 
dose 
-  Yes  Yes  Yes  -  -  metoprolol 
pindolol 
PO  100 
5 
- 
Dorow.
190 
 
12  single 
dose 
-  Yes  Yes  Yes  1.6  -  bisoprolol 
atenolol 
PO  20 
100 
p=NS 
p=NS 
Macquin-Mavier.
191  9  single 
dose 
-  Yes  Yes  Yes  -  80  bisoprolol 
acebutolol 
PO  10 
400 
- 
Dorow.
192  34  12 weeks  -  Yes  Active  Yes  1.7  -  celiprolol  PO  200, 400, 600  p=NS 
McGavin.
193 
 
9  single 
dose 
Yes  -  -  Yes  1.1  40  metoprolol 
propranolol 
PO  100 mg 
80 mg 
0.03 
0.27 
Sinclair.
194 
 
10  single 
dose 
Yes  -  Yes  Yes  1.3  -  metoprolol 
propranolol 
IV  0.12 mg/kg 
0.06 mg/kg 
0.07 
0.20 
Wunderlich.
198  
 
35  2 days  Yes  -  Yes  Yes  1.3  -  metoprolol 
propranolol 
PO  100 bd 
80 bd 
16% 
36% 
Butland.
195 
 
12  4 weeks  Yes  -  Yes  Yes  -  26  metoprolol 
atenolol 
PO  100 od 
100 od 
11% 
10% 
Fogari.
196 
 
10  1 week  Yes  Yes  -  -  1.3  -  atenolol 
celiprolol 
oxprenolol 
propranolol 
PO  100 
200 
80 
80 
p=NS 
p=NS 
14% 
16% 
Fenster.
197  6  1 week  Yes  Yes  Yes  -  -  45  metoprolol  PO  50 qds  6%   45 
The doses used were those employed for treating hypertension or angina.  
This contrasts with the low dose initiation and gradual titration in patients with HF.  
Information is particularly limited for β-blockers conferring benefit in HF: while 
many trials used metoprolol, only two single dose studies used bisoprolol,
190,191 and 
none carvedilol or nebivolol. 
 
1.5.5  Effect of  cardioselective  β-blockade in COPD with reversible airflow 
obstruction 
The long term effect of cardioselective β-blockers in patients with COPD and 
significant reversibility is unknown.  Of the 20 trials included in the Cochrane meta-
analysis, 7 involved patients with reversible airflow obstruction, defined by FEV1 
improvement  of  at  least  15%  following  β2-agonists.
187,188,190-192,196,197  FEV1  was 
unaffected by either single dose or longer duration cardioselective β-blockade (-1.8% 
and -1.26% respectively).  However, the ‘long term’ data derive primarily from a 
single  randomised  trial lasting just  12 weeks.
192  Celiprolol, a rarely used 
cardioselective  β-blocker  with  mild  β2-agonism  and  α2-antagonism, caused no 
significant change in FEV1  in  34 patients with moderate reversible airflow 
obstruction. 
Two small, single dose studies suggest the greater β1-selectivity of bisoprolol 
is clinically relevant in patients with significant reversibility.
190,191  In the first, 100 
mg of atenolol significantly increased airway resistance compared to 20 mg of 
bisoprolol.
190  In the second, acebutolol (a moderately β1-selective blocker) but not 
bisoprolol inhibited the bronchodilator response to salbutamol.
191  The longest study 
to  date  examining  β-blockade in COPD contradicts these results, but was not   46 
included in the meta-analysis.  In a randomised, double-blind, cross-over trial, 40 
patients with mild COPD and significant reversibility received bisoprolol 5 mg or 
atenolol 50 mg.
201  FEV1 declined significantly over 6 months by approximately 0.2 
litres in both treatment arms.  Although the study lacked a concurrent placebo group, 
lung function variables normalised during the placebo cross-over period, suggesting 
β-blockade directly caused bronchoconstriction. 
  The Cochrane meta-analysis reported no significant inhibition of β2-agonist 
response  by  cardioselective  β-blockers.  These  results  derive from four  small 
studies,
187,194,196,199  two  of which excluded patients with significant 
reversibility.
194,199  The  apparent  lack  of  interaction  between  β-blockade  and  β2-
agonist mediated bronchodilatation is unsurprisingly  given the minimal baseline 
reversibility.  Only a single study of 10 patients, lasting  one  week,  specifically 
included patients with reversible airflow obstruction.
196  Neither atenolol nor 
celiprolol antagonised the effect of inhaled salbutamol. 
 
1.5.6  Effect of cardioselective β-blockade on severe airflow obstruction 
  The same caveats apply to the evidence for β-blockade in patients with severe 
COPD.  The few existing studies are small, of limited duration, predominantly used 
metoprolol, had no dose titration and excluded patients with HF (Table 1.8).  The 
Cochrane library separately analysed 6 trials with mean baseline FEV1 less than 1.4 
litres or 50% of normal predicted values.
193-198  No significant change occurred in 
FEV1 following single dose (-0.71% [CI, -5.69 to 4.27]) or longer term β-blocker 
therapy (-3.11% [CI, -8.62 to 2.41]).
2  Four trials enrolled patients with fixed airflow 
obstruction, of which two used single doses
193,194 and another lasted just two days.
198    47 
In the remaining study of 12 patients, atenolol and metoprolol each significantly 
reduced FEV1 by around 10% over four weeks.
195  A further two studies included 
patients with both severe and reversible airways obstruction, each lasting one 
week.
196,197  Metoprolol and atenolol caused no significant change in FEV1 in 6 and 
10 patients respectively.  A recent study without placebo control also deserves 
mention.
202  In 50 patients with coronary artery disease and COPD (21 with severe 
airflow obstruction),  pulmonary function was unaffected by metoprolol over 3 
months. 
 
1.5.7  Effect of cardioselective β-blockade on symptoms 
Only one patient in each of the β-blocker and placebo groups experienced 
increased respiratory symptoms in the Cochrane meta-analysis.
2  The longer duration 
treatment ranged from just 2 days to 12 weeks.  Over short periods patients may 
curtail typical daily activities, thus underestimating the effect on symptoms.   
Furthermore, many studies only describe dyspnoea of sufficient magnitude to merit 
voluntary self-reporting.  Moderate and less acute symptoms may be inadequately 
assessed.  The perception of respiratory effort and associated distress is subjective 
and variable with time, reflecting a complex interaction between psychology and 
physiology.
203  No trial formally graded dyspnoea at baseline and follow-up using 
validated scales.  Quantification  based on  physical exertion also fails to reflect 
mental health and social functioning.
204  The effect of β-blockade on health related 
quality of life has never been assessed in patients with COPD.   48 
Almost  all  trials  evaluating  β-blockade in HF excluded patients with 
significant pulmonary disease, documented COPD, or bronchodilator therapy (Table 
1.9). 
Table 1.9  Exclusion criteria, prevalence of COPD and respiratory symptoms in 
major β-blocker trials 
 
Acronym  Year  Exclusion Criteria  Prevalence 
Of COPD 
β-Blocker  Respiratory 
Symptoms 
(β-blocker vs 
placebo) 
MDC 
205 
1993  obstructive lung disease requiring β2-
agonists 
not 
reported 
metoprolol  not reported 
CIBIS I 
206 
1994  asthma  not 
reported 
bisoprolol  not reported 
US Carvedilol 
Trials
207 
1996  any condition limiting exercise or 
survival,  such as pulmonary 
disease
208 
not 
reported 
carvedilol  cough 
8% vs 10% 
MOCHA 
209 
1996  obstructive pulmonary disease 
requiring  oral bronchodilator or 
steroid therapy 
not 
reported 
carvedilol  respiratory 
disorder 
5% vs 11% 
PRECISE 
210 
1996  any condition limiting exercise or 
survival, such as pulmonary disease 
not 
reported 
carvedilol  not reported 
ANZ 
211 
1997  chronic obstructive airways disease, 
or current treatment with a β-agonist 
not 
reported 
carvedilol  not reported 
CIBIS II 
212 
1999  reversible obstructive lung disease
213  not 
reported 
bisoprolol  not reported 
MERIT-HF 
214 
1999  contraindication to β-blockade
215  not 
reported 
metoprolol  not reported 
RESOLVD 
216 
2000  chronic reversible airways disease 
requiring therapy 
not 
reported 
metoprolol  not reported 
BEST 
217 
2001  contraindication to β-blockade,
218 
or β-agonists 
not 
reported 
bucindolol  not reported 
COPERNICUS 
219 
2001  severe primary pulmonary disease, 
or contraindication to β-blocker 
therapy 
not 
reported 
carvedilol  not reported 
CAPRICORN 
220 
2001  significant pulmonary impairment,
221 
or  therapy  with  inhaled  β2-agonists 
or steroids 
not 
reported 
carvedilol  not reported 
COMET 
222 
2003  history of asthma or chronic 
obstructive pulmonary disease 
not 
reported 
carvedilol, 
metoprolol 
not reported 
CIBIS III 
223 
2004  obstructive lung disease 
contraindicating  bisoprolol 
treatment
224 
not 
reported 
bisoprolol  not reported 
SENIORS 
225 
2005  regular inhaled bronchodilators,
226 
or history of bronchospasm or 
asthma 
not 
reported 
nebivolol  not reported 
 
Those involving bisoprolol had less stringent criteria, though investigators 
may avoid recruiting patients with severe airflow obstruction.  Only the Multicenter   49 
Oral Carvedilol Heart failure Assessment trial reported respiratory adverse events.
209  
This trial excluded patients with COPD requiring oral bronchodilator or steroid 
therapy, so extrapolation to patients with severe or reversible airflow obstruction is 
inadvisable.  Patients receiving carvedilol experienced fewer ‘respiratory disorders’ 
(5% vs 11%, p=0.09), with ‘approximately equivalent’ frequency of ‘upper 
respiratory illness’ and ‘cough’.  Tolerability in the U.S. Carvedilol Studies was also 
biased by the open label β-blocker run-in period prior to randomisation.  No trial 
specifically reported bronchospasm.  Whether this reflects genuine tolerability, 
limited detection strategies, or exclusion of patients with airflow obstruction is 
unclear. 
 
1.5.8  Effect of non-cardioselective β- and α-blockade on airflow obstruction 
Carvedilol is the only non-cardioselective  β-blocker approved for treating 
HF.  Most of the trials in the Cochrane meta-analysis reported adverse side effects 
with  other  non-selective  β-blockers.  Propranolol significantly reduced FEV1,
185-
187,193,194,196,198,199  antagonised  β-agonists,
185,187,194,196,198,199  increased 
dyspnea,
185,186,193,194,198  and even necessitated withdrawal of patients from 
studies.
185,186,193,198  The purported mitigating effect of α-blockade is circumstantial at 
best.  In a small study involving 10 patients, FEV1 and response to salbutamol were 
unchanged following single doses of labetolol.
187  However, at equipotent 
antihypertensive  doses  labetolol  exerts  half  the  β-blocking  effect  of  the  other  β-
blockers investigated, thus producing less bronchoconstriction.
187 
Two retrospective Australian analyses have assessed tolerability of carvedilol 
in patients with  HF and  airflow obstruction.  The first studied 808 consecutive   50 
patients commencing open label treatment.
169  Among 89 patients with coexistent 
COPD or asthma, 85% tolerated carvedilol.  No comment was made regarding the 
severity and reversibility of airflow obstruction, or the reasons for intolerance.  The 
analysis  also  excluded patients in whom carvedilol was never initiated due to 
anticipated  β-blocker intolerance.  The results undoubtedly  reflect selection bias 
rather than true tolerability.  The second study examined 31 patients with 
concomitant moderate COPD without significant reversibility (mean FEV1  62% 
predicted, reversibility 4%).
170  84% tolerated carvedilol, with only one patient 
withdrawing due to wheeze.  However, patients were predominantly young men and 
only 39% used inhaled bronchodilators.  Applicability to ‘real world’ patients  is 
limited. 
A recent retrospective UK report concluded that most patients with HF and 
COPD  safely  tolerate  β-blockers.
172  Over half of those  prescribed  a  β-blocker 
received carvedilol.  Among 356 patients attending a HF clinic, 124 (35%) were 
diagnosed with ‘obstructive airways disease’ using handheld spirometry at baseline.  
Many diagnostic pitfalls exist.
1  The reduced FEV1 and FEV1:FVC ratio may reflect 
restrictive ventilation, fluid overload, and the elderly population (mean age 71 years).  
Notably, 24% of patients said to have moderate to severe airways obstruction had 
never smoked.  The lack of bronchodilator therapy was likewise surprising given the 
beneficial effects on symptoms, pulmonary function, quality of life, and frequency of 
exacerbations.
5  Only 43 patients (12%) were receiving bronchodilators despite three 
times this number having significant airways disease.  To conclude, there are no 
robust data supporting the safety or efficacy of carvedilol in patients with moderate 
to severe or reversible airways disease.   51 
 
1.5.9  Effect of β-blockade on mortality in patients with HF and COPD 
In observational studies, use of β-blockers is associated with better survival in 
patients with HF and concurrent COPD,
128,166,227 a finding corroborated in post MI 
populations  (Table  1.10).
228,229  None of the studies assessed pulmonary function, 
limiting inference  to  patients with severe or reversible airflow obstruction.  
Prescribing bias is inevitable due to perceived or documented intolerance to β-
blockers.  This is compounded by recruitment bias in analyses from clinical trials, 
whose enrolment criteria often excluded patients with significant pulmonary disease.  
The lower mortality of patients receiving β-blockers may also reflect less severe lung 
disease. 
 
Table  1.10  Association  between  β-blockade and mortality in patients with 
cardiovascular disease and COPD 
 
Reference  Population 
with concurrent 
COPD 
n with 
COPD 
Prevalence of 
β-blockade (%) 
Follow-up  Mortality 
Staszewsky.
128  HF  628  22  mean 23 months  17% vs 31%, p<0.001 
Sin.
166  HF  3834  6  median 21 months  HR 0.78 (0.63-0.95) 
Gottlieb.
228  post MI  41814  22  2 year  HR 0.60 (0.57-0.63) 
Chen.
229  post MI  6628  31  1 year  HR 0.85 (0.73-1.00) 
 
COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio; LVSD, left 
ventricular systolic dysfunction; MI, myocardial infarction 
 
 
In the Valsartan Heart Failure Trial, 140 (22%) of the 628 participants with 
physician recorded  COPD  received  β-blockers.
128  Mortality over a mean of 23 
months was approximately 17%, as opposed to 31% in those with HF and COPD not 
prescribed β-blockers (p<0.001).  No statistical adjustment for baseline differences 
was performed.  A retrospective Canadian  study of 11942 elderly patients   52 
hospitalised for HF undoubtedly more accurately represents real life.
166  Although 
the proportion with LVSD was unknown, just 242 (6%) of the 3834 patients with 
concurrent COPD received β-blockers.  Mortality during median follow-up of 21 
months was lower in those prescribed β-blockers, after comprehensive adjustment for 
age, sex, comorbidity and propensity scores (HR 0.78 [95% CI 0.63-0.95]).   
 
1.5.10  Effect of β-blockade on morbidity in patients with HF and COPD 
The long term impact of β-blockade on COPD exacerbations is unknown as 
regards to frequency, severity, pulmonary function, primary care burden  and 
hospitalisations.  This is particularly important in patients with HF.  Should 
bronchospasm  necessitate  abrupt  β-blocker withdrawal, rebound ischaemia, 
ventricular arrhythmias and death may ensue.
230   
 
1.6  β-agonist in HF 
 
1.6.1  Physiological rationale for adverse β-agonist effects 
Reduced organ perfusion in heart failure results in a compensatory increase in 
adrenergic drive.  Adrenaline and noradrenaline stimulate ventricular contraction and 
increase vascular resistance, maintaining cardiac output and blood pressure.  Longer 
term, increased mechanical stress, myocardial oxygen demand and ischaemia 
combine with maladaptive adrenergic signalling to depress myocardial function.  β1 
and β2 adrenoceptors mediate noradrenaline toxicity, fibrosis and necrosis.  Down 
regulation of β1 receptors with preservation of the β2 subpopulation reduces the β1/β2   53 
ratio.
231  The chronotropic and inotropic responsiveness (and likewise vulnerability) 
of the failing myocardium to β2-agonists thereby assumes greater importance.
232,233 
β2-agonists exert numerous unfavourable cardiovascular effects: tachycardia, 
hypokalaemia, QTc  prolongation, peripheral vasodilatation, disturbed autonomic 
modulation and depressed heart rate variability.
234-237  In susceptible patients, β2-
agonists may precipitate ischemic events.
238,239  Hypoxia, hypercapnia, acidosis and 
excess sympathetic activity in pulmonary disease all potentially amplify these 
sequelae.
234,240,241  When combined with the arrhythmic substrate of left ventricular 
dysfunction,
242  the risk of life threatening arrhythmias cannot be discounted.  
However, theoretical concerns may be misplaced.  Although  β-agonists may 
exacerbate hypokalaemia associated with diuretics, hyperkalaemia induced by 
intensive renin angiotensin inhibition may conversely be reduced.  The pros and cons 
of β-agonist use in patients with HF and COPD are rarely considered.  Even the 
prevalence of β-agonist prescription has only been reported  twice  (37% and 
74%).
97,128  Research is needed to define the overall impact of β-agonists in 
contemporary populations. 
 
1.6.2  Cautions regarding the adverse associations between β-agonists and HF 
β-agonists are associated with incident HF in patients with pulmonary 
disease, and with increased mortality and HF hospitalisation in those with existing 
HF or LVSD (Table 1.11).  However, the reported adverse associations merit careful 
scrutiny.  The evidence derives from retrospective cohort or case control analyses, all 
of which equated drug dispensing with drug use.  Three fundamental issues 
undermine conclusions: limited multivariate adjustment; confounding by collinear   54 
pulmonary disease; and bias by indication.  No causality may be inferred.  
Multivariable analyses are often restricted in epidemiological studies due to residual 
confounding by unmeasured covariates.  Cardiovascular risk factors and diseases 
both cluster in patients with COPD, along with underuse of β-blockers.
227,243 
 
Table 1.11  Association between β-agonists and heart failure 
 
Reference  Population  Route  Bronchodilator  Study 
Design 
n  Outcome  Risk associated with 
bronchodilator use 
[95% CI] 
Martin 
1998.
244  
asthma  oral  bambuterol  cohort  8098  HF  RR 3.41 [1.99-5.86], 
p<0.0001 
inhaled  salmeterol  cohort  15407  HF  RR 1.10 [0.63-1.91], 
p=0.7 
Coughlin 
1995.
245 
general 
population 
oral  β-agonist  case 
control 
387  DCM  OR 3.4 [1.1-11.0] 
inhaled 
nebulised 
β-agonist  case 
control 
387  DCM  OR 3.2 [1.4-7.1] 
Sengstock 
2002.
246 
cardiology 
clinic 
inhaled  β-agonist  case 
control 
190  DCM  OR 1.0 
Macie 
2008.
247 
COPD 
or asthma 
inhaled  β-agonist  case 
control 
59336  HF 
hospitalisation 
OR 1.74 [1.60-1.91] 
Au 
2004.
248 
HF  inhaled  β-agonist  case 
control 
1121  HF 
hospitalisation 
OR 1.5 [0.8-2.8] 1-2 
canisters 
OR 2.1 [1.0-4.3] ≥  3 
canisters 
general 
medical 
clinics 
inhaled  β-agonist  case 
control 
13012  HF 
hospitalisation 
OR 1.3 [0.9-1.8] 1-2 
canisters 
OR 1.1 [0.8-1.6] ≥  3 
canisters 
Au 
2003.
249 
LVSD  inhaled  β-agonist  cohort  1529  death  RR 0.9 [0.5-1.6] 1 
canister / month 
RR 1.4 [0.9-2.2] 2 
canister / month 
RR 2.0 [1.3-3.2] 3 
canister / month 
Singer 
2008.
250 
acute HF 
without 
COPD 
inhaled  any 
bronchodilator 
cohort  7299  death 
IV vasodilator 
use 
ventilation 
OR 1.02 (0.67-1.56) 
OR 1.40 (1.18-1.67) 
OR 1.69 (1.21-2.37) 
 
ACQUIP, Ambulatory Care Quality Improvement Project; CI, confidence interval; COPD, chronic 
obstructive pulmonary disease; DCM, idiopathic dilated cardiomyopathy; HF, heart failure; IV, 
intravenous; LVSD, left ventricular systolic dysfunction; OR, odds ratio; RR, relative risk 
 
Pulmonary disease may itself cause cardiac injury through hypoxia, 
arrhythmias or even atherosclerotic mechanisms.
139  The poor outcomes attributed to 
β-agonists may reflect the disease for which they are prescribed.  Separating the two   55 
is difficult.  Dose response relationships are limited without adjustment for severity 
of airflow obstruction and cumulative smoking burden.
239,249  Patients utilising more 
bronchodilators may simply have more severe pulmonary disease.  The indication for 
bronchodilator prescription or utilisation may confound results.  Physicians may 
mistakenly prescribe β-agonists or patients may increase β-agonist use for symptoms 
of HF.  Concurrent therapy with theophylline or anticholinergics confuses matters 
further as both are associated with adverse cardiovascular outcomes.
251,252  Finally, β-
agonists perhaps unmask rather than cause left ventricular dysfunction, as suggested 
by the higher risk observed early after prescription.
244 
 
1.6.3  β-agonists and incident heart failure. 
Five reports have addressed the association between β-agonists and incident 
HF in the general population or those with pulmonary disease.
244-248  Prescription 
event monitoring collates physician reports of adverse events associated with newly 
launched drugs.  Oral bambuterol, but not inhaled salmeterol, was associated with an 
increased incidence of HF in 8098 patients when compared with the reference drug 
nedocromil (RR 3.41 [95% CI 1.99-5.86], p<0.001).
244  However, the bambuterol 
cohort received fewer prescriptions for asthma (57.3% vs 70.2%) and more ‘other’ 
indications (12.8% vs 2.8%).  Bambuterol may therefore have unmasked previously 
undiagnosed HF, as suggested by the greater risk in the first month of exposure 
compared with months 2 to 6 (respectively 4.41 [1.90-10.27] vs 2.67 [1.30-5.47]). 
Two case control studies assessed the risk of idiopathic dilated 
cardiomyopathy defined by echocardiography associated with β-agonists.
245,246  Both 
suffer the inherent failings of case control methodology,
253 namely that selection bias   56 
arises if controls are not representative of the population at risk, or independent of 
the exposure of interest.  The numbers of events were limited, resulting in wide 
confidence intervals and statistical uncertainty.  Oral β-agonists were associated with 
a 3-fold increased risk in 387 patients recruited from the Washington DC area (OR 
3.4 [1.1-11.0]).
245  By contrast, the Detroit ABCHF study of 197 patients observed 
no significant relationship with inhaled β-agonists.
246  Although differences between 
oral and inhaled administration are possible, the disparity most likely relates to 
choice of control groups.  Whereas the Washington study selected community-based 
controls using random digit dialling, ABCHF employed clinic-based controls with 
ischemic  cardiomyopathy.  The former is confounded by biases such as 
socioeconomic status when using telephone controls, the latter by the association 
between β-agonists and ischemic events. 
Two nested case control studies yielded equally conflicting results.
247,248  782 
subjects and 12230 controls were selected from the multicentre Ambulatory Care 
Quality Improvement Project (ACQUIP), which examined health care reporting from 
general medical clinics.
248  Use of 1 to 2  β-agonist canisters per month was 
associated with HF hospitalisation (OR 2.6 [2.0-3.5]).  However, the relationship 
failed to achieve significance after adjusting for age, cardiovascular comorbidity, β-
blocker prescription and presence of COPD (OR 1.3 [0.9-1.8]).  By contrast, the 
adjusted 1 year risk of HF hospitalisation among patients with COPD or asthma 
selected from the Manitoba Health database was increased in  those  receiving  β-
agonists (OR 1.74 [1.60-1.91]).
247  Whether inhaled β-agonists are implicated in the 
development of HF therefore remains uncertain. 
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1.6.4  Oral β-agonists in heart failure 
Numerous small, short term controlled studies have  examined  the  oral  β-
agonists pirbuterol, prenalterol, salbutamol and terbutaline in patients with HF.
254  
The majority demonstrated acute haemodynamic improvements, including ejection 
fraction, cardiac index and pulmonary capillary wedge pressure.
255,256  However, 
only 3 studies recruited at least 20 patients and lasted longer than a month.
255-257  
Although symptoms and exercise tolerance improved,  no  β-agonist produced a 
sustained improvement in systolic function.  The trials lacked statistical power and 
were of insufficient duration to identify longer term impairment of systolic 
performance.  Significant arrhythmias were however observed.  Six of 20 patients 
with advanced HF developed recurrent ventricular tachycardia with oral salbutamol 
which subsided once discontinued, although two required cardioversion.
255 
Two large, randomised controlled trials investigated oral xamoterol, a partial 
β1-agonist.  The first randomised 433 patients with mild to moderate HF to receive 
xamoterol, digoxin or placebo.
258  Xamoterol improved exercise capacity, dyspnoea 
and fatigue.  The Xamoterol in Severe Heart Failure Study aimed to extend these 
findings in 516 patients with NYHA class III and IV symptoms.  However, the trial 
was terminated prematurely due to excess mortality in the xamoterol group within 
100 days of randomisation  (9.1% vs 3.6%, p=0.02).
259  Both sudden death and 
progressive pump failure contributed to the increased mortality. 
Respiratory guidelines favour inhaled over oral bronchodilators due to rapid 
therapeutic action, greater efficacy, and fewer side effects.
5  However, neither 
cardiologic nor pulmonary societies specifically counsel against oral agents in 
patients with cardiovascular disease.
4,5,44,160  This lack of guidance is concerning: in   58 
the Val-HeFT trial, 73% of patients with HF and concurrent COPD were prescribed 
oral β2-agonists.
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1.6.5  Nebulised β-agonists in heart failure 
Nebulised doses are typically ten times greater than standard inhalers.  Two 
facts should be considered.  Systemic adverse effects are dose dependent,
260,261 and 
pulmonary absorption delivers β-agonists to the heart without first pass metabolism.  
Nebulised β-agonists may precipitate arrhythmias and myocardial ischaemia.
262,263  
Four acute studies recruiting 44 patients in total have administered nebulised β2-
agonists to patients with HF.
264-267  No adverse events were reported.  In 13 patients, 
cardiac output and ejection fraction significantly increased within  10 minutes of 
inhalation, returning to baseline after 30 minutes.
264  The remaining three studies 
observed a reduction in airflow obstruction following nebulised salbutamol, but no 
consistent improvement in exercise capacity.
265-267  Given the limited patient 
numbers, clinical judgment is paramount.  Increasing from 2.5mg to 5mg salbutamol 
produces only limited incremental bronchodilatation.
268,269  Clinicians should 
minimise both the dose and frequency of nebulised therapy when treating patients 
with HF and concurrent COPD. 
 
1.6.6  Inhaled β-agonists in heart failure 
Standard metered dose β-agonist inhalers produce only minor systemic and 
biochemical abnormalities.
260,261,270  Whether these contribute to adverse events in 
patients with HF or LVSD is debatable.
248,249   Among 1529 patients with LVSD 
identified retrospectively through imaging records,  363  were  dispensed  β-agonist   59 
canisters in the 90 days prior to the index echocardiogram.
249  All cause mortality 
and HF hospitalisation  within  1  year  were  associated  with  β-agonist use, risk 
increasing with the average number of canisters dispensed per month.  After 
covariate adjustment, risk of HF admission was: 1.3 [0.9-2.0] (1 canister / month); 
1.7 [1.2-2.5] (2 canisters / month); 2.0 [1.3-3.0] (≥ 3 canisters / month).  Risk of 
death was similarly increased: 0.9 [0.5-1.6] (1 canister / month); 1.4 [0.9-2.2] (2 
canisters / month); 2.0 [1.3-3.2] (≥ 3 canisters / month).  However, any association is 
undermined by the indication for β-agonist use: increasing dyspnoea and resulting β-
agonist prescription may simply reflect worsening HF.  Without markers of HF 
severity the multivariate model was unable to adjust for such confounding. 
In the ACQUIP case control study,
248 β-agonists were associated with HF 
hospitalisation among those with existing HF (OR 1.8 [1.1-3.0]).  Adjustment for 
age, cardiovascular comorbidity, β-blocker prescription, presence of COPD and a 
marker of disease severity (steroid use) reduced the magnitude of association (OR 
1.6 [1.0-2.7]).  Adding smoking status and pack year history to the multivariate 
model rendered the relationship non-significant (OR 1.5 [0.8-2.8]).  The findings 
reinforce  concerns  that  the  purported  adverse  effects  of  β-agonists relate to 
underlying pulmonary disease and clustering of cardiovascular risk factors. 
A single study has prospectively investigated inhaled  β-agonists, 
administering salmeterol 84 µg twice daily to 8 patients with NYHA class II or III 
heart failure.
271  FEV1  improved by 6% compared with placebo (p=0.01).  
Concomitant airflow obstruction limits interpretation: mild COPD was not excluded, 
baseline FEV1 was reduced in all patients, and smoking history not documented.  The 
pharmacokinetic data proved more revealing.  The steady state trough and peak   60 
concentrations and half-life of salmeterol were at least double those reported in 
patients with asthma.    Physicians  must  be  wary  of  diminished  β-agonist hepatic 
metabolism in patients with HF. 
 
1.6.7  β-agonists in acute heart failure 
Inhaled β-agonists have never been prospectively evaluated in patients with 
decompensated HF, although the physiological actions are appealing: enhanced 
cardiac output, reduced peripheral vascular resistance and bronchodilatation.
272  
However, numerous clinical trials have tested therapies with favourable 
haemodynamic activity in patients with acute heart failure, none of which improved 
mortality.
4  Analogies with intravenous inotropic drugs acting through adrenergic 
pathways are inescapable.  Acute improvement may belie myocardial injury leading 
to increased mortality.
4,273  Evidence from 7299 patients without COPD enrolled in 
the Acute Decompensated Heart Failure National Registry supports these 
concerns.
250  Bronchodilators were administered to 14.3% of patients and associated 
with greater requirement for intravenous vasodilators (adjusted OR 1.40 [1.18-1.67]) 
and mechanical ventilation (OR 1.69 [1.21-2.37]).  Hospital mortality was similar 
regardless of bronchodilator therapy.  Physicians should use bronchodilators 
cautiously in those without established pulmonary disease. 
 
1.6.8  Interaction between β-blockers and β-agonists 
The evidence supporting an interaction between β-blockers and β-agonists is 
circumstantial  and derives largely from patients  suffering  myocardial infarction.  
Less benefit was apparent in clinical trials using β-blockers with intrinsic   61 
sympathomimetic activity post infarct.
274  β-blocker  use was  not associated with 
lower mortality among patients receiving concurrent β-agonists in the Cooperative 
Cardiovascular Project.
229  Conversely, the risk of acute coronary syndromes 
associated with β-agonists was lessened by concurrent β-blockade in a case control 
study using data from the Veterans Administration ACQUIP trial (p for interaction < 
0.0005).
239  The  aforementioned  interaction  between  β-blockers and  β-agonist 
bronchodilator response must also be considered.  While cardioselective β-blockers 
permit bronchodilatation, non-cardioselective β-blockers inhibit β-agonist response.  
This raises an interesting clinical conundrum – though symptomatically less well 
tolerated, would non-selective β-blockade reduce the possible adverse cardiovascular 
effects of β2-agonists more than cardioselective β1-blockade? 
 
1.7  Aims of the thesis 
 
Critical appraisal of the existing literature has revealed an array of diagnostic, 
epidemiological  and therapeutic questions.  The crude prevalence of COPD in 
patients with HF has been extensively reported.  Temporal trends, age and gender 
variations, and socioeconomic differences all require clarification.  Although these 
chronic diseases are predominantly managed in the community, the evidence largely 
derives from cohorts hospitalised with worsening HF.  The epidemiology and 
management of patients with HF and concurrent COPD in primary care is therefore 
particularly important.  The prognostic implications of COPD in patient with HF 
likewise merit careful examination.  The causes of increased mortality are unclear, as 
is the relationship between COPD and ischaemic or arrhythmic events.   62 
The opposing therapies of β-blockers and β-agonists undoubtedly pose the 
greatest  clinical conundrum.  Prescribing  rates  for  β-blockers have progressively 
increased in patients with HF.
275  Whether utilisation has improved in those with 
concurrent COPD is unknown.  Reluctance to prescribe β-blockers stems from the 
weakness  of  existing  evidence.    First  and  foremost,  β-blockade has never been 
studied in patients with HF and COPD.  Even among patients with COPD alone, the 
long term impact of β-blockade on pulmonary function, symptoms and quality of life 
is uncertain.  Clinical practice necessitates balancing  risk and benefit.  Both are 
poorly defined.  The morbidity and mortality benefits of β-blockade in patients with 
HF  are incontrovertible.  The evidence in those with concurrent  COPD  is 
rudimentary  by  comparison.    β-agonists present similar problems.  Given the 
potential for adverse effects, the characteristics and outcomes of patients prescribed 
bronchodilators are remarkably ill defined.  The studies presented in this thesis aim 
to address these deficits, and in doing so extend our understanding of this often 
overlooked group of patients. 
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Chapter 2 
 
Methods 
 
   64 
2.1  Study design 
 
The following methods provide the study protocol for my initial investigation of 
bisoprolol in patients with HF and concurrent COPD. 
 
2.1.1  Hypothesis 
The principal research objective is to demonstrate cardioselective β-blockade 
using bisoprolol is not inferior to placebo with regard to pulmonary function in 
patients with HF  and coexistent moderate or severe COPD  with or without 
significant reversibility. 
 
2.1.2  Specific research objectives 
A comprehensive literature search was performed utilising MEDLINE, 
CINAHL, EMBASE and Cochrane Database of Systematic Reviews.   Following 
review of all identified literature this research will specifically address the following 
areas in which current evidence of β-blockers use in COPD is limited. 
 
1) coexistent heart failure. 
2) moderate to severe airflow obstruction. 
3) presence of reversible airflow obstruction. 
4) quantification of dyspnoea. 
5) health related quality of life. 
6) response to inhaled β2-agonist. 
7) limited follow up duration.   65 
2.1.3  Design 
The study is a randomised, double-blind, placebo-controlled, single domain, 
clinical trial examining the effect on pulmonary function of cardioselective β-
blockade using bisoprolol compared with placebo in patients with HF and coexistent 
moderate or severe COPD with or without significant reversibility. 
 
2.1.4  Sample size calculation 
For the primary outcome FEV1, a sample size of 63 in each group, using a 
confidence interval approach to equivalence and a two group 0.05 one-sided t-test, 
will have 80% power to reject the null hypothesis of non-equivalence (difference in 
means 0.20 litres or further from zero in the same direction) in favour of the 
alternative hypothesis of equivalence (no significant difference in means of β-blocker 
and placebo groups), assuming the expected difference in means is 0.00 and the 
common standard deviation is 0.45 litres.  The mean FEV1 standard deviation of 
0.45l was assumed from previous studies involving patients with COPD.
184,193,276,277 
 
( ) ( ) [ ]
2
1 1 2
2 2  
β α z z
Δ
s
n − − + = for a 100(1-α)% one sided confidence interval. 
n =  ( )
( ) ( ) [ ]
2
2 0 1 05 0 1 2
2
2 0
45 0 2  
. . z z
.
.
− − + = 10.125×(1.64 + 0.84)
2 = 62.3 
 
For the secondary outcomes SF-36 Physical and Mental Component Summary 
scores, a sample size of 49 patients in each group is required to detect a difference in 
means of 6, assuming a standard deviation of 10.5, power of 80% and significance 
level of 5%.   66 
 
2.1.5  Inclusion criteria 
Subjects with stable chronic heart failure and coexistent moderate to severe chronic 
obstructive pulmonary disease and presence or absence of reversible airflow 
obstruction. 
 
a) Stable heart failure 
•  symptomatic NYHA II or III chronic heart failure. 
•  left ventricular systolic dysfunction  –  left ventricular ejection fraction < 40% 
measured by echocardiography or radionuclide ventriculography. 
•  stable cardiovascular state > 2 weeks before the study protocol.  
•  unchanged doses of concomitant cardiovascular therapy including angiotensin 
converting enzyme  inhibitors  (ACEI), aldosterone antagonists, digitalis, 
vasodilators, aspirin, statin, calcium channel blockers. 
 
b) Chronic obstructive pulmonary disease 
 
•  either moderate (50% ≤ FEV1 < 80%) or severe (30% ≤ FEV1 < 50%) GOLD 
classification of severity. 
•  FEV1/FVC < 70%. 
•  minimum 10 pack year smoking history. 
•  with or without significant reversibility defined by FEV1 ≥ 12% (and 200 ml) 
increase 30 minutes after short acting inhaled β2-agonist salbutamol.   67 
•  stable respiratory state for  2  weeks before the study protocol, including no 
respiratory tract infections, unchanged doses of concomitant respiratory therapy, 
and no objective evidence of increasing bronchoconstriction. 
 
2.1.6  Exclusion criteria 
 
a)  β-blocker contraindications 
•  resting bradycardia less than 60 beats per minute. 
•  sick sinus syndrome. 
•  trifascicular block. 
•  second or third degree atrioventricular block unless treated with a pacemaker. 
•  supine or sitting hypotension systolic arterial pressure < 100 mmHg during 
initiation. 
•  cardiogenic shock, intractable pulmonary oedema. 
•  acute heart failure requiring intravenous inotropic or mechanical support. 
•  standard clinical criteria of asthma including family history of asthma, young age 
of symptom onset, response to provocative stimuli. 
•  peripheral arterial disease with symptoms at rest, Raynaud's syndrome. 
•  unstable insulin dependent diabetes mellitus. 
•  untreated phaeochromocytoma. 
•  metabolic acidosis. 
•  previously documented hypersensitivity to bisoprolol or any excipients. 
 
b)  Confounding pulmonary disease   68 
•  pulmonary fibrosis. 
 
c)  Medication 
•  non-dihydropyridine (diltiazem / verapamil) calcium channel blockers. 
•  clonidine. 
•  monoamineoxidase inhibitors. 
•  class-I antiarrhythmic drugs e.g. disopyramide, quinidine. 
•  parasympathomimetic drugs. 
•  alternative β-blockers. 
•  prostaglandin synthetase inhibiting drugs, excluding aspirin. 
•  ergotamine derivatives. 
•  barbiturates. 
•  rifampicin. 
•  mefloquine. 
•  any investigative trial drug previous one month. 
 
d)  Comorbidity 
•  recent (2 weeks) coronary percutaneous intervention or coronary artery bypass 
graft surgery. 
•  haemodynamically significant valvular disease or hypertrophic cardiomyopathy. 
•  active myocarditis or pericarditis. 
•  recent (2 weeks) cerebrovascular accident or transient ischaemic attack. 
•  serious concurrent systemic disease, such as malignancy, resulting in likely 
reduced life expectancy.   69 
•  significant renal (serum creatinine > 300 μmol/L), hepatic (ALT / AST > 3 times 
the upper limit of normal), haematological (haemoglobin < 10 g/dL), metabolic, 
gastrointestinal or endocrine dysfunction. 
•  pregnancy, childbearing potential with inadequate contraception, breast feeding. 
 
e)  General 
•  mental or legal incapacitation. 
•  patients unable or unwilling to provide informed consent. 
•  anticipated poor compliance with the intervention. 
•  drug or alcohol abuse within the last 6 months. 
•  extensive travel planned during the trial period. 
•  planned discharge to long term residential care. 
•  residence outside the hospital’s catchment area. 
 
2.1.7  Study flow chart 
Patients attend for one baseline and initiation visit (Day 0 Study Protocol) 
and 5 follow up visits over 4 months (Weeks 2, 4, 8, 12, 16 Study Protocol).  
Participants were invited to attend the research unit at 8.30 on each study day after a 
light breakfast to minimise changes in bioavailability due to food intake.  Patients 
were advised to temporarily cease bronchodilator therapy and abstain from smoking 
tobacco for 12 hours prior to attendance.  Study medication was omitted on the 
morning of visit days.  Subjects were observed for 4 hours on test days and allowed 
home following pulmonary function testing. 
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Table 2.1  Study flow chart 
Visit Number  1  1  2  3  4  5  6 
Week  0  0  2  4  8  12  16 
Bisoprolol Dose  0  1.25  2.5  5  7.5  10  10 
Baseline characteristics   ×  -  -  -  -  -  - 
Consent  ×  -  -  -  -  -  - 
B-type natriuretic peptide  ×  -  -  -  -  -  - 
Electrocardiogram  ×  -  -  -  -  -  × 
Physical examination  ×  ×  ×  ×  ×  ×  × 
Concomitant medication  ×  -  ×  ×  ×  ×  × 
Medication Compliance  -  -  ×  ×  ×  ×  × 
Medication Dispense  -  ×  ×  ×  ×  ×  × 
Short Form 36 (SF-36v2)  ×  -  ×  ×  ×  ×  × 
Respiratory Questionnaire  ×  -  ×  ×  ×  ×  × 
Minnesota (MLHFQ)  ×  -  ×  ×  ×  ×  × 
PEFR 0, 1, 2, 3, 4 hours  -  ×  ×  ×  ×  ×  × 
Spirometry  ×  ×  ×  ×  ×  ×  × 
FEV1 Reversibility  ×  ×  ×  ×  ×  ×  × 
TLC, RV, FRC  ×  ×  ×  ×  ×  ×  × 
TLCO, KCO  ×  -  -  -  -  -  × 
 
Each visit included evaluation of symptoms, physical signs, pulse oximetry, 
health status, peak expiratory flow, spirometry and body plethysmography.  All 
patients were clinically euvolaemic at the time of pulmonary function testing.   
Carbon monoxide transfer factor, electrocardiography and arterialised earlobe 
capillary blood gases were performed at study onset and completion.  Health status 
was assessed using one generic and two disease specific instruments at each visit: the 
Short Form 36 (SF-36), Chronic Respiratory Questionnaire (CRQ) and the 
Minnesota Living with Heart Failure Questionnaire (MLHFQ).
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2.1.8  Trial completion. 
After completion of the 4 month follow up period patients were weaned off 
medication and the physician originally responsible for the patient’s care contacted to   71 
arrange appropriate follow up.  Blinded down titration using bisoprolol or equivalent 
placebo commenced after the final visit.  The dose was halved (rounding up) for one 
week. e.g. 5 mg from 10 or 7.5 mg, 2.5 mg from 5 mg, 1.25 mg from 2.5 mg.  The 
dose was halved for a second week following the first down titration. e.g. 2.5 mg 
from 5 mg, 1.25 mg from 2.5 mg.  All study medication was discontinued after these 
2 weeks.  Trial completion was defined as the date of the last treatment visit for the 
last patient.  All randomised treatment allocations were unblinded following trial 
completion. 
 
2.2  Study visits 
 
2.2.1  Baseline characteristics 
An electronic case report form (CRF)  was constructed using Microsoft 
Access 2003 for Windows database software (Microsoft Corporation, Seattle, 
Washington).  Age, gender, height, weight, smoking status, year started and stopped 
smoking, and cigarettes per day were recorded.  The following cardiac and non-
cardiac comorbidities were recorded in checkbox fashion:  hypertension, 
hypercholesterolaemia, type I diabetes mellitus, type II diabetes mellitus, elevated 
body mass index, clinical angina, previous myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass graft surgery, atrial fibrillation, 
peripheral arterial disease, transient ischaemic attack, cerebrovascular accident, 
permanent pacemaker, cardiac resynchronisation therapy, mitral regurgitation, aortic 
stenosis, aortic regurgitation, tricuspid regurgitation, chronic renal failure, 
osteoarthritis, rheumatoid arthritis, osteoporosis, inflammatory bowel disease.   72 
2.2.2  Physical examination 
Height in metres and weight in kilograms were measured at the initial visit, 
allowing calculation of body mass index.  Cardiorespiratory examination recorded 
the presence of elevated jugular venous pressure, peripheral pitting oedema, 
pulmonary crepitations and auscultatory signs of bronchospasm (wheeze).  Pulse 
oximetry was measured before, 2 and 4 hours post β-blocker.  Earlobe capillary 
sampling was performed on the first and last days. 
Heart rate was measured before, 2 and 4 hours post β-blocker after subjects 
were seated for 5 minutes from the left radial pulse, immediately prior to measuring 
blood pressure.  Blood pressure was measured  using a standard mercury 
sphygmomanometer in both arms at the  initial assessment unless  a concomitant 
condition favoured the use of a particular arm.  The arm with the higher average 
systolic blood pressure reading was  used for blood pressure determination 
throughout the study.  Korotkoff Phase V was used as the criterion for diastolic blood 
pressure.  All measurements were read to the nearest 2 mm Hg. 
 
2.2.3  Electrocardiography 
A 12 lead electrocardiogram (ECG) was recorded and computer analysed 
with the  subject rested for 5 minutes in the supine position.  One experienced 
observer interpreted results.  The following information was recorded: ventricular 
rate,  PR interval, QRS duration, QTc  interval, rhythm, AV block (1° / 2° / 3°), 
evidence of previous myocardial infarction, left ventricular hypertrophy, ST-T wave 
changes. 
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2.2.4  B-type natriuretic peptide 
Worsening of symptoms, particularly of dyspnoea or wheeze, was 
differentiated in standard fashion.  This included assessment of pulse, blood pressure, 
oxygen saturation, temperature, peak expiratory flow, clinical examination, blood 
tests including white cell count and C-reactive protein, chest radiograph and sputum 
culture.  In the event of diagnostic uncertainty, B-type natriuretic peptide would be 
compared against a baseline sample. 
Venous blood sampling was performed at baseline in a standardised fashion 
from the antecubital fossa with the patient in the supine position for a minimum of 30 
minutes prior to venesection.  Standard risks associated with the use of sharp 
instruments were minimised with adherence to appropriate procedures for handling 
sharps.  10 mls of venous blood was collected in 2 pre-prepared chilled 5 mL tubes 
containing EDTA.  These were centrifuged at  3000 rpm for  15 mins with 
refrigeration at 5°C.  The supernatant was removed and placed in separate freezer 
containers labelled with the patient subject number and stored frozen at -20˚C until 
required.  B-type natriuretic peptide concentration would  be measured using a 
validated and commercially available immunoassay (Roche diagnostics, Mannheim, 
Germany).  Identifiers  were  removed and the samples destroyed following 
completion of the experimental protocols. 
 
2.2.5  Symptom evaluation 
Symptom evaluation was performed according to standard reference manuals 
for the rating tools, with results recorded directly into the electronic case report form.  
Three tools were employed.   74 
 
a) Short Form 36v2 
The SF-36v2 is the most widely evaluated generic health outcome measure, 
with experience documented in 4000 publications describing 200 diseases and 
conditions.  It comprises 36 questions derived from the Medical Outcomes Study, 
and is particularly useful as a generic core with additional disease specific measures 
of health status.  The form is suitable for self-administration in 5 to 10 minutes with a 
high degree of acceptability and data quality.  8 scales form 2 distinct higher ordered 
summary measures of physical and mental health (Physical Component Summary 
(PCS) and Mental Component Summary (MCS) measures).  85% of the reliable 
variance in the 8 scales is represented in the summary measures.  This reduces the 
number of statistical comparisons involved in analysing the SF-36 without 
substantial loss of information.  Reliability estimates for physical and mental 
summary scores usually exceed 0.90.  The content, construction and predictive 
validity has been proven in numerous studies.  The minimal important difference to 
standard deviation ratio is relatively high (standardised difference) producing a small 
sample size.
279,280 
 
b) Chronic Respiratory Questionnaire 
The interviewer led CRQ was the first instrument developed to measure 
quality of life in patients with COPD.  The self-reported CRQ was developed in 
conjunction with the original author.
281  The overall score is derived from 20 items.  
Answers are scored on a 7 point scale ranging from 1 (maximum impairment) to 7 
(no impairment).  Questions are divided into four component domains, namely   75 
‘Dyspnoea’ (5 items), ‘Fatigue’ (4 items), ‘Emotional Function’ (7 items) and 
‘Mastery’ (4 items).  A lower score in each dimension reflects a greater degree of 
dysfunction.  Questions covering the domains of fatigue, emotional function and 
mastery are standardised.  The dyspnoea domain is ‘individualised’ by the patient 
identifying 5 everyday activities causing the greatest shortness of breath, so each 
patient has a unique list of activities.  The patient selects activities causing 
breathlessness from a list on the questionnaire, or may volunteer additional activities.  
Dyspnoea is rated on these self-selected activities at baseline and during subsequent 
administrations of the CRQ on a 7 point scale ranging from 1 (extremely short of 
breath) to 7 (not at all short of breath).  The entire questionnaire takes approximately 
10 minutes to complete.  Results are expressed as the mean score for each domain 
and the mean overall score.  Numerous studies have demonstrated reproducibility 
and responsiveness.
278,281-286 
 
c) Minnesota Living With Heart Failure Questionnaire 
The self-administered MLHFQ consists of 21 questions assessing the 
patient’s perception of heart failure impairing their emotional or physical state.  The 
effects of heart failure on physical, emotional, social and mental dimensions of 
quality of life are assessed.
287,288  Each question employs a stable 6 point Likert scale 
from zero (no impairment) to five (severe impairment).  The sum of responses 
reflects the overall severity of heart failure.  A relatively low standardised difference 
produces a large sample size.  A change of 7 points is considered clinically 
meaningful. 
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2.2.6  Peak expiratory flow 
Patients were instructed and observed while using the peak flow meter.  The 
maximum of three technically satisfactory measurements was utilised.  Baseline peak 
expiratory flow (PEF) was measured on the first study day prior to administration of 
β-blocker.  Subsequent measurements were made hourly following administration of 
study medication. 
 
2.2.7  Spirometry 
Spirometry and lung volumes were measured using body plethysmography 
(Sensormedics, V6200 Autobox, California, USA) 3 hours after administration of 
study medication and at least 12 hours after inhaled bronchodilators.  The variables 
measured were FEV1, vital capacity (VC), residual volume (RV), total lung capacity 
(TLC), specific airways resistance, and specific airways conductance.  Tests were 
performed by the same investigator according to the American Thoracic Society / 
European Respiratory Society (ATS/ERS) guidelines.
289  The maximum of at least 
three technically satisfactory and reproducible manoeuvres  with less than 10% 
variation in FEV1 were accepted.  Significant reversibility was defined as greater 
than 12% increase in FEV1 15 minutes after inhalation of 400 µg of salbutamol, in 
agreement with ATS/ERS guidelines.
43  Values were corrected for body temperature, 
ambient pressure and water saturation.  Normal values were determined using the 
regression equations derived from the European coal and mineworkers’ database, 
including height, age and sex as independent variables.
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2.2.8  Transfer coefficient 
Diffusing capacity of the lung for carbon monoxide (DLCO) was quantified 
with the single breath technique using the Transflow System (Morgan Medical) 
corrected for haemoglobin concentration.  Carbon monoxide transfer coefficient 
(KCO) was calculated from DLCO adjusting for lung volume. 
 
2.3  Study medication 
 
2.3.1  Description 
•  Generic name bisoprolol fumarate. 
•  Proprietary name Cardicor. 
•  Anatomical Therapeutic Chemical classification system ATC Code: C07AB07. 
•  Active substance bisoprolol fumarate. 
•  Legal status POM. 
•  Principle characteristic β1-selective adrenoceptor blocking agent. 
•  Dosage 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg. 
•  Form film-coated tablet. 
•  Frequency once daily. 
•  Route oral. 
•  Manufacturer Merck Pharmaceuticals. 
•  Marketing authorisation number: PL 00493/0179 – 84. 
•  Blister container of a polyvinylchloride base film and an aluminium cover foil. 
•  Chemical name (±)-1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxyl-3-[(1-
methylethyl)amino]-2-propanol(E)-2-butenedloate (2:1) (salt).   78 
•  Empirical formula (C18H31NO4)2 • C4H4O4. 
•  Structure  asymmetric  carbon  atom,  racemic  mixture, S(-) enantiomer is 
responsible for most of the β-blocking activity. 
•  Molecular Weight 766.97. 
•  White crystalline powder. 
•  Approximately equally hydrophilic and lipophilic. 
 
2.3.2  Administration 
Merck Pharmaceuticals supplied bisoprolol and matching placebo.  
Packaging,  labelling  and dispensing of  all study medication was  performed by 
Glasgow Royal Infirmary Pharmacy in compliance with local regulations.  Eligible 
consenting patients were  assigned in equal proportions to receive bisoprolol or 
placebo according to a computer generated randomisation list.  Bisoprolol  was 
administered under supervision as coded identical tablets containing either bisoprolol 
or matching  placebo.  The starting dose of 1.25 mg once daily was increased 
successively to 2.5 mg, 5.0 mg, 7.5 mg, and 10 mg according to tolerance.  Patients 
were  instructed to take one tablet every morning with water without chewing or 
crushing.  A temporary dose down titration was permitted at any time in the event of 
an intolerable side effect believed to relate to study medication.  Subjects were re-
challenged at a higher dose once clinically acceptable. 
 
2.3.3  Compliance 
Medication compliance was evaluated  by  the number of pills prescribed 
compared to the number of pills ingested as reported by the subject and confirmed by   79 
counting the number of pills returned at each attendance.  Patients were reinstructed 
on correct medication usage if compliance was below 80% or above 120%. 
 
2.3.4  Concomitant medication 
The following concomitant medication were recorded in checkbox fashion in 
the electronic CRF: short-acting  β2-agonist, long-acting  β2-agonist, short-acting 
antimuscarinic, long-acting antimuscarinic, standard-dose corticosteroid, high-dose 
corticosteroid, modified-release oral theophylline, leukotriene receptor antagonist, 
nebulised short-acting  β2-agonist, nebulised anticholinergic, oral corticosteroid, 
aspirin, clopidogrel, warfarin, angiotensin converting enzyme inhibitor, angiotensin 
receptor blocker, digoxin, amiodarone, aldosterone blockers, statin. 
 
2.3.5  Prohibited medication 
Use of the following medications was prohibited in subjects entering the 
study and during the course of the study: non-dihydropyridine (diltiazem / verapamil) 
calcium  channel blockers,  clonidine,  monoamineoxidase inhibitors,  class-I 
antiarrhythmic drugs e.g. disopyramide, quinidine,  parasympathomimetic drugs, 
alternative  β-blockers,  ergotamine derivatives,  barbiturates,  mefloquine,  any 
investigative trial drug previous one month, previously documented hypersensitivity 
to bisoprolol or any excipients. 
 
2.3.6  Safety 
The sponsor’s reporting requirements under the EU Clinical Trials Directive 
are set out in the European Commission document, ‘Detailed guidance on the   80 
collection, verification and presentation of adverse reaction reports arising from 
clinical trials on medicinal products for human use’ (ENTR/CT3 revision 1, April 
2004).  The guidance describes requirements for reporting both to the competent 
authority and the ethics committee in each member state. In the UK, the competent 
authority is the MHRA and the ethics committee is the research ethics committee 
(REC) which gave a favourable opinion of the research.  Safety reports may be 
submitted by the sponsor, or by the sponsor’s representative, or by the chief 
investigator. 
 
2.3.7  Suspected unexpected serious adverse reactions 
The Medicines for Human Use (Clinical Trials) Regulations 2004 define an 
‘adverse reaction’ as  any untoward and unintended response in a subject to an 
investigational medicinal product which is related to any dose administered to that 
subject.  An adverse reaction is ‘unexpected’ if its nature and severity are not 
consistent with the information about the medicinal product in question set out in the 
case of a product with a marketing authorisation, in the summary of product 
characteristics for that product.  All Suspected Unexpected Serious Adverse 
Reactions (SUSARS) would be reported to the following three institutions. 
a) North Glasgow University Hospitals Division. 
b) Medicines and Healthcare products Regulatory. 
c) Local Research Ethics Committee. 
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2.3.8  Expected serious adverse events 
An adverse reaction is ‘serious’ if it  results in death,  is life-threatening, 
requires  hospitalisation  or prolongation of existing hospitalisation,  results in 
persistent or significant disability or incapacity, or consists of a congenital anomaly 
or birth defect.  There was no routine requirement to report serious adverse events 
(SAEs) other than SUSARs. 
All acute hospital admissions were reviewed and discussed with the receiving 
physician.  The aim was to continue the current study dose during an exacerbation of 
HF or COPD with a concurrent increase in appropriate therapy e.g. bronchodilators, 
diuretics.  The following services were considered non-serious: accident and 
emergency or casualty visits, outpatient and ambulatory procedures, day and short-
stay units, rehabilitation facilities, hospice facilities, respire care, nursing homes, 
custodial care facilities, general practitioner visits. 
 
2.3.9  Adverse Drug Reactions 
The following adverse drug reactions were defined. 
 
a)  Common (≥1% and <10%) 
•  feeling of coldness or numbness in the extremities. 
•  tiredness, exhaustion. 
•  dizziness. 
•  headache. 
•  nausea, vomiting, diarrhoea, constipation. 
   82 
b)  Uncommon (≥0.1% and <1%) 
•  muscular weakness and cramps. 
•  bradycardia, AV disturbances. 
•  worsening of heart failure. 
•  orthostatic hypotension. 
•  sleep disturbances. 
•  depression. 
•  bronchospasm. 
 
c)  Rare (≥0.01% and <0.1%) 
•  nightmares, hallucinations. 
•  hypersensitivity reactions (itching, flush, rash). 
•  increased liver enzymes (ALT, AST), hepatitis. 
•  increased triglycerides. 
•  potency disorders. 
•  hearing impairment. 
•  allergic rhinitis. 
•  dry eyes, conjunctivitis. 
•  provoke or worsen psoriasis or induce psoriasis-like rash. 
•  alopecia. 
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2.3.10  Discontinuations 
A discontinuation was defined by an enrolled subject ceasing participation in 
the study prior to completion of the protocol.  The primary reason for discontinuation 
was recorded in the CRF and appropriate follow-up arranged for the patient. 
 
2.4  Ethical considerations 
 
2.4.1  Good clinical practice 
The study  was  conducted in compliance with accepted standards of the 
International Conference on Harmonisation Good Clinical Practice guidelines, and 
conformed with all national and local laws, rules and regulations relating to clinical 
study conduct.  The protocol was approved by the local hospital Research Ethics 
Committee via the Central Office for Research Ethics Committees. 
 
2.4.2  Informed consent 
During the screening visit an unambiguous written patient information sheet 
in simple language was provided, with sufficient time to fully read this information.  
The study was then discussed in greater detail, allowing for specific questions and 
providing additional information regarding the study.  Each potential subject was 
adequately informed of the aims, methods, anticipated benefits and potential risks of 
the study and any discomfort it may entail.  Patients were informed of their liberty to 
abstain from participation in the study and freedom to withdraw consent to 
participation at any time.  Those who agree to participate in the study were invited to 
attend the Respiratory Function Laboratory at Glasgow Royal Infirmary on a later   84 
date and to read the patient information sheet again at home in the interim.  Freely 
given written informed consent was obtained from all subjects before enrolment. 
 
2.4.3  Confidentiality 
Patients were assigned an individual participant number immediately after 
providing written informed consent.  All electronic documents pertaining to personal 
data, study protocol and results were stored securely by the investigator on home and 
laptop personal computers, solely accessible by the investigator. 
 
2.4.4  Monitoring 
Continuous monitoring was  undertaken throughout by supervisors Dr FG 
Dunn, Dr G Chalmers and Dr R Carter.  The study was subject to review at any time 
by the West Glasgow Local Research Ethics Committee. 
 
2.4.5  Amendments 
A notice of amendment was submitted to the Research Ethics Committee  and 
the Medicines and Healthcare products Regulatory Agency in the event of any 
substantial amendment to the Clinical Trial Authorisation, study protocol, or 
supporting documentation.  A substantial amendment was defined as any amendment 
that is likely to affect to a significant degree:  the safety or physical or mental 
integrity of the trial participants,  the scientific value of the trial,  the conduct or 
management of the trial,  the quality or safety of any investigational medicinal 
product used in the trial. 
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2.4.6  Sponsor 
North Glasgow University Hospitals Division served as trial sponsor. 
 
2.4.7  Registration numbers 
ClinicalTrials.gov, number: NCT00702156 
European Clinical Trials Database (EudraCT) Number: 2004-005152-14 
REC reference number: 05/S0709/2 
 
2.5  Recruitment 
 
2.5.1  Methods 
 
Patients suitable to participate in the study were contacted initially by 
telephone or in person during the hospital admission or out-patient department visit.  
The nature of the study was verbally explained and patients were asked if they were 
interested in participating.  Those expressing an interest were invited to attend for a 
screening visit. 
Study participants were identified by screening of patients within a single 
domain (North Glasgow University Hospitals Division) at three hospital sites 
(Stobhill Hospital, Royal Infirmary, Western Infirmary).  Screening sources included 
the heart failure nurse led service database, cardiology out-patient clinics, emergency 
or elective admissions to the cardiology or general medical wards, and 
correspondence relating to outpatient clinics and hospital discharges.   86 
Numerous strategies were employed to improve recruitment.  Additional sites 
were added through major protocol amendments, including the Victoria Infirmary.  
Patients attending the transplant unit and chest clinics were screened.  The study 
outline and enrolment criteria were presented to groups involved in the care of 
potential patients.  These were followed up using written material, emails, phone 
calls and personal visits.  Posters and information leaflets were provided in the 
relevant clinical areas. 
 
2.5.2  Limitations 
 
Recruitment was challenging for numerous reasons.  Surprisingly few 
patients had moderate to severe airflow obstruction.  Many had only mild airflow 
obstruction or were misdiagnosed with COPD.  Similarly, patients were unsuitable 
due to misdiagnosis of HF, isolated right heart failure, or heart failure with preserved 
ejection fraction.    Many patients with COPD were already prescribed β-blockers.  
β-blockers were often contraindicated or considered inappropriate for reasons other 
than COPD.  These included atrioventricular block, bradycardia, hypotension, 
asthma, dementia, poor compliance, advanced malignancy and palliative care.  
Diltiazem use was surprisingly common and difficult to substitute with study 
medicine that may be placebo.  Physical incapacity, extensive comorbidities  and 
reluctance to visit hospital were problematic in this elderly population.  Finally, 
patients with HF and  COPD had significant symptoms and were reluctant to 
participate in a trial, particularly during the winter months. 
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Chapter 3 
 
Bisoprolol in patients with heart failure and moderate to 
severe chronic obstructive pulmonary disease; a 
randomised controlled trial. 
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3.1  Introduction 
 
Heart failure and chronic obstructive pulmonary disease are global epidemics, 
each affecting in excess of ten million patients.
4,5  The combination presents many 
diagnostic and therapeutic dilemmas.
1  International guidelines are clear in defining 
the unequivocal morbidity and mortality benefits of β-blockade in patients with 
HF.
4,158  They are less clear in defining when, or indeed whether, β-blockers should 
be avoided in patients with COPD (with or without reversible airflow obstruction).  
Pulmonary  disease  was  the  most  powerful  independent  predictor  of  β-blocker 
underutilisation in the Euro Heart Failure Survey (odds ratio 0.35 [95% CI 0.30 – 
0.40]).
173  Concerns stem from reports of acute bronchospasm in asthmatic patients 
given non-cardioselective β-blockers.
161-163  No study has prospectively examined β-
blockade tolerability and efficacy in populations with both HF and COPD.  The 
evidence derives from those with COPD alone.  We  conducted a randomised, 
double-blind, placebo controlled study examining the effect of bisoprolol on 
pulmonary function and quality of life in patients with HF and coexistent moderate to 
severe COPD. 
 
3.2  Methods 
 
3.2.1  Study design 
The primary research objective was to demonstrate that cardioselective β-
blockade using bisoprolol was not inferior to placebo with regard to pulmonary 
function in patients with HF and coexistent moderate to severe COPD with or   89 
without significant reversibility.  Secondary outcomes included health status, 
dyspnoea ratings and arterial gases.  The study was approved by the regional ethics 
committee and all patients provided written informed consent.  Patients were 
prospectively randomised in equal proportions and double-blind manner to receive 
bisoprolol or matching placebo.  A sample size of 126 was estimated to provide 80% 
power (α=0.05) to detect equivalent pulmonary function (difference FEV1 less than 
0.2 litres), assuming a standard deviation of 0.45 litres.  The study is registered with 
ClinicalTrials.gov, number: NCT00702156.  Recruitment commenced in March 2005 
and was terminated in July 2008 after limited enrolment. 
 
3.2.2  Entry criteria 
The principal inclusion criteria were: 1) stable symptomatic HF; 2) LVEF < 
40% by echocardiography or radionuclide ventriculography; 3) moderate or severe 
COPD defined by the Global Initiative for Chronic Obstructive Lung Disease criteria 
(Table  1.1); 4) a minimum 10 pack year smoking history.  Reversible airflow 
obstruction was not an exclusion criteria, unless in conjunction with pre-existing 
asthma. 
The principal exclusion criteria included standard contraindications to β-
blocker therapy: atrioventricular block greater than first degree without a pacemaker; 
bradycardia less than 60 beats per minute, systolic blood pressure less than 100 
mmHg; acute heart failure or cardiogenic shock; peripheral arterial disease with 
symptoms at rest; and standard clinical criteria of asthma including young age of 
symptom onset or response to provocative stimuli.  Concurrent treatment with non-  90 
dihydropyridine  calcium  channel blockers, antiarrhythmic drugs other than 
amiodarone and digitalis, and alternative β-blockers was not permitted. 
 
3.2.3  Protocol 
Patients attended one baseline and initiation visit (Day 0) and 5 follow up 
visits over 4 months (Weeks 2, 4, 8, 12, 16).  Medication was administered under 
supervision.  The starting dose of 1.25 mg once daily was increased successively to 
2.5 mg, 5.0 mg, 7.5 mg, and 10 mg according to tolerance.  In patients with 
worsening HF, baseline therapy was increased before the study drug was decreased.  
Each visit included evaluation of symptoms, physical signs, pulse oximetry, health 
status, peak expiratory flow, spirometry and body plethysmography.  All patients 
were clinically euvolaemic at the time of pulmonary function testing.  Carbon 
monoxide transfer factor, electrocardiography and arterialised earlobe capillary blood 
gases were performed at study onset and completion.  Health status was assessed 
using one generic and two disease specific instruments at each visit: the Short Form 
36, Chronic Respiratory Questionnaire and the Minnesota Living with Heart Failure 
Questionnaire.
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3.2.4  Pulmonary function tests 
Spirometry and lung volumes were measured using body plethysmography 
(Sensormedics, V6200 Autobox, California, USA) 3 hours after administration of 
study medication and at least 12 hours after inhaled bronchodilators.  The variables 
measured were FEV1, vital capacity, residual volume, total lung capacity, specific 
airways resistance, and specific airways conductance.  Diffusing capacity of the lung   91 
for carbon monoxide was quantified with the single breath technique using the 
Transflow System (Morgan Medical) corrected for haemoglobin concentration.  
Carbon monoxide transfer coefficient was calculated from DLCO adjusting for lung 
volume.  Tests were performed by the same investigator according to the American 
Thoracic Society / European Respiratory Society (ATS/ERS) guidelines.
289  The 
maximum of at least three technically satisfactory and reproducible manoeuvres with 
less than 10% variation in FEV1 were accepted.  Significant reversibility was defined 
as greater than 12% increase in FEV1  15 minutes after inhalation of 400 µg of 
salbutamol, in agreement with ATS/ERS guidelines.
43  Values were corrected for 
body temperature, ambient pressure and water saturation.  Normal values were 
determined using the regression equations derived from the European coal and 
mineworkers’ database, including height, age and sex as independent variables.
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3.2.5  Statistical analysis 
Baseline characteristics of patients are presented as means with standard 
deviations for continuous variables or by frequencies and percents for categorical 
variables.  The data were assessed for normality using the Shapiro-Wilk’s test.  
Means were compared using the Wilcoxon rank sum test or Student t-test (with 
Levene’s test for equality of variances) depending on the distribution of the data.  
Proportions were compared using the Chi-square test, or Fisher’s Exact test when the 
observed frequencies were less than five.  A 2-tailed P value of less than 0.05 was 
considered statistically significant.  All analyses were performed on an intention to 
treat basis.  Pulmonary function and quality of life scores were analysed as change   92 
from baseline to the final visit, comparing bisoprolol and placebo groups.  Statistical 
analyses were performed using SPSS Version 13 (SPSS Inc., Chicago, Illinois). 
 
3.3  Results 
 
3.3.1  Recruitment 
  458 patients with a case record diagnosis of HF and COPD were identified.  
Of these, 27 patients were enrolled.  The remainder were excluded for the following 
reasons: existing β-blocker therapy (n=144), no airflow obstruction on spirometric 
testing (n=43), heart failure with preserved ejection fraction (n=36), mild airflow 
obstruction (n=27), concurrent diltiazem (n=26), declined participation (n=24), 
asthma (n=22), physical incapacity (n=22), heart failure secondary to valvular heart 
disease (n=18), cancer or receiving palliative care (n=16), hypotension (n=11), 
bradycardia (n=9), dementia (n=9), poor compliance (n=8), cor pulmonale with 
preserved left ventricular systolic function (n=6), very severe airflow obstruction 
(n=6), and atrioventricular block (n=4).   
 
3.3.2  Baseline Characteristics and Titration 
The baseline characteristics of each group were comparable (Table 3.1).  
Patients were elderly (mean age 70.8  ±  9.1 years) and predominantly male.  
Cardiovascular comorbidity and smoking history were similar in the two groups 
(48.6 vs 43.4 pack years, p=0.64).  All patients were receiving treatment with either 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers, diuretics   93 
and inhaled β-agonists.  Resting heart rates were alike, but blood pressure was 
greater in the bisoprolol group (129/69 vs 117/63, p=0.02). 
 
Table 3.1  Baseline characteristics and details of bisoprolol titration 
 
mean ± SD or n (%)  Bisoprolol 
n=14 
Placebo 
n=13 
Demographics     
Age (years)  72.8 ± 7.4  68.7 ± 10.6 
Male Sex  9  (64)  10 (77) 
Body Mass Index  29.2 ± 5.6  26.9 ± 4.4 
Smoking History (Pack Years)  48.6 ± 33.3  43.4 ± 22.0 
Airflow Obstruction     
FEV1  1.37 ± 0.42  1.26 ± 0.42 
Percent predicted normal value (%)  57 ± 15  50 ± 14 
GOLD Moderate  9 (64)  7 (54) 
GOLD Severe  5 (36)  6 (46) 
Reversibility     
FEV1 change post salbutamol  0.11 ± 0.08  0.22 ± 0.19 
FEV1 percent reversibility (%)  10.4 ± 10.8  17.9 ± 17.9 
Proportion > 12% reversibility  5 (36)  7 (54) 
Cardiovascular History     
Ejection Fraction (%)  28.1 ± 5.9  27.1 ± 6.2 
Angina  4 (29)  4 (31) 
Myocardial infarction  5 (36)  6 (46) 
Atrial fibrillation  4 (29)  3 (23) 
Medications     
ACEI or angiotensin receptor blocker  14 (100)  13 (100) 
Diuretic  14 (100)  13 (100) 
Inhaled β-agonist  14 (100)  13 (100) 
Inhaled antimuscarinic  6 (43)  8 (62) 
Inhaled steroid  9 (64)  10 (77) 
Examination     
Heart rate baseline (beats/min)  82.9 ± 15.7  84.5 ± 15.9 
Systolic BP (mm Hg)  128.9 ± 14.0*  116.8 ± 9.5 
 
*P<0.05 compared with placebo 
 
 
Mean baseline FEV1 was 1.37 L (57% predicted) and 1.26 L (50% predicted) 
in those receiving bisoprolol and placebo respectively (p=0.52).  Similar proportions 
were classified as having moderate or severe airflow obstruction.  Peak expiratory 
flow rates were also comparable (209 L/min vs 216 L/min respectively).  Significant 
reversibility, defined as >12% increase post salbutamol, was observed in 36% of   94 
patients receiving bisoprolol and 54% of those allocated to placebo (p=NS).  Mean 
baseline residual volume was increased in both groups, consistent with gas trapping 
secondary to airflow obstruction (respectively 2.85 L vs 3.21 L, 118% vs 138% 
predicted, p=0.37). 
The mean final dose of study medication was 7.3 mg and 8.4 mg in the 
bisoprolol and placebo groups respectively.  Titration was limited by bradycardia in 
6 patients receiving β-blockade, but in none receiving placebo (p=0.02).  During 
titration the mean heart rate reduction for bisoprolol compared to placebo was 21.0 
beats per minute (p<0.001).  This was paralleled by a non-significant decrease in 
systolic blood pressure of 6.6 mmHg relative to placebo.  Two patients in each group 
withdrew during the course of the study, citing fatigue (bisoprolol), personal reasons 
(bisoprolol), dyspnoea (placebo) and insomnia (placebo). 
 
3.3.3  Effect of Bisoprolol on Pulmonary Function 
A significant reduction in pre-bronchodilator FEV1 occurred after 4 months 
following treatment with bisoprolol compared with placebo (–70 ml vs +120 ml, 
p=0.01).  An analogous trend in PEF was observed (–13 L/min vs +12 L/min, 
p=0.06).  Post-bronchodilator FEV1 was also reduced (respectively –90 ml vs +20 
ml, p=0.03).  Reversibility following inhaled β2-agonist  was not however 
significantly impaired by bisoprolol (Table 3.2). 
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Table 3.2  Effect of bisoprolol on pulmonary function 
 
mean ± SD  Bisoprolol 
n=14 
Placebo 
n=13 
FEV1 (L)     
Baseline  1.37 ± 0.42  1.26 ± 0.42 
Change  -0.07 ± 0.08*  0.12 ± 0.21 
FEV1 Reversibility (L)     
Baseline  0.11 ± 0.08  0.22 ± 0.19 
Change  -0.03 ± 0.09  -0.10 ± 0.08 
FEV1 Post Salbutamol (L)     
Baseline  1.48 ± 0.40  1.48 ± 0.50 
Change  -0.09 ± 0.10*  0.02 ± 0.15 
Peak Expiratory Flow (L/min)     
Baseline  209 ± 60  216 ± 75 
Change  -13 ± 17  12 ± 40 
Vital Capacity (L)     
Baseline  2.66 ± 0.91  2.56 ± 0.74 
Change  -0.07 ± 0.19  0.10 ± 0.30 
Residual Volume (L)     
Baseline  2.85 ± 0.94  3.21 ± 1.09 
Percent Predicted Normal Value (%)  118 ± 29  138 ± 44 
Change  0.06 ± 0.56  -0.04 ± 0.51 
Total Lung Capacity (L)     
Baseline  5.51 ± 1.35  5.83 ± 1.25 
Change  -0.01 ± 0.57  -0.02 ± 0.54 
 
*P<0.05 compared with placebo 
 
 
The mean bronchodilator response in those receiving bisoprolol (+90 ml) was 
of similar magnitude to the reduction in FEV1  from baseline.  Lung volumes 
including VC and TLC were unaffected.  Residual volume, which reflects the degree 
of air trapping, exhibited no significant change (+60 ml vs –40 ml, p=0.63).  Given 
the small patient numbers, the change in FEV1  from baseline was examined by 
scatterplot for consistency and outliers (Figure 3.1).  This confirmed an increase in 
airflow obstruction in most patients. 
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Figure 3.1  Mean change in forced expiratory volume with bisoprolol 
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3.3.4  Health Status 
All measures of health status exhibited non-significant trends to improvement 
in patients receiving bisoprolol (Table 3.3).  The SF-36 physical and mental 
component scores both increased relative to placebo (2.6 vs 0.5 and 0.8 vs –0.3 
respectively).  Similarly, the MLHFQ score decreased (–2.5 vs 3.5) and CRQ total 
increased (0.07 vs –0.24), both indicating improvement.  Finally, the CRQ 
component score examining dyspnoea also increased (0.51 vs –0.14).  The mean 
number of exacerbations of COPD during the study was similar in the bisoprolol and 
placebo groups (respectively 0.50 and 0.31, p=0.44).   97 
 
Table 3.3  Effect of bisoprolol on health status* 
 
mean ± SD  Bisoprolol 
n=14 
Placebo 
n=13 
SF-36 PCS     
Baseline  31.7 ± 7.5  32.6 ± 8.1 
Change   2.6 ± 5.4  0.5 ± 4.5 
SF-36 MCS     
Baseline  42.3 ± 9.9  38.6 ± 11.8 
Change   0.8 ± 6.0  -0.3 ± 9.5 
MLHFQ     
Baseline  49.4 ± 25.5  47.4 ± 21.0 
Change   -2.5 ± 12.3  3.5 ± 11.1 
CRQ Total     
Baseline  3.94 ± 0.85  3.75 ± 0.95 
Change   0.07 ± 0.64  -0.24 ± 0.68 
CRQ Dyspnoea     
Baseline  2.57 ± 0.81  3.08 ± 1.22 
Change  0.51 ± 1.19  -0.14 ± 1.27 
 
* For all scales, except MLHFQ, a positive change equates to an improvement; for MLHFQ, a 
negative change equates to improvement.  SF-36 = Short Form 36; PCS = physical component score; 
MCS = mental component score; MLHFQ = Minnesota Living with Heart Failure Questionnaire; 
CRQ = Chronic Respiratory Questionnaire 
 
 
3.3.5  Arterial blood gases and diffusing capacity of lung 
Baseline blood gases revealed significant hypoxaemia (Table 3.4).  Mean 
resting partial pressure of oxygen (PaO2) was similar in the bisoprolol and placebo 
groups (9.49 vs 8.83, p=0.09).  Resting partial pressure of carbon dioxide (PaCO2) 
was also comparable (5.10 vs 5.48, p=0.09).  No significant change occurred in 
PaO2, PaCO2 or oxygen saturation following treatment with bisoprolol as compared 
to placebo.  Baseline transfer coefficient was impaired in both groups, respectively 
58% and 54% of predicted normal values.  A significant reduction in transfer 
coefficient was observed in those receiving bisoprolol relative to placebo (-0.33 
mmol/min/kPa/l vs 0.17 mmol/min/kPa/l, p=0.01). 
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Table 3.4  Effect of bisoprolol on transfer coefficient and blood gases 
 
mean ± SD   Bisoprolol 
n=14 
Placebo 
n=13 
Transfer coefficient (mmol/min/kPa/l)     
Baseline  4.49 ± 1.52  4.36 ± 1.60 
Percent Predicted Normal Value (%)  58 ± 19  54 ± 15 
Change  -0.33 ± 0.45*  0.17 ± 0.50 
PaO2 (kPa)     
Baseline  9.49 ± 0.90  8.83 ± 1.00 
Change  -0.30 ± 0.85  0.26 ± 1.27 
PaCO2 (kPa)     
Baseline  5.10 ± 0.29  5.48 ± 0.70 
Change  0.10 ± 0.36  -0.15 ± 0.63 
SaO2 (%)     
Baseline  95.6 ± 1.45*  93.5 ± 3.27 
Change  -0.55 ± 1.61  0.12 ± 3.71 
 
*P<0.05 compared with placebo 
 
PaO2  = partial pressure of oxygen; PaCO2  = partial pressure of carbon dioxide; SaO2  = oxygen 
saturation 
 
 
3.4  Discussion 
 
This is the first randomised  controlled study to examine the effect of β-
blockade in patients with heart failure and concurrent COPD.  An especially 
challenging group of patients with heart failure was selected to study the effects of 
bisoprolol:  those with moderate or severe COPD with and without reversibility, who 
physicians had thus far not considered candidates for β-blockers.  Participants 
exhibited significant airflow obstruction (mean FEV1 1.32 L) akin to previous studies 
in moderate to severe COPD.
194,196,198,276,291  The mean dose (7.3 mg) and heart rate 
reduction (21.0 bpm) compare favourably with the CIBIS II trial (7.5 mg and 9.8 
bpm).
292  The study has the longest follow up period of any placebo controlled trial 
of  β-blockade in COPD, and additionally reports the impact on quality of life.  
Several key findings emerged.  Treatment with bisoprolol was associated with an   99 
increase in airflow obstruction.  Bronchodilator response to inhaled β2-agonist was 
preserved.    While  baseline  health  status  was  significantly  impaired,  β-blockade 
exerted no adverse effect on health related quality of life or functional status. 
A Cochrane Library meta-analysis concluded that long term cardioselective 
β-blockade is safe and well tolerated in COPD.
2,180  This evaluated pulmonary 
function in 20 randomised, controlled trials of cardioselective β-blockers in patients 
with COPD.  The available evidence has major limitations.  Only two studies 
involved greater than 20 patients,
192,198  two were single rather than double-
blinded,
196,197 and others lacked placebo controls.
182,192,193,196  Not one study included 
patients with HF.  Eleven trials involved single doses and only one lasted longer than 
a month.
192  The effect of long  term  β-blockade is therefore largely unknown.  
Information is particularly limited for β-blockers conferring benefit in HF: only two 
single dose studies used bisoprolol,
190,191 and none carvedilol.  The present report in 
part addresses these shortcomings. 
The FEV1 response to bisoprolol was consistent with existing evidence.  The 
Cochrane analysis observed no significant change in FEV1  with longer term 
cardioselective β-blockade (–2.39% [CI –5.69% to 0.91%]).
2  However, the trials 
included in the meta-analysis exhibited a degree of heterogeneity.  In the longest 
study of patients with severe COPD, atenolol and metoprolol each significantly 
reduced FEV1 by around 10% over four weeks.
195  I observed a reduction in FEV1 of 
similar magnitude (post-bronchodilator 110 ml, 7%).  The two prior randomised 
controlled studies of bisoprolol administered only single doses in patients with mild 
to moderate COPD.
190,191  The  bronchodilator  response  to  the  inhaled  β2-agonist   100 
salbutamol was unaffected.  The present study corroborates these findings in more 
severe airflow obstruction over longer term follow up. 
The findings have sound physiological rationale.  Bronchodilatation is 
mediated by autonomic muscarinic cholinoceptors and β adrenoceptors, the dominant 
subtypes being M3  and  β2  respectively.
293  Β-blocker cardioselectivity is dose 
dependent, with competitive antagonism of both β1 and β2-adrenoceptors occurring at 
higher plasma concentrations.
175,294-296  With higher doses of cardioselective β-
blockers, β2 receptor blockade may cause minor increases in airflow obstruction in 
susceptible patients,
201,294-296  possibly through unopposed parasympathetic 
bronchoconstriction.
293,297  Bisoprolol is highly β1-selective, providing a wide split 
between β1 and β2-adrenoceptor blockade.
175,190,191,295,296,298  At therapeutic levels, 
response to β2-agonists remains largely preserved and counteracts any change in 
airway resistance.
190,191,294,296,299 
Patients with HF or  COPD have a high symptom burden which is often 
overlooked by traditional assessments.
300  No previous study has formally assessed 
health status or symptoms in patients with both conditions.  The mean baseline 
scores all indicated worse health status than in two contemporary studies involving 
50 and 30 patients with heart failure: mean MLHFQ 48.4 ± 23.0 (versus 41.8 ± 24.9 
and 44.5 ± 26.6); mean SF-36 PCS 32.1 ± 7.7 (versus 33.5 ± 10.7 and 32.8 ± 8.8); 
mean SF-36 MCS 40.5 ± 10.8 (versus 48.7 ± 10.3 and 46.6 ± 12.0).
280,301  The mean 
CRQ dyspnoea score of 2.8 ± 1.0 was similar to that in trials of pulmonary 
rehabilitation involving patients with moderate to severe COPD.
278,286  My results 
suggest that patients with both HF and COPD have significantly impaired quality of   101 
life.  This highlights the need for strategies to detect and improve symptoms as well 
as prognosis. 
To my knowledge, the effect of β-blockade on health status has never been 
assessed in any cohort with COPD.  Many studies only describe dyspnoea of 
sufficient magnitude to merit voluntary self-reporting.  Moderate and less acute 
symptoms may be inadequately assessed.  The perception of respiratory effort and 
associated distress is subjective and variable with time, reflecting a complex 
interaction between psychology and physiology.
203  No trial formally graded 
dyspnoea at baseline and follow-up using validated scales.  Furthermore, 
quantification based on physical exertion also fails to reflect mental health and social 
functioning.
204  My results are encouraging for three reasons.  Most importantly, β-
blockade exerted no adverse effect on health related quality of life or functional 
status.    Secondly, all three measures of health status and components including 
dyspnoea score improved.  Though not statistically significant, the consistent 
directionality of change is reassuring.  Finally, the observations are concordant with 
the stable residual volume, as hyperinflation predicts exercise capacity better than 
FEV1.
302 
Resting hypoxaemia reflects the severity of gas exchange impairment and 
predicts prognosis in patients with COPD.
303  The mean PaO2 and PaCO2 of my 
cohort were similar to previous trials in severe airflow obstruction,
195,304 and not 
significantly influenced by bisoprolol.  This corroborates a prior study in 12 patients 
with severe COPD, in which gas tensions were unaffected by metoprolol over a 4 
week period.
195  The reduction in transfer coefficient confirms reports using 
carvedilol and propranolol.
305,306  However, in a recent study bisoprolol increased   102 
diffusing capacity of the lung compared to carvedilol in 53 patients with HF.
299  This 
was attributed to changes in membrane conductance relating to regulation of alveolar 
fluid balance mediated by β2-receptors.  Differences in population and study design 
may explain the disparity.  Lung diffusing capacity depends on ventilation, 
membrane conductance and capillary blood volume.  My patients had significant 
airflow obstruction (mean FEV1 1.32 L vs 2.71 L) and received higher doses of 
bisoprolol (7.3 mg vs 4.8 mg) than in the aforementioned study.  I also compared 
bisoprolol to placebo as opposed to carvedilol, which reduces DLCO in patients with 
HF.
305 
Several shortcomings must be acknowledged, foremost being the limited 
recruitment.  Many patients tolerated β-blockers, had preserved ejection fraction, or 
only mild airflow obstruction.  β-blockers were often contraindicated or considered 
inappropriate for reasons other than COPD.  Finally, physical incapacity and 
reluctance to visit hospital were problematic in this elderly population.   This 
information should prove useful when planning future β-blocker trials in patients 
with HF and COPD.  The limited numbers increase the risk of type II statistical error, 
namely of missing a real difference.  For example, the current sample size provides 
63% power to detect a reduction in mean SF-36 PCS of 6.0 (the accepted minimal 
important difference) using the observed standard deviation of 7.7.  The advanced 
age and comorbidity of patients prohibited cardiopulmonary exercise  testing.  
Assessment of oxygen consumption, anaerobic threshold and ventilatory response 
would improve our understanding of the exertional impairment that characterises this 
patient cohort.  Finally, measurement of diffusion components using the Roughton   103 
and Forster method was not included in the protocol to reduce patient burden.  The 
mechanism of reduction in diffusing capacity is therefore uncertain. 
 
3.5  Conclusion 
 
Patients with HF and COPD represent a large and often ignored population.  
For the first time, I  have prospectively examined the controversial issue of β-
blockade in patients with both conditions.  A significant reduction in FEV1  was 
observed following treatment with bisoprolol.  No reduction in quality of life 
accompanied this change.  These  findings pose crucial questions and provide 
direction for larger randomised controlled trials.  Is an asymptomatic reduction in 
FEV1 an acceptable sacrifice given the established prognostic benefits of β-blockers?  
Will symptoms and quality of life improve significantly over longer follow up?  Are 
the effects of β-blockade on airflow obstruction and reversibility dose dependent?  
Would combining long acting β-agonist and antimuscarinic therapy offset the effects 
of β-blockade?  Robust clinical trials are required to provide the answers which may 
finally allay physicians’ mistrust of β-blockers in patients with COPD. 
 
   104 
 
Chapter 4 
 
Primary care burden and treatment of patients with heart 
failure and chronic obstructive pulmonary disease in 
Scotland.   105 
4.1  Introduction 
 
Heart failure is an important public health problem in industrialised countries 
with ageing populations.
88,307  Chronic obstructive pulmonary disease is among the 
commonest reasons for consulting a general practitioner and frequently coexists with 
heart failure.
88  Both conditions are increasing in prevalence and present significant 
challenges to healthcare providers.
4,308,309  Few reports have addressed this often 
ignored combined presentation of disease,
61 and fewer still the consequences of both 
conditions co-existing in the community.
137  In randomised controlled trials, many 
drugs confer significant morbidity and mortality benefits in patients with HF: 
angiotensin converting enzyme inhibitors, β-blockers, spironolactone and angiotensin 
receptor blockers.  Uptake of these advancements into routine clinical care has been 
limited.
88  Concurrent COPD is often cited as an obstacle to implementing β-
blockers.
310  
To further understand the relationship between these two conditions, this 
study examines  the incidence and prevalence of COPD in patients with HF in 
Scotland.  The  study focuses on temporal trends, age related variation, and 
socioeconomic differences. Finally, the comorbid diagnoses and prescribed 
treatments in patients with and without COPD are described. 
 
4.2  Methods 
 
  In Scotland every citizen receives free primary care through the National 
Health Service, and all patients receiving emergency hospital care are discharged   106 
back to the care of their general practitioner (GP).  All prescriptions are provided via 
primary care, with the exception of a short supply of drugs provided by hospitals 
immediately after a patient is discharged from hospital.  Subsequent repeat 
prescriptions are provided through primary care, as are those for treatments 
recommended during hospital clinic visits.  The continuous morbidity recording 
(CMR) scheme prospectively collects detailed information from primary care 
practices.
88,311  Practices are weighted to form a national sample that is broadly 
representative of the whole population in terms of age, sex, socioeconomic status and 
rural-urban mix.
311  By 2004, 61 practices with 377,439  patients (covering 
approximately 7% of the Scottish population) had participated in the CMR and 
contributed data to the Primary Care Clinical Informatics Unit at the University of 
Aberdeen.  The scheme allows accurate estimates of the national prevalence, 
incidence, consultation rates, concomitant medical problems and drug treatment for 
patients with heart failure in primary care.
88 
Practices participating in the CMR scheme record every face to face contact 
between patients and doctors (including temporary residents and locum doctors).  For 
each contact doctors may record up to 10 problems, describing each as specifically as 
possible in diagnostic terms.  Each diagnosis is assigned a Read code and ‘modifier’ 
of ‘first’, ‘recurrent’ or ‘persistent’ to denote whether the problem is new, recurrence 
of a previous problem or a continuing problem, respectively.  Details of drugs 
prescribed and repeat prescriptions are also recorded.  A quality assurance 
programme of rolling practice visits compares CMR data with practice held records. 
From 1 April 1999 to 31 March 2004, all patients diagnosed with HF (Read 
codes: G58.. and below, G34y., G34y1 and G34y2) or COPD (H3…, H31.. and   107 
below (excluding H3101, H31y0, H3122), H32.. and below, and H36.. to H3z..) were 
identified. The period prevalence for each condition was estimated using the 
alternate condition as denominator.  The incidence was estimated by including all 
patients with a Read code modifier of ‘first’.  Contact rates were determined as the 
total number of consultations involving that condition (‘contacts’) over the year.  
Indirect standardisation was used to adjust incidence, prevalence and contact rates 
for age and sex differences in the practice population.
312  Individuals were assigned a 
Carstairs deprivation category (a validated measure of socioeconomic status) from 
one (least deprived) to five (most deprived) based on postcodes of residence.
313  
These categories are derived from 1991 census data on the proportion of residents 
who are unemployed, occupy overcrowded accommodation, lack a car, or belong to a 
low occupational social class. 
Comorbidity and prescribing data were compared in  patients with and 
without COPD.  A two-tailed P value of less than 0.05 was considered statistically 
significant.  Chi square tests, z tests and exact tests were used where appropriate for 
categorical data, proportions and means.  Logistic regression was used to determine 
factors associated with the prescription of β-blockers.  Variables were entered into 
the model based on clinical relevance and published predictors of β-blocker use. The 
final model included the following covariates: age, sex, year, and presence of COPD, 
angina, previous myocardial infarction, atrial fibrillation and hypertension.  Age was 
treated as a continuous variable.  Adjusted odds ratios and 95% confidence intervals 
were calculated.  All analyses were performed using SPSS for Windows v16.0 (SPSS 
Inc., Chicago, Illinois). 
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4.3  Results 
 
4.3.1  Prevalence of HF and COPD in the general population 
  The crude prevalence of clinically reported HF in the CMR population 
increased from 1.31% in 1999 to 1.55% in 2002, but appeared to plateau thereafter.  
By contrast, the prevalence of COPD increased every year rising from 2.35% to 
3.10% in 2004 (p for trend <0.001), becoming nearly twice as prevalent as HF. 
 
4.3.2  Prevalence of COPD in patients with HF 
As in the general population, the crude prevalence of COPD in patients with 
HF increased every year between 1999 and 2004, from 19.8% to 23.8% (Table 4.1).  
The age standardised prevalence also rose over this period (p=0.003). 
 
Table 4.1  Prevalence and incidence of COPD (per 100 population with HF), 
stratified by year 
 
Year  CMR 
Population 
Prevalence 
of HF (n) 
Prevalence of 
COPD (n) 
Prevalence 
of COPD in 
HF patients 
(n) 
Age 
standardised 
prevalence 
of COPD in 
HF patients 
Incidence 
of COPD in 
HF patients 
(n) 
Age 
standardised 
incidence of 
COPD in 
HF patients 
1999  354041  1.31 (4628)  2.35 (8309)  19.8 (916)  9.7  1.6 (73)  0.3 
2000  376085  1.40 (5253)  2.51 (9447)  20.5 (1078)  9.9  1.2 (63)  0.3 
2001  375916  1.49 (5590)  2.70 (10162)  21.8 (1217)  11.8  1.3 (71)  0.3 
2002  375280  1.55 (5829)  2.89 (10853)  22.9 (1333)  12.6  1.2 (68)  0.7 
2003  372967  1.56 (5826)  3.00 (11188)  23.6 (1375)  13.9  1.3 (75)  0.7 
2004  374893  1.56 (5834)  3.10 (11631)  23.8 (1389)  13.5  1.3 (77)  0.9 
p for trend    0.007  <0.001  0.001  0.003  0.340  0.017 
 
Age, gender and socioeconomic differences were examined in the most recent 
year, 2004 (Tables 4.2 and 4.3).  The prevalence of COPD was similar in men and 
women (24.8% vs 22.9%).  Prevalence was lowest in younger patients with heart 
failure (9.4%), rising to around 26% in those aged 55 to 85 years, before declining to   109 
18.0% in those aged over 85 years.  The prevalence of COPD increased with greater 
socioeconomic deprivation rising from 18.6% in the least deprived to 31.3% in the 
most deprived group (rate ratio 1.27 [95% CI 1.05–1.55], p=0.01).  The prevalence 
of smoking likewise rose from 24.9% to 42.1% in the least and most deprived 
stratum respectively (p=0.011) (Table 4.3). 
 
Table 4.2  Prevalence, incidence and contact rates for COPD (per 100 population 
with HF), stratified by age and sex for April 2003 to March 2004 
 
Age and 
gender 
Population 
with HF 
Prevalence of 
COPD (n) 
Incidence of 
COPD (n) 
Contact rate 
for HF or 
COPD (n) 
Sex         
Male  2732  24.8 (678)  1.8 (48)  69.3 (1893) 
Females  3102  22.9 (711)  0.9 (29)  55.5 (1723) 
p value  0.090  0.006  <0.001 
Age         
< 55  298  9.4 (28)  0.7 (2)  28.9 (86) 
55 – 64  693  26.0 (180)  2.2 (15)  63.8 (442) 
65 – 74  1648  26.2 (432)  1.4 (23)  66.3 (1093) 
75 – 84  2193  25.9 (569)  1.3 (29)  65.3 (1433) 
≥ 85  1002  18.0 (180)  0.8 (8)  56.1 (562) 
p value for trend  0.55  0.178  0.32 
 
 
Table 4.3  Prevalence, incidence and contact rates for COPD (per 100 population 
with HF), stratified by socioeconomic status for April 2003 to March 2004 
 
Deprivation 
Category 
Population 
with HF 
Prevalence 
of smoking 
in HF 
patients (n) 
Prevalence 
of COPD in 
HF patients 
(n) 
Age 
standardised 
prevalence 
Incidence of 
COPD in HF 
patients (n) 
Age 
standardised 
incidence 
Contact rate 
for HF or 
COPD (n) 
Age 
standardised 
contact rate 
1 (least)  902  24.9 (225)  18.6 (168)  18.6  1.1 (10)  1.1  59.0 (532)  58.3 
2  1106  23.6 (261)  22.2 (246)  22.0  1.4 (15)  1.4  69.2 (765)  68.4 
3  1639  32.7 (536)  24.5 (402)  24.6  1.7 (28)  1.7  66.7 (1094)  66.8 
4  1322  33.7 (445)  22.8 (302)  22.8  1.0 (13)  1.0  54.5 (720)  54.7 
5 (most)  865  42.1 (364)  31.3 (271)  31.5  1.3 (11)  1.3  58.4 (505)  59.3 
Rate Ratio 
(95% CI) 
    1.27 
(1.05-1.55) 
1.63 
(0.89-3.06) 
1.18 
(0.49-2.91) 
1.18 
(0.49-2.91) 
0.98 
(0.67-1.43) 
1.02 
(0.70-1.49) 
p value for 
trend 
  0.011  0.01  0.05  0.84  0.84  0.92  0.60 
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4.3.3  Incidence of COPD in patients with HF 
The crude incidence of COPD in patients with HF remained relatively stable 
with a range of 1.2 – 1.6% between 1999 and 2004 (Table 4.1).  However, the age 
standardised incidence increased from 0.3% to 0.9% over this period (p for 
trend=0.017).  Age, sex and socioeconomic differences were again examined in the 
most recent year (Tables 4.2 and 4.3).  The incidence of COPD among men with HF 
was double that observed in women (1.8% vs 0.9%).  As with prevalence, incidence 
was lowest in the young (under 55 years) and elderly (over 85 years).  The incidence 
was highest in those aged 55 to 64 years (2.2%).  No significant difference was 
observed in the incidence of COPD according to socioeconomic deprivation (p for 
trend = 0.84), although the number of cases in each category was small. 
 
4.3.4  Contact rates for HF and COPD 
The contact rate for HF or COPD in patients with both conditions was greater 
than the disease specific contact rate in patients with either condition alone (Table 
4.4).  Between 1999 and 2004 the contact rate for COPD alone was relatively stable 
(p=0.85).  No significant change was observed in the age standardised contact rate 
for those with both HF and COPD during the same period (p=0.96).  By contrast, the 
contact rate for HF alone more than halved (from 49.7 to 23.5 per 100 population 
with HF, p=0.011).  Age, sex and socioeconomic differences were examined in 
2003-4 (Tables 4.2 and 4.3).  The contact rate for HF or COPD was lower in women 
than in men, and in the young (< 55 years) and very elderly ( ≥  85  years).    No 
significant difference was observed in the contact rate for HF or COPD according to 
deprivation class.   111 
Table 4.4  Contact rates for HF and COPD (per 100 population), stratified by year 
 
Year  Patients with HF alone  Contact rate for HF (n)  Age standardised contact 
rate 
1999  3712  82.5 (3061)  49.7 
2000  4175  72.9 (3045)  38.8 
2001  4373  57.0 (2494)  33.9 
2002  4496  55.2 (2480)  39.2 
2003  4451  50.8 (2262)  26.7 
2004  4445  38.9 (1729)  23.5 
      p for trend = 0.011 
Year  Patients with COPD alone  Contact rate for COPD (n)  Age standardised contact 
rate 
1999  7393  72.2 (5340)  44.6 
2000  8369  67.4 (5640)  35.9 
2001  8945  66.8 (5973)  40.7 
2002  9520  65.6 (6241)  40.6 
2003  9813  64.4 (6318)  42.8 
2004  10242  60.9 (6241)  41.6 
      p for trend = 0.85 
Year  Patients with HF and 
COPD 
Contact rate for HF or 
COPD (n) 
Age standardised contact 
rate 
1999  916  222.2 (2035)  130.1 
2000  1078  202.5 (2183)  136.2 
2001  1217  178.7 (2175)  135.0 
2002  1333  168.4 (2245)  131.2 
2003  1375  167.2 (2299)  137.7 
2004  1389  135.8 (1886)  129.7 
      p for trend = 0.96 
 
 
4.3.5  Comorbidity in patients with HF with and without COPD 
In 2003-4 the majority (76%) of patients with HF and COPD were recorded 
as current or previous smokers, as opposed to 47% of those without COPD 
(p<0.001).  Despite this, the prevalence of smoking related cardiovascular and non-
cardiovascular comorbidity was similar in the two groups (Table 4.5).  This included 
prior history of myocardial infarction, angina, stroke and cancer.  The prevalence of 
hypertension in HF patients with COPD was significantly lower than in those 
without COPD (49% vs 57%, p<0.001). 
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Table 4.5  Comorbidity in patients with HF, comparing those with and without 
COPD for April 2003 to March 2004 
 
Condition 
n (%) 
HF patients with 
COPD 
(n=1389) 
HF patients 
without COPD 
(n=4445) 
COPD patients 
without HF 
(n=10242) 
Cardiovascular risk factors       
Diabetes  241 (17)    852 (19)  825 (8) 
Hypertension  679 (49)*  2516 (57)  3446 (34) 
Hypercholesterolaemia  288 (21)    923 (21)  1147 (11) 
Smoker  660 (48)*  1171 (26)  5949 (58) 
Ex-smoker  396 (29)*    931 (21)  2057 (20) 
Cardiovascular disease       
Previous myocardial infarction  378 (27)  1264 (28)  660 (6) 
Angina  737 (53)  2388 (54)  1882 (18) 
Previous stroke  276 (20)    886 (20)  969 (10) 
Atrial fibrillation  316 (23)†  1160 (26)  459 (5) 
Non-cardiovascular comorbidity       
Cancer  381 (27)  1173 (26)  2398 (23) 
Anxiety  359 (26)*    928 (21)  2640 (26) 
 
*P<0.001 compared with patients without COPD, †P<0.05 compared with patients without COPD. 
 
 
4.3.6  Pharmacological treatment of HF patients with and without COPD 
Only 18% of patients with HF and COPD were prescribed β-blockers in 
2003–4, as opposed to 41% of those without COPD (p<0.001).  This contrasted 
strikingly with the prescription of ACE inhibitors, angiotensin receptor blockers, 
spironolactone and digoxin where no significant difference was noted between the 
groups (Table 4.6).  More patients with COPD were prescribed loop diuretics (64% 
vs 55%, p<0.001) and calcium channel blockers (33% vs 27%, p<0.001).  β-agonists 
were the most frequent therapy for COPD (57%), followed by inhaled corticosteroids 
(51%) and antimuscarinic drugs (24%).  Despite having no formal diagnosis of 
COPD, 9% of the remaining patients with HF were prescribed β-agonists and 6% 
inhaled corticosteroids. 
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Table 4.6  Pharmacological treatment of patients with HF, comparing those with and 
without COPD for April 2003 to March 2004 
 
Treatment 
n (%) 
HF patients with 
COPD 
(n=1389) 
HF patients 
without COPD 
(n=4445) 
COPD patients 
without HF 
(n=10242) 
Cardiovascular treatment       
β-blocker  246 (18)*  1838 (41)  1018 (10) 
ACE inhibitor  671 (48)  2225 (50)  1625 (16) 
Angiotensin receptor blocker  120 (9)    423 (10)  376 (4) 
Spironolactone  151 (11)    406 (9)  85 (1) 
Digoxin  230 (17)    784 (18)  183 (2) 
Loop diuretic  893 (64)*  2462 (55)  1200 (12) 
Calcium channel blocker  461 (33)*  1194 (27)  1933 (19) 
Amiodarone    68 (5)    223 (5)  52 (1) 
Aspirin  753 (54)  2524 (57)  2586 (28) 
Clopidogrel  146 (11)†    380 (9)  365 (4) 
Warfarin  219 (16)†    838 (19)  282 (3) 
COPD treatment       
β-agonist  794 (57)*    395 (9)  5492 (54) 
Inhaled antimuscarinic  333 (24)*      49 (1)  1750 (17) 
Inhaled steroid  704 (51)*    255 (6)  4796 (47) 
Oral steroid  300 (22)*    213 (5)  1873 (18) 
 
*P<0.001 compared with patients without COPD, †P<0.05 compared with patients without COPD. 
 
 
Overall prescribing of β-blockers in patients with HF increased from 17% to 
36% between 1999 and 2004 (adjusted odds ratio 2.27 [95% CI 2.06–2.51], 
p<0.001).  The proportion of patients being prescribed β-blockers increased from 
20% to 41% in those without COPD, and from 7% to 18% in those with COPD 
(Figure 4.1).  Patients with concurrent COPD were consistently less likely to receive 
β-blockers.  There was no interaction between year of diagnosis and presence of 
COPD on the odds of being prescribed a β-blocker (p for interaction=0.848).  The 
adjusted odds ratio for β-blocker prescription in those HF patients with COPD versus 
those without was 0.30 (95% CI 0.28–0.32). 
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Figure 4.1  Trends in β-blocker prescribing in patients with HF, comparing those 
with and without COPD 
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4.4  Discussion 
 
This is the first study examining the epidemiology and management of 
patients with HF and coexistent COPD in the community.
1  Prior reports involved 
cohorts hospitalised with worsening HF,
97,167 attending specialised HF clinics,
171 or 
enrolled in clinical trials.
128,227  Using data collected in primary care I found that the 
prevalence of COPD in patients with HF increased year on year, was similar in men 
and  women, and was associated with greater socioeconomic deprivation.   
Significantly, less than a fifth of patients with both HF and COPD in the community 
receive β-blockers and this has not improved over time. 
   115 
4.4.1  Prevalence and incidence of COPD in patients with HF 
Many factors influence estimates of COPD prevalence: surveillance systems, 
measurement techniques, diagnostic criteria applied, population age structure and 
risk factor exposure, most notably smoking.
59,309  The prevalence of COPD was 
approximately sevenfold greater in patients with HF than in the general primary care 
population.  This predominantly reflects advancing age and smoking history (Figure 
4.2). 
 
Figure 4.2  Prevalence of COPD in selected populations for April 2003 to March 
2004 
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The prevalence of COPD in the general practice population  ≥ 65 years was 
12%, closely matching that observed in the Cardiovascular Health Study (13%).
60  
The reported prevalence of COPD in patients with HF ranges widely from 11% to   116 
52% in North America, and from 9% to 41% in European cohorts.
1  The majority of 
studies were hospital rather than community based.  However, the prevalence of 
23.8% in 2004 is commensurate with a recent Dutch primary care study (24.5%).
69 
Between 1999 and 2004 the prevalence of COPD in patients with HF 
progressively increased from 19.8% to 23.8%.  A similar trend was noted in three 
U.S. studies following patients hospitalised with HF during the 1990s.
63-65  These 
changes may previously have been attributed to an ageing population or increasing 
age of presentation.
1  However,  the trend remained significant after age 
standardisation.  The incidence of COPD in patients with HF has not previously been 
reported.  As with prevalence, the age standardised rate increased significantly over 
time.  These changes most likely reflect improved detection in primary care, 
although an increase in disease burden is also possible. 
The prevalence and incidence of COPD were lowest in the young and very 
elderly under 55 and over 85 years of age respectively.  This non-linear relationship 
between age and frequency of concurrent COPD has been noted previously.
66-69  It 
may be possible that the presence of COPD reduces survival beyond this age.  
Alternatively, the elderly may undergo less intensive diagnostic testing.  Finally, a 
clear socioeconomic gradient was observed, with prevalence greatest in the most 
deprived.  Smoking, the main risk factor for COPD, increased in parallel.  Poor 
housing conditions, home dampness, urban habitats with greater air pollution and 
occupational differences may also contribute.
309,314 
 
4.4.2  Primary care burden   117 
The impact of COPD on consultation rates in patients with HF has not 
previously been reported.  As expected, the number of contacts for HF or COPD 
exceeded that for either condition alone.  The trends in primary care burden proved 
more surprising.  Both crude and age standardised contact rates for HF decreased by 
half between 1999 and 2004, whereas no significant change was observed in COPD 
consultation rates.  These figures initially appear at odds with the aging population, 
declining mortality, and consequent increase in HF prevalence.
315  However, two 
crucial therapeutic interventions have accompanied these trends.  Β-blocker 
utilisation, which doubled during the same period, is associated with reduced 
hospitalisation rates.
316  A rapid expansion of nurse led intervention including home 
visits also occurred,
317  with proven reductions in emergency room and hospital 
attendances.
318  These improvements in clinical stability may well extend to primary 
care contact rates.  In addition, the introduction of the Quality and Outcomes 
Framework (QOF) in the United Kingdom financially incentivised performance of 
echocardiography in patients with HF.  Estimates of prevalence may decrease as 
incorrect diagnoses are removed from patients. 
 
4.4.3  Comorbidity 
A smoking history was present in 76% of patients with COPD, consistent 
with existing evidence.
309  A recent analysis of the Valsartan in Acute Myocardial 
Infarction trial reported clustering of cardiovascular risk factors (diabetes, 
hypertension, dyslipidaemia) and comorbidity (myocardial infarction, angina, stroke) 
in patients with COPD, associated with an increased risk of future atherosclerotic 
events.
227  That no such excess of smoking related cardiovascular disease was   118 
observed  is biologically implausible and cause for concern.  A number of 
explanations are possible.  Both patients and physicians may mistakenly attribute 
symptoms of angina or myocardial infarction to pulmonary disease.  However, the 
diagnosis of hypertension or diabetes is based solely on objective measures.  Airflow 
obstruction was associated with both these conditions in the Atherosclerosis Risk in 
Communities Study and the Cardiovascular Health Study.
243  The association 
between smoking and hypertension is equally well established.
319  This suggests that 
common cardiovascular risk factors are being under diagnosed (and likely under 
treated) in patients with HF and COPD. 
 
4.4.4  Pharmacotherapy 
Only one study from the UK DIN-LINK database has examined 
contemporary trends in β-blocker utilisation in primary care patients.
164  The overall 
prevalence of β-blocker prescription in 2005 (37%) was similar to the present study 
in 2004 (36%).  As with previous reports,
164,168 I observed a steady rise in β-blocker 
use suggesting that evidence is translating into practice.  Whether the gap between 
patients with and without COPD is diminishing was previously unknown.  The 
results are disappointing.  Despite the overall improvement, the relative difference 
between those with and without COPD remained unchanged.  These findings are 
congruent with the Euro Heart Failure Survey, in which pulmonary disease was the 
most powerful independent predictor of β-blocker underutilisation (odds ratio 0.35 
[0.30 - 0.40]).
173  Two simple facts should encourage improvement.  Firstly, the 
majority of primary care patients with COPD have only mild or moderate airflow 
obstruction.
320  Secondly, the majority of patients with HF in the UK receive   119 
bisoprolol which is highly cardioselective.
164,298   Only a small minority of patients 
will therefore be truly intolerant.  With appropriate follow-up approximately 80% of 
patients with HF and COPD in the community tolerate β-blockade.
168,172 
Two other classes of medication are often overshadowed by the controversial 
issue of β-blockade and deserve mention.  Patients with COPD were more frequently 
prescribed calcium channel blockers (33% vs 26%, p<0.001).  Although 
dihydropyridine and non-dihydropyridine classes were not distinguished, rate 
limiting calcium channel blockers are often substituted for β-blockade in patients 
with coronary artery disease or arrhythmias.  In patients with left ventricular systolic 
dysfunction these medications are associated with worsening heart failure and 
adverse cardiovascular events.
158,321  Inhaled β-agonists are likewise associated with 
increased hospitalisations and mortality in patients with LVSD.
249  β-agonists are 
first line therapy and a necessity in those with COPD.  However, 9% of patients with 
HF but without COPD were also prescribed inhaled β-agonists.  Although a small 
proportion may have asthma, physicians should be wary of prescribing 
bronchodilators to patients with HF before objectively demonstrating airflow 
obstruction. 
 
4.4.5  Limitations 
The limitations of epidemiological studies (such as unknown confounding) 
are well known.  In addition, the evidence on which diagnoses are based was not 
recorded.  Objective measures of HF and COPD severity are also unavailable.   
Patients with reduced and preserved left ventricular function are not differentiated: 
the evidence for prescribing β-blockers for HF with normal ejection fraction is   120 
substantially weaker.
225  Nevertheless, the information provides a ‘real world’ 
perspective of patients with both conditions who are managed in primary care.  
Finally, changing incentives in primary care over time may influence reporting 
practices.
322 
 
4.5  Conclusion 
 
The prevalence of COPD is increasing in patients with HF and creates major 
challenges in primary care.  Consultation rates in patients with both conditions are 
higher than in patients with either condition alone.  Each diagnosis requires objective 
testing to which access may be limited.  This  analysis suggests that COPD is a 
barrier to the diagnosis of cardiovascular comorbidity in patients with HF.  The 
therapeutic consequences are equally concerning to primary care physicians.   
Underuse of β-blockers and inappropriate prescribing of β-agonists may both 
increase hospitalisations and mortality.  In the Study of Heart Failure Awareness and 
Perception in Europe, COPD was a common perceived contraindication to β-
blockade among primary care physicians.
310  In the United Kingdom, the Quality and 
Outcomes Framework financially remunerates practices achieving evidence based 
indicators.  Remarkably, the heart failure QOF currently requires only that a patient 
undergoes echocardiography and receives treatment with either an ACE inhibitor or 
angiotensin receptor blocker.
323  The inclusion of β-blocker targets in the framework 
for 2009/10 will hopefully improve utilisation in those with concurrent COPD.  
Primary care physicians require greater support in managing patients with HF and 
COPD.   121 
 
Chapter 5 
 
How many patients with heart failure and  chronic 
obstructive pulmonary disease receive or have alternative 
reasons precluding β-blockade? 
 
   122 
5.1  Introduction 
 
Chronic obstructive pulmonary disease is a frequent comorbidity in heart 
failure and a perceived contraindication to β-blockade.  In the Euro Heart Failure 
Survey pulmonary disease was the most powerful independent predictor of β-blocker 
underutilisation (odds ratio 0.35 [95% CI 0.30 - 0.40]).
173  However, management of 
patients with both conditions poses complex patient level decisions which are 
inadequately assessed by epidemiological and cohort studies.  Many simple clinical 
questions remain unanswered.  How many patients have alternative reasons 
precluding β-blockade? How many have severe airflow obstruction? Do patients with 
COPD receive cardioselective β-blockers, and at what doses? How many HF patients 
without COPD receive inappropriate bronchodilator therapy?  I performed a detailed 
case record review to define these issues. 
 
5.2  Methods 
 
5.2.1  Participants 
Stobhill Hospital is a large urban hospital serving a local population of 
200,000 people.  Consecutive hospital admissions between June 2005 and March 
2006 were included.  Patients with heart failure were identified by an ICD 10 
discharge code for HF in any diagnostic position.  The following codes were used: 
150.0, congestive heart failure 150.1, left ventricular failure; 150.9, heart failure 
unspecified; 111.0, hypertensive heart failure; 142.0, dilated cardiomyopathy; 125.5, 
ischaemic cardiomyopathy; 142.9, cardiomyopathy unspecified.   123 
 
5.2.2  Data Retrieval 
  Stobhill Hospital employs an electronic ‘incremental discharge letter system’ 
for all hospital admissions.  Two letters are produced for every patient.  The first 
‘immediate’ discharge summary is written by junior or middle grade doctors on the 
day of discharge.  All medications are re-checked by the ward pharmacist.  A 
subsequent ‘final’ discharge summary by middle grade or consultant physicians 
includes additional comments or corrections.  The final discharge summaries and 
medications of all patients with HF were reviewed.  I examined the case records of 
patients where a diagnosis of COPD was suggested by discharge code, physicians’ 
comments, or prescription of inhalers.  The results of investigations were retrieved 
from case records.  Further data were acquired by searching databases of the 
radiology, echocardiography and pulmonary function departments.  The use of 
anonymised data was discussed with the local ethics committee and did not require 
additional formal ethical approval. 
 
5.2.3  Diagnostic Criteria 
  In accordance with European Society of Cardiology guidelines the diagnosis 
of HF required both compatible symptoms and objective evidence of cardiac 
dysfunction.  Response to therapy was not mandatory but conferred added weight to 
the diagnosis of HF.  The study aim was to examine patients with an indication for β-
blocker treatment.  Those with preserved systolic function were therefore excluded.  
Left ventricular systolic dysfunction was graded semi-quantitatively (mild, moderate 
or severely impaired) in accordance with the hospital’s usual practice.  Patients were   124 
categorised  according to physician diagnosis of COPD to reflect actual clinical 
practice.  Severity of airflow obstruction was classified using the Global Initiative for 
Chronic Obstructive Lung Disease guidelines (Table 1.1). 
 
5.2.4  Statistical Analysis 
Baseline characteristics of patients with and without COPD are presented as 
means with standard deviations for continuous variables or by frequencies and 
percents for categorical variables.  Means were compared using the Student t-test and 
proportions using the chi-square test.  A 2-tailed P value of less than 0.05 was 
considered statistically significant. 
 
5.3  Results 
 
5.3.1  Prevalence of COPD 
In total 449 consecutive HF admissions were screened for the presence of 
COPD.  Miscoding, re-admissions, and patients with preserved systolic function 
were excluded (n=24, 108 and 55 respectively).  Of the remaining admissions, 75 of 
262 patients (29%) had a physician diagnosis of COPD.  A smoking history was 
present in 83% of those with COPD.  The demography, investigations and 
medications of patients with and without COPD are presented in Table 5.1.  Both 
groups were elderly (mean age 76.2 ± 11.9 years) with similar proportions being 
male and female. 
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Table 5.1  Baseline characteristics of patients with heart failure according to COPD 
status 
 
Characteristics  COPD 
n=75 (28.6%) 
No COPD 
n=187 (70.4%) 
Demographics     
Age (years)  75.7 ± 9.4  76.4 ± 12.7 
Male  39 (52.0)  89   (47.6) 
Cardiac Medications     
ACE inhibitor  36 (48.0)  109 (58.3) 
Angiotensin receptor blocker  13 (17.3)  26   (13.9) 
Spironolactone  13 (17.3)  28   (15.0) 
Digoxin  25 (33.3)  42   (22.5) 
Diltiazem  11 (14.7)*  5     (2.7) 
β-Blocker  31 (41.3)  101 (54.0) 
Loop Diuretic  68 (90.7)  163 (87.2) 
Inhaled Therapy     
Short Acting β2-Agonist  52 (69.3)*  4     (2.1) 
Long Acting β2-Agonist  39 (52.0)*  4     (2.1) 
Inhaled Corticosteroid  52 (69.3)*  7     (3.7) 
Tiotropium  24 (32.0)*  3     (1.6) 
Nebulised β2-Agonist  7   (9.3)*  1     (0.5) 
Oral Corticosteroid  4   (5.3)†  1     (0.5) 
Investigations     
Echocardiography Ever  70 (93.3)†  156 (83.4) 
•  LVSD Mild  18 (26.1)  38   (25.3) 
•  LVSD Moderate  32 (46.4)  56   (37.3) 
•  LVSD Severe  19 (27.5)  56   (37.3) 
Chest Radiograph  75 (100.0)  184 (98.4) 
•  Cardiomegaly  50 (66.7)  137 (73.3) 
•  Pleural Effusions  29 (38.7)  84   (44.9) 
•  Alveolar Oedema  38 (50.7)  87   (46.5) 
Pulmonary Function Tests  53 (70.7)*  35   (18.7) 
•  GOLD None  9   (12.0)  22   (11.8) 
•  GOLD Mild  14 (18.7)*  5     (2.7) 
•  GOLD Moderate  17 (22.7)*  7     (3.7) 
•  GOLD Severe  13 (17.3)*  1     (0.5) 
 
*P<0.001 compared with patients without COPD, †P<0.05 compared with patients without COPD. 
Values are means ± SD or n (%). 
 
ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; LVSD, left ventricular systolic dysfunction 
 
5.3.2  Investigations 
Pulmonary function test results were available in 53 (71%) patients with 
COPD.  Mean FEV1 was 1.51L (± 0.58L) and mean percentage of predicted FEV1 
was 67% (± 20%).  Only a minority had severe airflow obstruction  (17%).  
Pulmonary function tests had been performed recently in many patients (Figure 5.1).   126 
 
Figure 5.1  Date of pulmonary function testing in patients with heart failure and 
chronic obstructive pulmonary disease 
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Echocardiography results were available in 86% of patients with HF.  No 
significant difference was observed in the severity of left ventricular systolic 
dysfunction between those with and without COPD.  Radiological findings were 
likewise similar in the two groups. 
 
5.3.3  Pharmacotherapy 
Patients with COPD were more often prescribed diltiazem compared to those 
without COPD (15% vs 3%, p<0.001).  Short acting β-agonists and inhaled 
corticosteroids were the most frequent therapies for COPD (69%), followed by long 
acting β-agonists (52%) and antimuscarinic drugs (32%).  Only a small proportion of   127 
patients without a physician diagnosis of COPD received β-agonists (2%) or other 
bronchodilators. 
 
5.3.4  β-blockade 
31 (41%) of the 75 patients with COPD received β-blockers.  In 19%, β-
blockers were contraindicated or considered inappropriate for reasons other than 
COPD.  These included bradycardia, conduction disturbance, hypotension, severe 
peripheral arterial disease or advanced malignancy and dementia.  The remaining 30 
patients (40%) did not receive β-blockers. 13% (n=10) had severe airflow obstruction 
(Figure 5.2). 
 
Figure 5.2  β-blocker status and degree of airflow obstruction in patients with heart 
failure and chronic obstructive pulmonary disease 
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27% (n=20) had milder obstruction or no documented pulmonary function 
tests and may have been inappropriately denied treatment with a β-blocker.  The 
choice and dose of β-blocker in patients with COPD was examined.  Of the 31 
patients, all but one received a cardioselective β-blocker.  The mean dose expressed 
as a percentage of the maximum target dose was similar in those with and without 
COPD (37% vs 36% respectively). 
 
5.4  Discussion 
 
The present study addresses simple clinical issues that are overlooked by 
larger cohort studies or subgroup analysis of clinical trials.  β-blocker utilisation is 
often criticised in patients with COPD.  However, the proportion with alternative 
reasons precluding β-blockade was previously unclear.  In approximately one fifth of 
patients,  β-blockers were contraindicated or considered inappropriate for reasons 
other than COPD.  Nevertheless, 27% of patients with HF and COPD failed to 
receive a β-blocker despite lacking severe airflow obstruction or an alternative reason 
precluding β-blockade. 
Estimates of COPD prevalence vary according to the population studied, 
diagnostic criteria applied, measurement tools and surveillance systems.
59  The 
reported prevalence of COPD ranges from 11% to 52% in North American patients 
with HF, and from 9% to 41% in European cohorts.
1  The observed prevalence of 
29% is consistent with contemporary European cohorts hospitalised with worsening 
HF.   129 
Surprisingly few studies report the prevalence of β-blocker use in patients 
with HF and concomitant COPD (Table 1.6).  Analysis from 152 UK general 
practices  indicated that 24% of primary care patients with both conditions were 
prescribed β-blockers.
164  Italian and Danish studies observed comparable levels on 
admission to hospital with worsening HF in 241 and 182 patients with concurrent 
COPD (respectively 16% and 27%).
97,165  Similarly, 22% of patients with HF and 
COPD enrolled in the Valsartan Heart Failure Trial received β-blockers.
128  Four 
specialised HF clinics reported far higher but equally consistent results, with between 
81% and 86% of outpatients with COPD tolerated β-blockers.
169-172 
The present  cohort consisted of elderly hospitalised patients managed by 
general physicians and cardiologists.  The prevalence of β-blockade in those with 
COPD (41%) was greater than observed in the community but lower than achieved in 
HF clinics.  Numerous factors determine β-blocker utilisation: contraindications, 
including hypotension, bradycardia, high grade atrioventricular block, severe 
peripheral arterial disease or airflow obstruction;
168,169,324-326  ineligibility due to 
advanced malignancy, dementia or general frailty;
325 and symptomatic intolerance or 
patient choice.
168,169,172,325,326  Referral bias undoubtedly excludes many ineligible 
patients from HF clinics.  The prevalence of β-blocker use is consequently lower in 
unselected populations.  However, one factor remains a barrier to β-blocker therapy 
irrespective of patient characteristics or the clinical setting: physicians’ perception.  
In the recent Study of Heart Failure Awareness and Perception in Europe,
310 COPD 
was a common perceived contraindication to β-blockade among general internists 
and primary care physicians.   130 
β-blockade was cardioselective in almost all patients, with no dose reduction 
associated with the presence of COPD.  The explanation is twofold.  Firstly, the 
majority of patients with HF in the UK receive bisoprolol.
164  Secondly, 
cardioselective  β-blockers are well tolerated in patients with mild to moderate 
COPD.
2  Only one other report has assessed β-blocker dose in patients with HF and 
COPD, likewise finding no difference between those with and without airflow 
obstruction.
172 
A recent US study revealed significant disparities in confirmatory testing 
practices.
58  Among 219 patients discharged from a tertiary centre with both HF and 
COPD, 82% had documented echocardiography as opposed to 36% pulmonary 
function testing.  I found less discrepancy between investigations.  The majority of 
patients had spirometry results available, most performed in recent years.  This is 
reassuring,  as both inhaled therapy and β-blockade are dictated by the degree of 
airflow obstruction.  Only one previous study has defined the severity of airflow 
obstruction in patients with HF and COPD according to GOLD criteria.
171  Severe 
obstruction was found in 23% of the 73 patients, akin to the 17% observed in my 
cohort. 
Two other classes of medication are often overshadowed by the controversial 
issue of β-blockade and merit consideration.  Patients with COPD were more 
frequently prescribed diltiazem (15% vs 3%, p<0.001).  Rate limiting calcium 
channel blockers are often substituted for β-blockade in patients with coronary artery 
disease or arrhythmias.  In patients with LVSD these medications are associated with 
worsening heart failure and adverse cardiovascular events.
158,321,327  Extensive safety 
data from the BEAUTIFUL trial now supports the use of ivabradine in patients with   131 
LVSD and coronary artery disease.
328  This should provide a safer alternative to 
diltiazem in patients with HF and COPD who are truly intolerant of β-blockade.  
Finally, inhaled β-agonists are associated with increased hospitalisations and 
mortality in patients with LVSD.
249  β-agonists are first line therapy and a necessity 
in those with COPD.  However, they represent an unnecessary risk and should be 
avoided in the absence of COPD.  I observed a low prevalence of bronchodilator use 
in such patients. 
Several limitations to the  present study must be acknowledged, foremost 
being the retrospective data collection.  Data loss was minimised by searching 
multiple electronic databases in addition to the printed case records.  Reasons for β-
blocker intolerance may not always be documented.  I  examined only discharge 
medications as this information was checked by both doctors and pharmacists.  
Comparing these to admission medications may have provided useful information 
regarding discontinuation of therapy. 
 
5.5  Conclusion 
 
Patients with  HF and COPD often tolerate or have alternative reasons 
precluding  β-blockade. Only a minority have severe airflow obstruction.  The 
remainder may have β-blocker therapy inappropriately withheld.  I  estimate an 
achievable target for β-blocker utilisation lies between 60% and 70% in unselected 
patients with HF and COPD.  Regional or national registries (such as ADHERE or 
OPTIMIZE-HF)
329,330  are needed for prospective data collection and quality 
improvement.  Using pre-discharge protocols improves the prescription of β-  132 
blockers.
331  These measures would promote higher levels of β-blocker use and help 
inform clinical practice.   133 
 
Chapter 6 
 
Chronic obstructive pulmonary disease is an independent 
predictor of death but not atherosclerotic events in patients 
with myocardial infarction: analysis of the Valsartan in 
Acute Myocardial Infarction trial (VALIANT).   134 
6.1  Introduction 
 
Chronic obstructive pulmonary disease is a global epidemic affecting 5 to 
15% of all adults.
309  Both prevalence and mortality are increasing and projected to 
escalate still further.  Cardiovascular and pulmonary deaths are equally common, 
accounting for 3 million lives per year worldwide.
332  The shared aetiology of 
tobacco smoking is partly responsible.  However, airflow obstruction independently 
predicts cardiovascular mortality in population studies, even after adjusting for 
smoking history.
143  Atherosclerotic consequences of chronic systemic inflammation 
in COPD have been postulated.
139,333,334  Whether these aggravate established 
coronary artery disease is uncertain. 
Two contemporary studies have examined patients with myocardial infarction 
and concomitant COPD.
335,336  Both found COPD to be an independent predictor of 
long  term mortality.
335,336  Neither report investigated the relationship between 
COPD and mode of death or risk of non-fatal cardiovascular events.  Furthermore, 
the increased mortality was confined to patients without heart failure (HF) in one 
study.
335  I used the Valsartan in Acute Myocardial Infarction (VALIANT) trial to 
characterise the impact of COPD on treatment and clinical outcomes in patients with 
MI complicated by heart failure, left ventricular systolic dysfunction, or both. 
 
6.2  Methods 
 
6.2.1  Trial design   135 
VALIANT enrolled 14,703 patients with myocardial infarction complicated 
by left ventricular systolic dysfunction, heart failure, or both.  The former was 
defined by ejection fraction ≤ 0.35 on echocardiography or contrast angiography and 
≤ 0.40 on radionuclide ventriculography, the latter by clinical signs of heart failure or 
radiologic evidence of pulmonary venous congestion.
337  The randomised, double-
blind, active-controlled design compared treatment with valsartan, captopril, or both.  
The rationale, methods, inclusion and exclusion criteria and main outcomes have 
been reported previously.
337,338  The study was approved by local ethics committees 
in all participating centres and all patients provided written informed consent. 
 
6.2.2  Trial endpoints 
The primary outcome was mortality from any cause within 3 years following 
the index MI.  Secondary prespecified endpoints included: cardiovascular death and 
components (sudden cardiac death, fatal myocardial infarction and fatal worsening 
HF); non-fatal myocardial infarction; hospital admission for worsening HF; and the 
composite of cardiovascular death, myocardial infarction, or HF hospitalisation.  
Presence of clinically recognised COPD was recorded using a yes/no check box by 
individual site investigators at study entry according to their clinical judgement. 
All prespecified endpoints were adjudicated by an independent clinical 
endpoint committee.  Definitions of the endpoints are published previously.
338  
Hospitalisation for HF was defined as admission with symptoms or signs of HF 
requiring intravenous treatment with diuretic, inotropic, or vasodilator therapy.  
Members of the committee distinguished HF from COPD using clinical judgement 
supported by hospital records and results of investigations.   136 
 
6.2.3  Statistical analysis 
Data analyses were performed independently by the Duke Clinical Research 
Institute.  The COPD status is defined as having a known history prior to the 
qualifying MI for the trial. Baseline characteristics of patients with and without 
COPD are presented as means with standard deviations for continuous variables or 
by frequencies and percents for categorical variables.  Means were compared using 
the Wilcoxon rank sum test or Student t-test depending on the distribution of the 
data, and proportions using the Chi-square test.  All analyses were performed on an 
intention to treat basis.  Cumulative event rates were estimated using the Kaplan-
Meier method and were compared using log-rank test.  A 2-tailed P value of less than 
0.05 was considered statistically significant. 
The prognostic significance of COPD was evaluated for predefined 
outcomes, including the primary endpoint and other major cardiovascular events.  
The estimated hazard ratios were adjusted for all important predictors of mortality 
and morbidity using Cox proportional hazards models.  A separate model was built 
for each outcome of interest.  Starting from over 70 candidate variables collected at 
randomisation, both backward elimination and stepwise selection were used to 
identify independent factors.  A p value of 0.10 was required for a variable to enter 
and 0.05 to stay in the model.  Bootstrap method with a resample of 200 was 
employed to validate the selection.  Randomised treatments were added to the final 
model.  The multivariable model for mortality included the following covariates: age, 
heart rate, systolic and diastolic blood pressure, weight, baseline creatinine, smoking 
status, diabetes, dyslipidaemia, history of hypertension, Killip classification, anterior   137 
MI, new left bundle branch block, thrombolytic therapy, primary percutaneous 
intervention, coronary artery bypass graft surgery after the qualifying MI, history of 
heart failure, atrial fibrillation, previous MI, angina or unstable angina, previous 
stroke, peripheral arterial disease, renal insufficiency, alcohol abuse, country of 
enrolment,  β-blocker use, randomised  treatment.  The multivariate model for 
mortality stratified by COPD status and baseline β-blocker was employed to estimate 
the adjusted death rates for each of the four strata at different time points within the 3 
year follow-up period.  Event curves were created to display the cumulative adjusted 
mortality rates over time (Figure 6.1). 
An analysis of post randomisation periods (‘landmarks’) was employed to 
address potential survivor bias in analysis of the composite atherosclerotic outcome 
of MI or stroke.  Patients with COPD may die earlier than their counterparts, before 
developing arterial disease.  The association between COPD and atherosclerotic 
events may thus be underestimated due to unequal survivorship.  To minimise this 
effect, the relationship between COPD and atherosclerotic events was examined in 
four different periods: inpatient (1–16 days since randomisation), post discharge (17–
45 days), early (46–198 days) and later (199–1096 days) follow-up.  Only patients 
alive at the beginning of each period were included in each analysis.  When the risk 
is similar cross intervals, a combined HR was estimated by treating each interval as a 
cluster in the Cox model.  All analyses were performed using SAS software version 8 
(SAS Institute, Cary, North Carolina). 
 
6.3  Results 
   138 
6.3.1  Baseline Characteristics 
VALIANT enrolled 14703 patients, 1258 (8.6%) of which had a diagnosis of 
COPD.  The median duration of follow-up was 24.7 months.  The baseline 
characteristics of patients with and without COPD differed significantly (Table 6.1). 
 
Table 6.1  Baseline characteristics of patients with COPD 
 
Characteristics 
 
COPD 
Beta-Blocker 
n=643 (4.4%) 
COPD 
No Beta-
Blocker 
n= 615(4.2%) 
No COPD 
Beta-Blocker 
n=9709 
(66.0%) 
No COPD 
No Beta-
Blocker 
n=3736 (25.4%) 
Demographics         
Age (years) *  67.0 ± 10.1  69.2 ± 9.5  63.5 ± 12.1  67.3 ± 11.1 
Female Sex  166 (25.8)  197 (32.0)  2915 (30.0)  1291 (34.6) 
Body Mass Index (kg/m
2)†  28.1 ± 5.6  26.9 ± 5.4   28.0 ± 4.8  27.6 ± 4.9 
CV Risk Factors         
Current smoker*  277 (43.1)  251 (40.8)  3114 (32.1)  1022 (27.4) 
Previous smoker*  259 (40.3)  259 (42.1)  2966 (30.6)  1195 (32.0) 
Diabetes mellitus†  178 (27.7)  145 (23.6)  2047 (21.1)  1029 (27.5) 
Hypertension†  397 (61.7)  334 (54.3)  5326 (54.9)  2063 (55.2) 
Dyslipidaemia*  257 (40.2)  196 (32.4)  2883 (30.2)  998 (27.2) 
Previous Comorbidity         
Heart failure*  163 (25.3)  180 (29.3)  1184 (12.2)  647 (17.3) 
Myocardial infarction*  274 (42.6)  228 (37.1)  2512 (25.9)  1090 (29.2) 
Angina*  297 (46.2)  283 (46.0)  3680 (37.9)  1581 (42.3) 
PCI*  88 (13.7)  50 (8.1)  724 (7.5)  205 (5.5) 
Stroke†  53 (8.2)  50 (8.1)  545 (5.6)  247 (6.6) 
Peripheral arterial disease*  119 (18.5)  101 (16.4)  670 (6.9)  347 (9.3) 
Atrial fibrillation*  47 (7.3)  73 (11.9)  533(5.5)  307 (8.2) 
Characteristics of MI         
Heart Rate*  75.5 ± 12.7  81.1 ± 13.7  74.6 ± 12.3  79.6 ± 13.2 
Systolic BP (mm Hg)†  123.1 ± 16.3  124.7 ± 17.4  122.0 ± 16.7  123.9 ± 17.6 
Diastolic BP (mm Hg)†  71.0 ± 11.4  71.6 ± 11.2  72.2 ± 11.2  73.1 ± 11.5 
Killip class III-IV*  148 (23.0)  221 (35.9)  1847 (19.0)  1244 (33.3) 
Radiologic LV failure†  251 (39.0)  283 (46.0)  3412 (35.1)  1796 (48.1) 
ECG Site – Anterior*  324 (53.7)  283 (48.9)  5768 (61.8)  2016 (56.1) 
Q-wave MI*  324 (53.3)  308 (52.9)  6413 (68.4)  2396 (66.4) 
Non Q-wave MI*  267 (44.6)  253 (44.0)  2812 (30.4)  1126 (31.7) 
Ejection fraction  34.2 (9.9)  33.8 (10.4)  35.5 (10.2)  35.1 (10.8) 
Initial Treatment of MI         
Aspirin*  547 (85.1)  518 (84.2)  8783 (90.5)  3233(86.5) 
Thrombolysis*  178 (27.7)  168 (27.3)  3733 (38.5)  1090 (29.2) 
Catheterisation  205 (31.9)  147 (24.0)  2959 (30.5)  810 (21.7) 
Primary PCI*  72 (11.2)  61 (9.9)  1646 (17.0)  398 (10.6) 
Medications         
Aspirin*  572 (89.0)  529 (86.0)  9044 (93.2)  3273 (87.6) 
β-blocker*  643   (51.1)  0 (0)  9707   (72.2)  0 (0) 
Digoxin*  125 (19.4)  143 (23.3)  941 (9.7)  647 (17.3) 
Statin  244 (37.9)  155 (25.2)  3702 (38.1)  913 (24.4) 
Calcium channel blocker*  76 (11.8)  138 (22.4)  619 (6.4)  428 (11.5) 
 
*P<0.0001 compared with patients without COPD, †P<0.05 compared with patients without COPD.   139 
Values are means ± SD or n (%). 
 
COPD = chronic obstructive pulmonary disease; CV = cardiovascular; ECG = electrocardiogram; PCI 
= percutaneous coronary intervention; MI = myocardial infarction. 
 
Patients with COPD were older with more cardiovascular risk factors 
including current or previous smoking, diabetes, hypertension and dyslipidaemia.  
Comorbidity was likewise greater in patients with COPD, particularly coronary (MI, 
PCI, angina), peripheral and cerebrovascular disease.  At randomisation patients with 
COPD had a higher heart rate, Killip classification and frequency of radiological 
pulmonary oedema.  The qualifying electrocardiogram and ensuing treatment also 
varied.  Patients with COPD more frequently presented with non Q-wave MI (44.3% 
vs 30.8%).  Fewer patients with COPD received primary percutaneous intervention 
(10.6% vs 15.2%) or thrombolysis (27.5% vs 35.9%), although a similar proportion 
underwent cardiac catheterisation.  Patients with COPD were less likely to receive 
some risk-modifying cardiovascular medications, most notably β-blockers (51.1% vs 
72.2% at randomisation). 
 
6.3.2  Mortality 
  COPD was independently associated with increased mortality.  A total of 382 
patients with COPD (30.4%) died from any cause, compared with 2496 (18.6%) of 
those without (Table 6.2).  After adjusting for additional predictors of mortality, the 
risk of death was increased by 14% in patients with COPD (HR 1.14 [95% CI 1.02–
1.28]).  Mortality was greater in those with COPD, regardless of β-blocker 
prescription (Figure 6.1).  Increased incidence of both non-cardiovascular death 
(6.0% vs 2.4%, HR 1.86 [1.43–2.42]) and sudden death (10.0% vs 5.9%, HR 1.26 
[1.03–1.53]) contributed to the excess mortality in patients with COPD (Table 6.2).    140 
However, the overall risk of cardiovascular death was not significantly elevated after 
correcting for baseline differences.  The increased risk of sudden death was 
independent of age, β-blocker use, ischaemic heart disease, diabetes and other 
recognised predictors of sudden death.  Of the 75 non-cardiovascular deaths in 
patients with COPD, two thirds were attributed to pulmonary disease (25%, n=19), 
malignancy (33%, n=25) or infection (9%, n=7).  The respective frequencies in 
patients without COPD were 9% (n=30), 43% (n=137) and 13% (n=43). 
 
Table 6.2  Risk of death and cardiovascular events in patients with COPD 
 
Outcome 
 
 
COPD 
present 
n=1258 (%) 
COPD 
absent 
n=13445 (%) 
Unadjusted 
HR (95% CI) 
p value  Adjusted HR 
(95% CI) 
p value 
All cause mortality 
 
382 (30.4)  2496 (18.6)  1.70 
(1.53-1.90) 
<0.0001  1.14 
(1.02-1.28) 
0.021 
Non-cardiovascular 
death 
75   (6.0)  319   (2.4)  2.61 
(2.02-3.36) 
<0.0001  1.86 
(1.43-2.42) 
<0.0001 
Cardiovascular death 
 
307 (24.4)  2177 (16.2)  1.57 
(1.39-1.77) 
<0.0001  1.04 
(0.92-1.19) 
0.506 
Sudden death 
 
126 (10.0)  799   (5.9)  1.77 
(1.47-2.14) 
<0.0001  1.26 
(1.03-1.53) 
0.025 
HF hospitalisation  317 (25.2)  2071 (15.4)  1.77 
(1.57-1.99) 
<0.0001  1.19 
(1.05-1.34) 
0.007 
MI or stroke  190 (15.1)  1570 (11.7)  1.58 
(1.27-1.94) 
<0.0001  0.98 
(0.77-1.23) 
0.871 
CV death, MI, HF 
hospitalisation 
567 (45.1)  4047 (30.1)  1.64 
(1.50-1.79) 
<0.0001  1.14 
(1.04-1.25) 
0.005 
 
COPD = chronic obstructive pulmonary disease; CI = confidence interval; CV = cardiovascular; HF = 
heart failure; HR = hazard ratio; MI = myocardial infarction. 
 
 
6.3.3  Cardiovascular Morbidity and Mortality 
  COPD was an independent predictor of hospitalisation for heart failure (HR 
1.19 (1.05–1.34).  The combined endpoint of CV death, MI or HF hospitalisation 
occurred in 45% of patients with COPD, compared to 30% of those without.  The   141 
adjusted risk for the combined endpoint remained significantly increased in patients 
with COPD (1.14 [1.04-1.25]). 
A composite atherosclerotic outcome was examined, incorporating fatal or 
non-fatal MI and stroke.  This combined endpoint occurred in 190 (15.1%) as 
opposed to 1570 (11.7%) patients with and without COPD respectively.  The 
adjusted risk of atherosclerotic events was not increased (0.98 [0.77–1.23], p=0.871).  
According to the analysis of landmarks, the adjusted HR of the relation between 
COPD and atherosclerotic events was 0.94 ([0.70–1.25], p=0.657), 1.36 ([0.96–1.93], 
p=0.085), 0.91 ([0.71–1.17], p=0.381) and 0.86 ([0.70–1.07], p=0.648) for inpatient, 
post discharge, early and later follow up respectively.  The higher hazard of 
atherosclerotic events during the post discharge period was not statistically 
significant (p=0.085).  Combining results from all periods yielded a similar hazard 
ratio (0.94 [0.81–1.08], p=0.348). 
  The impact of COPD on atherosclerotic events was far outweighed by 
alternative cardiovascular risk factors (Table 6.3).  The chi square statistic indicates 
the relative contribution of each factor to the variance of the outcome.  Multivariate 
analysis revealed diabetes to be the strongest determinant of MI or stroke (HR 1.36 
[1.24–1.50] , p<0.001).  Smoking, hypertension, obesity and established coronary, 
peripheral and cerebrovascular disease were all independent predictors of 
atherosclerotic events. 
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Table 6.3  Independent predictors of myocardial infarction or stroke 
 
Predictor 
 
Hazard Ratio (95% CI)  p value 
Diabetes  1.36 (1.24-1.50)  <0.001 
Age (per 10 years)  1.17 (1.11-1.24)  <0.001 
Angina  1.31 (1.19-1.44)  <0.001 
Previous MI  1.28 (1.16-1.42)  <0.001 
Killip Class 3  1.42 (1.22-1.66)  <0.001 
Killip Class 4  1.49 (1.23-1.81)  <0.001 
Previous stroke  1.28 (1.12-1.47)  <0.001 
Heart failure post-MI  1.19 (1.08-1.31)  <0.001 
Heart rate (per 10 bpm)  1.06 (1.03-1.10)  <0.001 
Current smoker  1.21 (1.08-1.36)   0.002 
Previous unstable angina  1.17 (1.06-1.30)   0.002 
Hypertension  1.17 (1.06-1.30)   0.002 
Angina post-MI  1.16 (1.05-1.28)   0.003 
Peripheral vascular disease  1.19 (1.05-1.35)   0.007 
Killip Class 2  1.18 (1.03-1.34)   0.014 
New diabetes  1.28 (1.04-1.57)   0.018 
Left bundle branch block  1.23 (1.03-1.45)   0.019 
Weight (per 10 kg)  1.55 (1.07-2.22)   0.019 
Previous CABG  1.19 (1.03-1.37)   0.020 
Previous heart failure  1.13 (1.01-1.26)   0.035 
 
CABG = coronary artery bypass grafting; CI = confidence interval; MI = myocardial infarction. 
 
6.3.4  Relationship Between β-Blocker Use And Outcomes 
Mortality was significantly lower in patients receiving β-blockers, 
irrespective of airways disease (Figure 6.1).  Overall, the adjusted hazard ratio for 
mortality comparing patients with and without β-blockade was 0.74 [0.68–0.80], 
p=0.002.  In patients with COPD, 25.2% of those prescribed β-blockers died from 
any cause, compared to 35.0% of those not prescribed β-blockers.  Results were 
similar in patients without COPD (mortality 15.1% vs 27.9% respectively).  Formal 
testing for interaction between COPD and β-blocker use with respect to mortality 
revealed no significant difference.  β-blocker use was not associated adversely with 
any pre-specified outcome in patients with COPD. 
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Figure 6.1  Adjusted cumulative all cause mortality rate by COPD status and β-
blocker use 
 
 
 
 
6.4  Discussion 
 
Numerous studies have addressed the prognosis of patients with myocardial 
infarction, heart failure, or both.  Remarkably few have described the impact of 
pulmonary comorbidity.  COPD is known to independently reduce survival after 
myocardial infarction.
335,336  My findings extend prior reports by defining the relative 
risk of cardiovascular and non-cardiovascular death, together with ischaemic and 
non-fatal events. 
COPD was an independent predictor of mortality, largely due to increased 
non-cardiovascular and sudden death.  The former is expected.  Cigarette smoking   144 
and COPD predispose to fatal outcomes from malignancy, pneumonia and 
respiratory failure.
339  The excess risk of sudden death corroborates findings of the 
recent TORCH (Towards a Revolution in COPD Health) trial.
291  This was the first 
international trial of COPD therapy to employ all cause mortality as the primary 
endpoint, and the first to adjudicate cause of death using a clinical endpoint 
committee.  16% of deaths were classified as sudden, and speculated to be the 
consequence of acute respiratory failure.
339 
Sudden death was explicitly defined in VALIANT as death that occurred 
suddenly and unexpectedly in a patient in otherwise stable condition and included 
witnessed deaths.
340  Some out of hospital acute respiratory failure may be included 
in the category of sudden death.  However, numerous substrates for ventricular 
arrhythmia exist in patients with COPD: hypoxia, acidosis, hypercapnia, sympathetic 
activation, tachycardia, hypokalaemia and QTc prolongation secondary to inhaled β2-
agonists.
234,235  Although  safe  in  unselected  populations,  inhaled  β2-agonists may 
precipitate cardiovascular events in susceptible patients.
234,235,249  After myocardial 
infarction the risk of sudden death is greatest in the early months and among those 
with lowest ejection fraction.
340  In high risk patients with COPD, early treatment of 
exacerbations and correction of arrhythmic substrates is therefore paramount. 
  In a recent cohort study of 2481 patients presenting with acute MI, 
rehospitalisation rates were 22% higher among patients with COPD.
336  The reasons 
for admission were not defined.  The present  analysis reveals COPD to be an 
independent predictor of HF hospitalisation after infarction.  This mirrors findings in 
patients with chronic HF, in whom COPD is a frequent comorbidity and infection a 
recognised precipitant of decompensation.
78,86  Once hospitalised, concomitant   145 
pulmonary disease also prolongs inpatient stay and increases risk of 
readmission.
78,103 
COPD is increasingly considered a systemic inflammatory disorder with 
putative atherosclerotic consequences.
139,333,334  The hypothesis is founded on the 
epidemiological association between airflow obstruction and cardiovascular 
mortality.
143  The key issue is whether COPD contributes to atherosclerosis, or 
merely serves as a marker of cardiovascular disease.  This is the first analysis to 
evaluate COPD as a modifier of cardiovascular events in subjects with pre-existing 
coronary disease.  Previous studies have focused on overall survival following 
myocardial infarction,
228,335,336,341  percutaneous intervention,
342,343  or surgical 
revascularisation.
344,345  Although I expected a strong association with atherosclerotic 
events, this was not found and merits careful consideration. 
Many population studies adjusted only for age, gender and smoking 
history.
143  Residual confounding by established risk factors and unmeasured 
variables limits such reports.  Numerous potential confounders exist: diabetes, 
hypertension, blood pressure, dyslipidaemia, low socioeconomic class, occupation, 
poor diet, sedentary lifestyle and obesity.  In the high risk VALIANT cohort, all 
major cardiovascular risk factors occurred more frequently among patients with 
COPD.  The prevalence of existing coronary, peripheral and cerebrovascular disease 
was likewise increased.  Finally, patients with COPD received fewer risk-modifying 
medications, notably β-blockers.  All these factors are established predictors of worse 
clinical outcomes.  Comprehensive multivariate adjustment is thus crucial when 
considering prognosis.  The 58% increased risk of atherosclerotic events was reduced 
by adjusting in multivariate analyses (HR 0.98 [0.77-1.23]).  Exploring the relative   146 
contribution of covariates to the atherosclerotic endpoint confirmed my suspicions.  
The independent predictors of MI or stroke were all established cardiovascular risk 
factors or comorbidity.  These findings corroborate those of the TORCH study, in 
which just 3% of the 911 adjudicated deaths were attributed to myocardial 
infarction.
339 
Population studies have further limitations.  Survival estimates are potentially 
biased by loss to follow-up.  Reliance on hospital coding and death certificates 
overestimates the burden of cardiovascular events in the community.
346,347  Sudden 
death may be incorrectly attributed to coronary events.  As discussed earlier, there 
are numerous other arrhythmic substrates.
234,235  Unmeasured changes in baseline 
risk factors may influence survival during long follow-up periods.  Differences in 
cardiovascular treatment are likewise unaccounted for.  β-blockers are underutilised 
in patients with airflow obstruction and concomitant hypertension, heart failure, 
angina or myocardial infarction.
173,229  The robust epidemiological association 
between airflow obstruction and cardiovascular mortality does not necessarily equate 
to COPD causing atherosclerosis. 
Two observational cohort studies from the Cooperative Cardiovascular 
Project suggested β-blockers are safe and effective post MI in patients with 
COPD.
228,229  Neither reported the outcomes of patients with HF or LVSD.  The 
present analysis extends the prognostic benefit of β-blockade to this important patient 
group.  Furthermore, no adverse effects were observed for any prespecified endpoint.  
In particular, non-cardiovascular mortality was not increased in patients with COPD 
receiving  β-blockers.  This observation should help alleviate historical concerns 
regarding safety.  As with previous reports,
228,229 interpretation is hindered by the   147 
lack  of spirometry or stratification of COPD severity.  Recruitment bias and 
preferential prescribing habits confound applicability to patients with severe or 
reversible airflow obstruction. 
Several limitations must be acknowledged, foremost being the investigator 
derived diagnosis of COPD.  This was obtained from hospital records, pulmonary 
function if available, and questioning the patient.  No prespecified criteria were 
defined in the investigators brochure.  Misdiagnosis is unavoidable and inherent to 
all clinical trials lacking spirometry.
128,335,341  The prevalence of COPD in VALIANT 
(8.6%) was akin to these trials and also the general population.
128,335,341,348  No study 
has assessed the validity of self-reported COPD in patients with myocardial 
infarction.  Only one has examined those admitted with heart failure, confirming 
airflow obstruction in 67%.
165  However, the proportion of that cohort with HF and 
COPD was higher than in VALIANT (HF 100% vs 15% and COPD 22% vs 9%), 
providing far greater scope for misdiagnosis.  Furthermore, the VALIANT COPD 
group is characterised by the three major predictors of COPD: male gender (71%), 
advanced age, and smoking history (83%).
349,350  Recruitment bias will exclude many 
individuals with severe pulmonary disease.  However, the generalisability of results 
is reasonable as severe airflow obstruction is also uncommon in the wider 
population.
139 
 
6.5  Conclusion 
 
In summary, COPD is an independent predictor of mortality in patients with 
myocardial infarction, specifically of non-cardiovascular and sudden death.  No   148 
excess risk of atherosclerotic events was observed after adjusting for baseline risk 
factors and comorbidity.  The proposed atherosclerotic effects of COPD are of 
limited clinical significance, at least during intermediate follow-up.  There is a 
simple message.  We must optimise both pulmonary and cardiovascular therapies in 
patients with COPD.  Greater collaboration is required between the specialties to 
achieve this.  Intensive treatment of established cardiovascular risk factors and 
disease is essential to improve outcomes in this high risk group. 
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Chapter 7 
 
Baseline characteristics and outcomes of patients with heart 
failure receiving bronchodilators: evidence from the 
CHARM programme. 
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7.1  Introduction 
 
Heart failure and chronic obstructive pulmonary disease are common partners 
with common problems.
1  Remarkably few studies have addressed this intersection 
between cardiovascular and pulmonary disease.  The combination presents 
diagnostic challenges,
1 limits the use of β-blockers,
173 and is associated with worse 
survival.
1  The causes of higher mortality have been studied in a very limited 
fashion.
128  Use of bronchodilators, both β-agonist and antimuscarinic, is associated 
with adverse cardiovascular outcomes in patients with pulmonary 
disease.
234,235,247,251,351  The prognosis of patients with HF prescribed bronchodilators 
is however ill defined.
248,249  In particular there is little information regarding the 
prevalence of bronchodilator use in HF with and without systolic dysfunction, or the 
relationship between bronchodilator use and outcomes.  In the Candesartan in Heart 
failure Assessment of Reduction in Mortality and morbidity (CHARM) programme, 
candesartan significantly reduced cardiovascular deaths and hospital admissions for 
heart failure.
352 The CHARM programme provides a unique opportunity to examine 
the prevalence and prognostic implications of bronchodilator use in a large cohort of 
patients with HF and wide range of left ventricular ejection fraction. 
 
7.2  Methods 
 
7.2.1  Trial design 
  Patients with symptomatic heart failure (New York Heart Association class 
II-IV) receiving standard therapy were enrolled into one of three parallel clinical   151 
trials according to LVEF and angiotensin converting enzyme inhibitor  treatment: 
LVEF ≤ 40% and not receiving an ACEI due to previous intolerance (CHARM-
Alternative); LVEF ≤ 40% receiving ACEI treatment (CHARM-Added); and LVEF 
> 40% (CHARM-Preserved).  There were 7599 patients randomised, 3803 receiving 
candesartan and 3796 placebo: 2028 in CHARM-Alternative, 2548 in CHARM-
Added, and 3023 in CHARM-Preserved. Details of the rationale, methods, exclusion 
criteria and main outcomes have been published previously.
352-354 The study was 
approved by local ethics committees in all participating centres and all patients 
provided written informed consent. 
 
7.2.2  Trial endpoints 
  The primary outcome was a composite of cardiovascular death or unplanned 
hospital admission for management of worsening HF. Secondary pre-specified 
endpoints and components included: cardiovascular death; hospital admission for 
HF; and composite of cardiovascular death, hospital admission for HF, non-fatal 
myocardial infarction or non-fatal stroke. The present study focused on the 
associations between bronchodilators and cardiovascular events in the cohorts with 
reduced (combined CHARM-Alternative / Added) and preserved (CHARM-
Preserved) LV systolic function.  Investigators at each participating centre employed 
a checkbox to record the use of bronchodilator therapy at baseline.  The specific type 
of bronchodilator was not recorded. 
 
7.2.3  Statistical analysis.   152 
  All data analyses were performed independently by the Medical Statistical 
Unit at the London School of Hygiene and Tropical Medicine, London, UK. Baseline 
characteristics of patients prescribed bronchodilators were summarised by mean 
(standard deviation) for continuous variables and by frequency (percentages) for 
categorical variables. Means were compared using the Student t-test and proportions 
compared using the chi-square test. All analyses were performed by intention to 
treat. The prognostic significance of bronchodilator use was evaluated for predefined 
clinically relevant outcomes, including the primary outcome and other major 
cardiovascular events. 
The estimated hazard ratios were adjusted for all important predictors of 
mortality and morbidity identified in the CHARM programme,
355 including age, sex, 
diabetes mellitus, NYHA class, rest dyspnoea, current cigarette smoking, previous 
hospitalisation for heart failure, first diagnosis of heart failure over 2 years ago, 
previous myocardial infarction, atrial fibrillation, heart rate, diastolic blood pressure, 
dependent oedema, pulmonary crackles, cardiomegaly, pulmonary oedema, mitral 
regurgitation, and candesartan treatment, using a multivariable Cox proportional 
hazards model.  A 2-tailed p value of less than 0.05 was considered statistically 
significant. Data from the two studies of patients with reduced LVEF were 
combined, as this group was prespecified as clinically important.  For combined 
analysis of the three trials, statistical heterogeneity tests were performed for each 
endpoint. To identify the independent predictors of bronchodilator prescribing, a 
logistic regression model was employed with demographic and disease-related 
characteristics as potential predictors. 
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7.3  Results 
 
7.3.1  Baseline characteristics 
The findings from 7599 patients were analysed. The median duration of 
follow-up was 37.7 months. A detailed review of patients’ baseline characteristics 
has previously been published.
354 The baseline characteristics of patients receiving 
bronchodilators are displayed in Table 7.1.  674 patients (8.9%) were prescribed 
bronchodilators.  The prevalence was similar in patients with reduced compared with 
preserved systolic function (respectively 8.7% vs 9.2%, p=0.46). 
Overall, a prior smoking history was more frequent in patients receiving 
bronchodilators (59.8% vs 47.7%, p<0.0001), although the proportion of current 
smokers was similar (16.2% vs 14.5%, p=0.24).  No significant difference was 
observed in cardiovascular comorbidity between those prescribed and not prescribed 
bronchodilators, including history of myocardial infarction, angina, stroke, diabetes, 
hypertension and atrial fibrillation.  A greater proportion of patients receiving 
bronchodilators had previously been hospitalised for worsening HF (77.7% vs 
70.8%, p=0.0001).  These findings were consistent irrespective of reduced or 
preserved ejection fraction. 
Patients prescribed bronchodilators had poorer functional status, as indicated 
by an increased prevalence of NYHA classification III to IV.  Overall, and in the 
reduced and preserved systolic function groups, clinical signs of HF were more 
common in those receiving bronchodilators.  These included elevated jugular venous 
pressure, peripheral oedema, pulmonary crepitations and wheeze.  Mean ejection   154 
fraction was however similar comparing those with and without bronchodilators 
(Overall 39.8% vs 38.8% respectively, p=0.10). 
Table 7.1  Baseline characteristics of patients receiving bronchodilators 
 
Characteristics 
 
Mean (SD) or n (%) 
Preserved LVEF 
n=3023 
Reduced LVEF 
n=4576 
Overall 
n=7599 
Bronchodilator 
 
n=277 (9.2) 
No 
Bronchodilator 
n=2746 (90.8) 
Bronchodilator 
 
n=397 (8.7) 
No 
Bronchodilator 
n=4179 (91.3) 
Bronchodilator 
 
n=674 (8.9) 
No 
Bronchodilator 
n=6925 (91.1) 
Demographics             
Age (years)  67.7 (10.5)  66.6 (11.1)  66.5 (9.8)  64.5 (11.1)  67.0 (10.1)  65.3 (11.1) 
Female Sex  116 (41.9)  1096 (39.9)  27.8 (5.5)  27.6 (5.1)  208 (30.9)  2192 (31.7) 
BMI  30.4 (7.1)  29.0 (5.6)  92 (23.2)  1096 (26.2)  28.9 (6.3)  28.2 (5.3) 
Smoking Status             
Current Smoker  37 (13.4)  372 (13.5)  72 (18.1)  633 (15.1)  109 (16.2)  1005 (14.5) 
Previous Smoker  151 (54.5)  1221 (44.5)  252 (63.5)  2080 (49.8)  403 (59.8)  3301 (47.7) 
Non Smoker  89 (32.1)  1153 (42.0)  73 (18.4)  1466 (35.1)  162 (24.0)  2619 (37.8) 
Medical History             
Myocardial Infarction  111 (40.1)  1229 (44.8)  230 (57.9)  2434 (58.2)  341 (50.6)  3663 (52.9) 
Angina  163 (58.8)  1654 (60.2)  234 (58.9)  2301 (55.1)  397 (58.9)  3955 (57.1) 
Stroke  23 (8.3)  245 (8.9)  36 (9.1)  359 (8.6)  59 (8.8)  604 (8.7) 
Hypertension  184 (66.4)  1759 64.1)  202 (50.9)  2041 (48.8)  386 (57.3)  3800 (54.9) 
Diabetes Mellitus  91 (32.9)  766 (27.9)  116 (29.2)  1190 (28.5)  207 (30.7)  1956 (28.2) 
Atrial Fibrillation  85 (30.7)  796 (29.0)  114 (28.7)  1088 (26.0)  199 (29.5)  1884 (27.2) 
Prior HF hospitalisation  212 (76.5)  1864 (67.9)  312 (78.6)  3038 (72.7)  524 (77.7)  4902 (70.8) 
Cancer  31 (11.2)  195 (7.1)  34 (8.6)  253 (6.1)  65 (9.6)  448 (6.5) 
Severity Markers             
Ejection Fraction  55.6 (10.1)  53.9 (9.3)  28.8 (7.6)  28.8 (7.5)  39.8 (15.8)  38.8 (14.8) 
NYHA II  113 (40.8)  1723 (62.7)  113 (28.5)  1467 (35.1)  226 (33.5)  3190 (46.1) 
NYHA III  157 (56.7)  983 (35.8)  259 (65.2)  2586 (61.9)  416 (61.7)  3569 (51.5) 
NYHA IV  7 (2.5)  40 (1.5)  25 (6.3)  126 (3.0)  32 (4.7)  166 (2.4) 
Physical Examination             
Heart Rate (bpm)  75.4 (12.7)  70.9 (12.4)  76.9 (13.2)  73.6 (13.3)  76.3 (13.0)  72.5 (13.0) 
Systolic BP (mm Hg)  134.8 (18.3)  136.3 (18.5)  127.1 (18.6)  127.4 (18.8)  130.3 (18.9)  130.9 (19.2) 
Diastolic BP (mm Hg)  77.3 (11.0)  77.9 (10.7)  74.2 (11.0)  76.0 (10.7)  75.5 (11.1)  76.7 (10.7) 
Elevated JVP  111 (40.1)  955 (34.8)  149 (37.5)  1393 (33.3)  260 (38.6)  2348 (33.9) 
Peripheral Oedema  83 (30.0)  752 (27.4)  98 (24.7)  921 (22.0)  181 (26.9)  1673 (24.2) 
Pulmonary Crepitations  72 (26.0)  418 (15.2)  87 (21.9)  655 (15.7)  159 (23.6)  1073 (15.5) 
Pulmonary Wheeze  30 (10.8)  51 (1.9)  49 (12.3)  100 (2.4)  79 (11.7)  151 (2.2) 
Electrocardiogram             
Atrial Fibrillation  43 (15.5)  435 (15.8)  61 (15.4)  609 (14.6)  104 (15.4)  1044 (15.1) 
Bundle Branch Block  50 (18.1)  384 (14.0)  141 (35.5)  1236 (29.6)  191 (28.3)  1620 (23.4) 
Chest X-Ray             
Pulmonary Oedema  8 (2.9)  74 (2.7)  11 (2.8)  118 (2.8)  19 (2.8)  192 (2.8) 
Cardiomegaly  55 (19.9)  439 (16.0)  115 (29.0)  1058 (25.3)  170 (25.2)  1497 (21.6) 
Concomitant Therapy             
β-blocker  90 (32.5)  1594 (58.0)  125 (31.5)  2394 (57.3)  215 (31.9)  3988 (57.6) 
•  Carvedilol  10(3.6)  194(7.1)  34(8.6)  742(17.8)  44(6.5)  936(13.5) 
•  Metoprolol  37(13.4)  734(26.7)  50(12.6)  1124(26.9)  87(12.9)  1858(26.8) 
•  Bisoprolol  9(3.2)  126(4.6)  8(2.0)  142(3.4)  17(2.5)  268(3.9) 
•  Atenolol  23(8.3)  339(12.4)  19(4.8)  219(5.2)  42(6.2)  558(8.1) 
•  Other β-blocker  11(4.0)  205(7.5)  15(3.8)  172(4.1)  26(3.9)  377(5.4) 
Calcium channel blocker 119 (43.0)  825 (30.0)  70 (17.6)  528 (12.6)  189 (28.0)  1353 (19.5) 
Amiodarone  32 (11.6)  214 (7.8)  60 (15.1)  457 (10.9)  92 (13.6)  671 (9.7) 
Digoxin  86 (31.0)  756 (27.5)  225 (56.7)  2187 (52.3)  311 (46.1)  2943 (42.5) 
ACE inhibitors  45 (16.2)  531 (19.3)  210 (52.9)  2339 (56.0)  255 (37.8)  2870 (41.4) 
Spironolactone  43 (15.5)  309 (11.3)  91 (22.9)  829 (19.8)  134 (19.9)  1138 (16.4) 
Diuretics  232 (83.8)  2027 (73.8)  366 (92.2)  3661 (87.6)  598 (88.7)  5688 (82.1) 
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  β-blocker utilisation was markedly lower in patients receiving 
bronchodilators compared to those without bronchodilator therapy: Overall 31.9% vs 
57.6%; Reduced 31.5% vs 57.3%; Preserved 32.5% vs 58.0% (all p<0.0001).  The 
proportion of patients receiving a β-1 selective adrenoceptor blocker (metoprolol, 
bisoprolol or atenolol) was similar in patients with and without bronchodilators 
(67.9% vs 67.3%, p=0.85).  The use of amiodarone, digoxin and calcium channel 
blockers was greater in those receiving bronchodilators, both overall and in patients 
with reduced or preserved ejection fraction.  Treatment with bronchodilators was 
also associated with greater use of diuretic therapy, including spironolactone. 
 
7.3.2  Independent predictors of use of bronchodilator therapy 
Multivariable analysis of predictors of bronchodilator prescribing revealed 
smoking history to be the strongest independent determinant (Table 7.2). 
 
Table 7.2  Independent predictors of bronchodilator use for CHARM overall 
 
Predictor  Odds Ratio (95% CI)  p value  Wald Chi 
Non-smoker  0.47 (0.39-0.56)  <0.0001  62.7 
Heart rate (per 10 bpm)  1.25 (1.18-1.32)  <0.0001  56.6 
Age  1.03 (1.02-1.03)  <0.0001  39.9 
BMI  1.04 (1.02-1.05)  <0.0001  21.2 
Diastolic blood pressure  0.99 (0.98-1.00)  0.0018  9.8 
Ischaemic heart disease  0.81 (0.68-0.96)  0.0131  6.2 
 
 
After adjusting for baseline variables including demographics, aetiology of 
heart failure and medical history, the odds of receiving bronchodilators for smokers 
were approximately twice those for non-smokers (odds ratio 0.47 [0.39-0.56],   156 
p<0.0001).  Age, body mass index, heart rate, blood pressure and presence of 
ischaemic heart disease were also independent predictors of bronchodilator use. 
 
7.3.3  Mortality 
  Bronchodilator therapy was independently associated with increased 
mortality.  32.6% of patients receiving bronchodilators died from any cause, 
compared with 23.3% of those without bronchodilators (Table 7.3). 
 
Table 7.3  Association between bronchodilator therapy and clinical outcomes by 
systolic function 
 
Outcomes/ 
Systolic 
Function 
Bronchodilator 
n=674 
No 
Bronchodilator 
n=6925 
Unadjusted HR 
(95% CI) 
p value  Adjusted HR 
(95% CI) 
p value  p value 
interaction 
* 
Cardiovascular death or HF hospitalisation   
Overall  303 (45.0)  2157 (31.1)  1.65 (1.47-1.87)  <0.0001  1.38 (1.22-1.56)  <0.0001  0.1452 
Reduced LVEF  198 (49.9)  1563 (37.4)  1.52 (1.31-1.76)  <0.0001  1.32 (1.14-1.53)  0.0003   
Preserved LVEF  105 (37.9)  594 (21.6)  2.00 (1.62-2.46)  <0.0001  1.52 (1.22-1.89)  0.0002   
All cause mortality   
Overall  220 (32.6)  1611 (23.3)  1.53 (1.33-1.76)  <0.0001  1.26 (1.09-1.45)  0.0015  0.4485 
Reduced LVEF  155 (39.0)  1195 (28.6)  1.49 (1.26-2.12)  <0.0001  1.27 (1.07-1.51)  0.0055   
Preserved LVEF  65 (23.5)  416 (15.1)  1.63 (1.26-2.12)  0.0002  1.26 (0.95-1.65)  0.1041   
Non cardiovascular death   
Overall  51(7.6)  320(4.6)  1.78(1.32-2.39)  0.0001  1.49(1.10-2.01)  0.0097  0.4383 
Reduced LVEF  31(7.8)  199(4.8)  1.81(1.24-2.64)  0.0021  1.57(1.07-2.31)  0.0214   
Preserved LVEF  20(7.2)  12(4.4)  1.73(1.08-2.78)  0.0231  1.35(0.82-2.22)  0.2394   
Cardiovascular death 
Overall  169 (25.1)  1291 (18.6)  1.47 (1.25-1.72)  <0.0001  1.21 (1.03-1.42)  0.0216  0.7738 
Reduced LVEF  124 (31.2)  996 (23.8)  1.43 (1.18-1.72)  0.0002  1.22 (1.01-1.47)  0.0412   
Preserved LVEF  45 (16.2)  295 (10.7)  1.59 (1.16-2.18)  0.0038  1.23 (0.89-1.71)  0.2171   
Death due to HF progression 
Overall  66 (9.8)  403 (5.8)  1.84 (1.42-2.38)  <0.0001  1.40 (1.07-1.82)  0.0128  0.6735 
Reduced LVEF  49 (12.3)  318 (7.6)  1.77 (1.31-2.39)  0.0002  1.39 (1.03-1.89)  0.0328   
Preserved LVEF  17 (6.1)  85 (3.1)  2.08 (1.23-3.50)  0.0059  1.51 (0.86-2.64)  0.1526   
Sudden death 
Overall  66 (9.8)  577 (8.3)  1.29 (1.00-1.66)  0.0532  1.13 (0.87-1.46)  0.3474  0.1283 
Reduced LVEF  47 (11.8)  462 (11.1)  1.17 (0.87-1.58)  0.3105  1.06 (0.78-1.43)  0.7094   
Preserved LVEF  19 (6.9)  115 (4.2)  1.72 (1.06-2.79)  0.0292  1.34 (0.81-2.22)  0.2594   
HF hospitalisation   
Overall  225 (33.4)  1450 (20.9)  1.81 (1.57-2.09)  <0.0001  1.49 (1.29-1.72)  <0.0001  0.5480 
Reduced LVEF  142 (35.8)  1016 (24.3)  1.66 (1.40-1.98)  <0.0001  1.43 (1.20-1.71)  0.0001   
Preserved LVEF  83 (30.0)  434 (15.8)  2.14 (1.69-2.71)  <0.0001  1.59 (1.25-2.04)  0.0002   
CV death, HF hospitalisation, non-fatal MI, non-fatal stroke   
Overall  317 (47.0)  2372 (34.3)  1.57 (1.39-1.76)  <0.0001  1.32 (1.17-1.76)  <0.0001  0.2775 
Reduced LVEF  205 (51.6)  1667 (39.9)  1.47 (1.27-1.70)  <0.0001  1.28 (1.10-1.48)  0.0010   
Preserved LVEF  112 (40.4)  705 (25.7)  1.78 (1.46-2.17)  <0.0001  1.43 (1.16-1.76)  0.0007   
               
* Interaction between bronchodilator (vs no bronchodilator) and reduced LVEF (vs preserved LVEF) 
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After adjusting for additional predictors of mortality, the risk of death was 
26% higher in patients prescribed bronchodilators (adjusted HR 1.26 [95% CI 1.09–
1.45]).  This higher risk of overall mortality reflected a higher incidence of both non-
cardiovascular death (7.6% vs 4.6%, HR 1.49 [1.10-2.01]) and cardiovascular death 
(25.1% vs 18.6%, HR 1.21 [1.03-1.42]).  The higher risk of cardiovascular death was 
largely attributable to death due to progressive pump failure (9.8% vs 5.8%, HR 1.40 
[1.07-1.82]).  The risk of sudden death was not elevated after correcting for baseline 
differences between patients receiving and not receiving bronchodilators.  The 
greater mortality associated with bronchodilator use was consistent in patients with 
reduced and preserved systolic function: all cause mortality (HR 1.27 vs 1.26 
respectively); cardiovascular death (HR 1.22 vs 1.23); and non-cardiovascular death 
(HR 1.57 vs 1.35). 
 
7.3.4  Cardiovascular morbidity and mortality 
Bronchodilator therapy was an independent predictor of worse fatal and non-
fatal cardiovascular outcomes in patients with heart failure (Table 7.3).  Overall, the 
primary outcome of cardiovascular death or HF hospitalisation occurred in 45.0% 
patients receiving bronchodilators as opposed to 31.1% of those without 
bronchodilators (adjusted HR 1.38 [1.22-1.56], p<0.0001, Table 7.3).  The risk of 
hospitalisation due to worsening HF associated with bronchodilators was likewise 
49% higher (HR 1.49 [1.29-1.72], p<0.0001).  Finally, the relative risk of sustaining 
a  major adverse cardiovascular event (defined as cardiovascular death, HF 
hospitalisation, non-fatal MI or non-fatal stroke) was  32% higher in those receiving 
bronchodilators (HR 1.32 [1.17-1.76], p<0.0001).   158 
As with mortality, the association between bronchodilator therapy and 
adverse outcomes was consistent in patients with reduced and preserved systolic 
function.  Risk of the primary endpoint, HF hospitalisation, and major adverse 
cardiovascular events was greater in patients receiving bronchodilators, irrespective 
of left ventricular ejection fraction.  Formal statistical testing for an interaction 
confirmed no significant difference between the cohorts (Table 7.3). 
 
7.3.5  Interaction between bronchodilators and concurrent β-blockers 
Bronchodilator use was  associated with adverse outcomes regardless of 
concurrent β-blocker therapy (Table 7.4). 
 
Table 7.4  Association between bronchodilator use and clinical outcomes according 
to background β-blocker therapy in CHARM overall 
 
Outcome, 
β-blocker 
Bronchodilator  No 
Bronchodilator 
Unadjusted HR 
(95% CI) 
p value  Adjusted HR 
(95% CI) 
p value  p value 
interaction
* 
Cardiovascular death or HF hospitalisation   
β-blocker  85 (39.5)  1054 (26.4)  1.73 (1.39-2.16)  0.0000  1.44 (1.15-1.80)  0.0015  0.2557 
No β-blocker  218 (47.5)  1103 (37.6)  1.22 (1.05-1.42)  0.0080  1.22 (1.05-1.42)  0.0080   
All cause mortality   
β-blocker  61 (28.4)  773 (19.4)  1.62 (1.25-2.10)  0.0003  1.32 (1.01-1.72)  0.0406  0.3804 
No β-blocker  159 (34.6)  838 (28.5)  1.14 (0.96-1.36)  0.1282  1.14 (0.96-1.36)  0.1282   
Non cardiovascular death   
β-blocker  15 (7.0)  153 (3.8)  1.99 (1.17-3.38)  0.0112  1.48(0.86-2.55)  0.1547  0.5878 
No β-blocker  36 (7.8)  167 (5.7)  1.39 (0.96-2.01)  0.0798  1.19(0.78-2.32)  0.1543   
Cardiovascular death 
β-blocker  46 (21.4)  620 (15.5)  1.52 (1.13-2.06)  0.0059  1.26 (0.93-1.71)  0.1318  0.4942 
No β-blocker  123 (26.8)  671 (22.8)  1.09 (0.90-1.33)  0.3629  1.09 (0.90-1.33)  0.3629   
Death due to HF progression   
β-blocker  15 (7.0)  161 (4.0)  1.94 (1.14-3.29)  0.0143  1.56 (0.91-2.69)  0.1064  0.4301 
No β-blocker  51 (11.1)  242 (8.2)  1.19 (0.87-1.62)  0.2738  1.19 (0.87-1.62)  0.2738   
Sudden death 
β-blocker  24 (11.2)  297 (7.4)  1.65 (1.09-2.51)  0.0178  1.46 (0.96-2.23)  0.0772  0.1181 
No β-blocker  42 (9.2)  280 (9.5)  0.93 (0.67-1.29)  0.6752  0.93 (0.67-1.29)  0.6752   
HF hospitalisation   
β-blocker  61 (28.4)  696 (17.5)  1.87 (1.44-2.43)  0.0000  1.55 (1.19-2.02)  0.0013  0.3402 
No β-blocker  164 (35.7)  754 (25.7)  1.30 (1.10-1.54)  0.0027  1.30 (1.10-1.54)  0.0027   
Cardiovascular death, HF hospitalisation, non-fatal MI, non-fatal stroke   
β-blocker  89 (41.4)  1187 (29.8)  1.60 (1.29-1.98)  0.0000  1.33 (1.07-1.65)  0.0115  0.4781 
No β-blocker  228 (49.7)  1185 (40.3)  1.19 (1.03-2.51)  0.0154  1.19 (1.03-1.38)  0.0154   
 
* Interaction between bronchodilator (vs no bronchodilator) and β-blocker (vs no β-blocker) 
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Among patients receiving β-blockers, bronchodilator use (compared to no 
bronchodilator use) was associated with greater all cause mortality (HR 1.32 [1.01-
1.72] versus 1.14 [0.96-1.36] in those not receiving a β-blocker), cardiovascular 
death or HF hospitalisation (HR 1.44 [1.15-1.80] versus 1.22 [1.05-1.42]), and major 
adverse cardiovascular events (HR 1.33 [1.07-1.65] versus 1.19 [1.03-1.38]).  No 
statistical interaction was observed between bronchodilator therapy and β-blockade 
with respect to any pre-specified outcome. 
 
7.3.6  Relationship between β-blockers and mortality 
Mortality was significantly lower in patients receiving β-blockers, 
irrespective of concurrent bronchodilator therapy (Figure 7.1). 
 
Figure 7.1  Adjusted survival  rate by bronchodilator and β-blocker 
use
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Overall, the adjusted hazard ratio for mortality comparing patients with and 
without  β-blockade was 0.77 [0.70–0.85], p<0.001.  In patients receiving 
bronchodilators, 28.4% of those prescribed β-blockers died, compared to 34.6% of 
those not prescribed β-blockers (HR 0.87 [0.64-1.18], p=0.354).  This relative risk of 
death in β-blocker treated patients was also lower in those not receiving 
bronchodilators (19.4% vs 28.5% respectively, HR 0.76 [0.69-0.85], p<0.001).  No 
interaction was observed between β-blockade and bronchodilator therapy. 
 
7.4  Discussion 
 
Although the association between bronchodilator use (both β-agonist and 
anticholinergic) and adverse cardiovascular events in patients with pulmonary 
disease is well recognised,
234,235,247,251,351 the relationship between the use of these 
drugs and outcomes in patients with HF is uncertain.
248,249  Several findings were 
noteworthy.  Bronchodilator use was associated with increased all cause mortality, 
cardiovascular death, HF hospitalisation and major adverse cardiovascular events.  
The adverse prognostic implications were consistent in patients with reduced and 
preserved systolic function, and remained significant after comprehensive 
multivariate  adjustment.  Moreover, the magnitude of risk associated with 
bronchodilators was comparable to recognised predictors such as NYHA class, 
bundle branch block, ischaemic heart disease, heart rate and blood pressure.
355  No 
interaction was observed between bronchodilators and β-blockade with respect to 
outcomes.   161 
Remarkably few reports describe bronchodilator use in patients with HF.  The 
prevalence in CHARM Overall (8.9%) was similar to that observed in a community 
heart failure clinic in the United Kingdom (12.1%).
172  Although pulmonary disease 
is more common in patients with HF and preserved ejection fraction,
1 the prevalence 
of bronchodilator use was similar in patients with reduced and preserved systolic 
function.  Symptoms and signs of HF were more frequent in patients prescribed 
bronchodilators despite similar ejection fractions, as were prior hospitalisations for 
decompensated HF.  The findings highlight the diagnostic dilemmas posed by the 
combination of HF and pulmonary disease.
1  No qualitative symptoms are unique to 
HF.
8  Signs are equally misleading.  Although cor pulmonale is rare in patients with 
COPD,
1,137,138  elevated jugular venous pressure is not.  A comprehensive study 
investigated 405 elderly patients with stable COPD.
137  Heart failure was diagnosed 
by an expert panel following chest radiography, electrocardiography, 
echocardiography and pulmonary function tests.  Nearly a quarter (23.3%) of the 322 
patients with COPD in whom HF was excluded had a raised jugular venous 
pressure.
18  A similar proportion of patients with COPD are reported to have mild 
pulmonary hypertension.
138  Pulmonary disease therefore appears to worsen the 
clinical syndrome of HF. 
The diversity and magnitude of adverse outcomes associated with 
bronchodilator therapy is surprising.  Cohorts defined by bronchodilator prescription 
undoubtedly represent a heterogeneous group of patients: COPD, asthma, restrictive 
lung disease, and those misdiagnosed with airflow obstruction.  The latter is common 
in patients with decompensated HF,
45,46 in whom interstitial oedema causes airway 
compression and bronchial hyperresponsiveness.
1,47  Non-cardiovascular deaths are   162 
inevitable in cohorts dominated by pulmonary disease.  The excess cardiovascular 
mortality is more concerning.  Bronchodilators were associated with a 40% higher 
risk of death due to progressive pump failure.  The risk of hospitalisation for 
worsening HF was likewise 49% greater. 
These findings corroborate and extend two prior studies examining patients 
with HF or LVSD prescribed inhaled β-agonists.
248,249  In 1529 subjects with LVSD 
identified retrospectively through imaging records,
249  all cause mortality and HF 
hospitalisation  within 1 year increased with the average number of canisters 
dispensed per month.  After covariate adjustment, the risk of HF admission was: 1.3 
[0.9-2.0] (1 canister / month); 1.7 [1.2-2.5] (2 canisters / month); 2.0 [1.3-3.0] (≥ 3 
canisters / month).  Risk of death was similarly increased: 0.9 [0.5-1.6] (1 canister / 
month); 1.4 [0.9-2.2] (2 canisters / month); 2.0 [1.3-3.2] (≥ 3 canisters /  month).  
However,  the  association  was  undermined  by  the  indication  for  β-agonist use: 
increasing dyspnoea and resulting β-agonist prescription may simply have reflected 
worsening HF.  Without markers of HF severity the multivariate model was unable 
to adjust for such confounding.  A second case control study observed a similar 
relationship  between  β-agonists and HF hospitalisation  in patients with existing 
HF.
248  The risk remained significant after adjustment for age, cardiovascular 
comorbidity, presence of COPD and β-blocker prescription (OR 1.6 [1.0-2.7]). 
The association between bronchodilators and worsening HF could be 
attributed to confounding by indication and the severity of underlying lung disease.  
Bronchodilators may simply be prescribed to patients with worse heart failure or 
airflow obstruction.  However, unlike previous studies, the former confounder 
(severity of heart failure) is minimised by comprehensive adjustment incorporating   163 
measures of heart failure signs, symptoms and functional class as well as history of 
heart failure hospitalisation and ejection fraction.  The latter confounder (severity of 
lung disease) is to some extent addressed in the current analysis as the CHARM 
enrolment criteria excluded patients with ‘severe obstructive pulmonary disease’.   
Furthermore, the recruitment bias inherent to clinical trials is also likely to have 
reduced inclusion of individuals with severe pulmonary disease.  Nonetheless, 
infection is a recognised precipitant of HF decompensation and may have contributed 
to the marked increase in fatal and non-fatal pump failure.
78,86 
Heart  failure  is  characterised  by  increased  adrenergic  drive.    β1  and  β2 
adrenoceptors mediate noradrenaline  toxicity, fibrosis and necrosis.  Down 
regulation of β1 receptors with preservation of the β2 subpopulation reduces the β1/β2 
ratio.
231  The inotropic responsiveness (and likewise vulnerability) of the failing 
myocardium to β2-agonists thereby assumes greater importance.
232,233  Although the 
specific types and doses of bronchodilator were not recorded, inhaled β2-agonists are 
baseline therapy for both COPD and asthma.  It is possible that bronchodilators 
compound maladaptive remodeling and further depress myocardial function.  Two 
observations temper this argument.  β2-agonists exert numerous arrhythmic effects: 
tachycardia, hypokalaemia, QTC prolongation, disturbed autonomic modulation and 
depressed heart rate variability.
234-237  The lack of an associated increase in sudden 
cardiac death, particularly in those with LVSD, suggests systemic consequences are 
minimal.  Secondly, if mediated by β-adrenergic stimulation, the adverse 
consequences would possibly be lessened by concurrent β-blocker use.  No such 
interaction was observed.  However, the majority of patients received cardioselective   164 
β1-blockers, namely metoprolol or bisoprolol.  Whether β1-blockade antagonises β2-
mediated effects is unknown. 
In three observational studies, β-blockers were consistently associated with 
better survival in patients with HF and concurrent COPD.
128,166,227  None reported the 
outcomes of patients receiving bronchodilators, in whom physicians may be wary of 
β-blockade.  This important patient group has now been examined.  Although limited 
by patient numbers, formal testing revealed no significant interaction between 
bronchodilator use and the better survival associated with β-blockade.  Moreover, no 
adverse effects were observed for any prespecified endpoint.  In particular, non-
cardiovascular mortality was not increased in patients taking bronchodilators who 
were also receiving  β-blockers.  This observation should help alleviate historical 
concerns regarding safety.  As with previous reports,
128,166,227 recruitment bias and 
the absence of pulmonary function data limit inference to patients with severe or 
reversible airflow obstruction. 
Several limitations must be acknowledged.  Whether bronchodilators were 
prescribed for COPD, asthma, or alternative reasons is unknown.  The specific types, 
administration routes and doses of bronchodilator were not recorded.  However, 
inhaled short acting β-agonists are recommended first line therapy.
5  Although the 
prevalence of β-agonists (particularly oral), anticholinergics and inhaled 
corticosteroids would be interesting, concurrent prescribing would inextricably 
merge their respective effects.  Finally, as with all observational studies, no causal 
relationship may be inferred. 
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7.5  Conclusion 
 
Bronchodilator use is a powerful independent predictor of worsening heart 
failure and increased mortality in a broad spectrum of patients with HF.  Whether 
this relates to a toxic effect of β-agonists (or other bronchodilators), underlying 
pulmonary disease or both is unclear.  There is a simple clinical message.  Vigilance 
is paramount when considering the prescription of bronchodilators in patients with 
HF.  Physicians should be rigorous in  their diagnosis of airways disease, obtain 
objective evidence of airflow obstruction and do so when patients are clinically 
euvolaemic.  β-agonists should only be prescribed in patients where these agents lead 
to documented reversal of airways obstruction.  Physicians should also be alert to the 
fact that use of bronchodilators identifies a patient at increased risk of worsening 
heart failure and death.  There are many challenges for future research.  The 
interaction between bronchodilators, pulmonary disease, and the syndrome of heart 
failure is complex.  Greater understanding of these relationships may in turn explain 
the association between bronchodilators, hospital admissions and increased 
mortality.  Only randomised controlled trials can conclusively prove or disprove the 
safety of bronchodilators in patients with heart failure. 
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Chapter 8 
 
Final Discussion 
   167 
Heart failure and chronic obstructive pulmonary disease are common partners 
with common problems.  Each condition affects in excess of ten million patients 
worldwide.
4,5  Reports addressing this intersection between cardiology and 
respiratory medicine are however few and far between.  The demise of the general 
physician and evolution of subspecialty medicine is partly responsible.  Cardiologists 
increasingly practice in tertiary centres devoid of other specialties.  Ironically, as we 
move towards single system medicine, the aging population presents with increasing 
comorbidities. 
Landmark clinical trials  have  transformed the treatment and prognosis of 
patients with HF.  ACE inhibitors, β-blockers, aldosterone antagonists, angiotensin 
receptor blockers and device therapies all confer unequivocal morbidity and 
mortality benefits.
4  With each advance the absolute survival gains of novel therapies 
in clinical trials has  diminished.  Despite this armamentarium, prognosis at the 
population level remains poor.
275  Two  issues predominate: limited uptake of 
evidence based therapies into clinical practice, and the impact of comorbidities.   
Heart failure is characterised by the latter: diabetes, COPD, anaemia, chronic kidney 
disease,  atrial fibrillation and  coronary disease.  Each condition is independently 
associated with worse clinical outcomes, through  mechanisms which remain 
incompletely defined.  Whether established therapies for each condition are 
beneficial in patients with concurrent HF is often uncertain. 
  Unlike other comorbidities, the coexistence of COPD exposes the patient to 
double jeopardy.  In addition to therapeutic dilemmas, the combination poses many 
diagnostic challenges.  These are comprehensively and critically appraised in this 
thesis.  Such review will hopefully prove useful to practicing physicians.  A number   168 
of simple conclusions may be drawn.  Symptoms and signs frequently overlap, as 
highlighted in the CHARM and VALIANT analyses.  The evaluation of cardiac and 
pulmonary function is often problematic and potentially  misleading.  
Echocardiography and pulmonary function tests should be performed in every patient 
with HF and suspected COPD.    Careful interpretation is required to avoid 
misdiagnosis and inappropriate treatment.  In particular, airflow obstruction must be 
demonstrated when the patient is euvolaemic,  assessed  by clinical signs (pitting 
oedema, elevated jugular venous pressure, pulmonary rales) and chest radiograph.  
Very high and very low concentrations of natriuretic peptides have high positive and 
negative predictive values for diagnosing HF in those with both conditions.  
Intermediate values are less informative.  In those with limited acoustic windows 
cardiac magnetic resonance imaging is the modality of choice. 
  The epidemiology of HF and COPD was previously ill defined.  This thesis 
has created a comprehensive reference source expanding more narrative publications.  
The information allows comparison of the prevalence of COPD in different 
environments, between countries, and to a degree over time.  The analysis from the 
Scottish Continuous Morbidity Recording scheme confirms  and extends  these 
observations.  The prevalence of COPD was approximately sevenfold greater in 
patients with HF than in  the primary care population.  More importantly, the 
prevalence increased year on year.  These changes may previously have been 
attributed to an ageing population or increasing age of presentation.  However, the 
trend remained significant after age  standardisation.  Finally,  I  observed a clear 
socioeconomic gradient, with prevalence greatest in the most deprived.  Smoking, 
the main risk factor for COPD, increased in parallel.  HF and COPD are clearly   169 
‘common partners’.  The results emphasise the need to promote smoking cessation, 
and target the most deprived patients with HF. 
The ‘common problems’ are both therapeutic and prognostic.  The former 
undoubtedly contributes to the latter.  The cornerstones of therapy are β-blockers and 
β-agonists, whose pharmacologic effects are diametrically opposed.  Each is 
purported to adversely affect the alternative condition.  β-blockers are well tolerated 
in patients with mild and fixed airflow obstruction.  Although patients with more 
severe disease  may tolerate β-blockers, the evidence is rudimentary.
2  Critical 
appraisal revealed several shortcomings, foremost being that no study had included 
patients with HF.  Of the 20 randomised controlled trials included in the Cochrane 
meta-analysis, 11 involved single doses and only one lasted longer than a month.  
The long term impact of β-blockade on pulmonary function, symptoms and quality of 
life was therefore largely unknown.  In particular, the effect on health status had 
never been assessed in any cohort with COPD. 
Although recruitment was challenging, the baseline characteristics of the 
cohort were well matched and consistent with previous studies in moderate to severe 
COPD.  Three key findings emerged.  Treatment with bisoprolol was associated with 
an increase in airflow obstruction.  However, bronchodilator response to inhaled β2-
agonist was preserved.  β-blockade exerted no adverse effect on health related quality 
of life or functional status.  The primary endpoint initially appears at odds with the 
Cochrane analysis, which observed no significant change in FEV1 with longer term 
cardioselective β-blockade (–2.39% [CI –5.69% to 0.91%]).
2  However, the trials 
included in the meta-analysis exhibited a degree of heterogeneity.  In the longest 
study of patients with severe COPD, atenolol and metoprolol each significantly   170 
reduced FEV1 by around 10% over four weeks.
195  I observed a reduction in FEV1 of 
similar magnitude (post-bronchodilator 110 ml, 7%).  A further randomised cross-
over trial supports my findings, though was not included in the meta-analysis.
201  
FEV1 declined significantly over 6 months by approximately 0.2 litres in patients 
with mild COPD and significant reversibility receiving bisoprolol or atenolol.  
Although lacking a concurrent placebo group, lung function parameters normalised 
during the placebo cross-over  period,  suggesting  β-blockade directly caused 
bronchoconstriction.  Furthermore, airway resistance increased with therapy duration 
despite unchanged β-blocker doses.  This highlights the need for longer term studies, 
particularly in patients with HF. 
The finding of preserved β2-agonist response corroborates two prior single 
dose studies of bisoprolol in patients with mild to moderate COPD.
190,191  Bisoprolol 
is  highly  β1-selective,  providing  a  wide  split  between  β1  and  β2-adrenoceptor 
blockade. At therapeutic levels, response to β2-agonists appears largely preserved 
and counteracts any change in airway resistance.  This is particularly important in 
patients with HF, in  whom abrupt β-blocker withdrawal may precipitate rebound 
ischaemia, ventricular arrhythmias and even death.  The ability to treat 
bronchospasm while continuing or reducing the dose of β1-blockade is reassuring. 
The assessment of health status was likewise encouraging.  Most importantly, 
β-blockade exerted no adverse effect on health related quality of life or functional 
status.  Secondly, all three measures of health status and components including 
dyspnoea score improved.  Though not statistically significant, the consistent 
directionality of change is reassuring.  Finally, the observations were concordant 
with the stable residual volume, which predicts exercise capacity better than FEV1.    171 
The  findings pose further  questions and hopefully provide direction for larger 
randomised controlled trials.  Is an asymptomatic reduction in FEV1 an acceptable 
sacrifice given the established prognostic benefits of β-blockers?  Will symptoms and 
quality of life improve significantly over longer follow up?  Are the effects of β-
blockade on airflow obstruction and reversibility dose dependent?  Only  robust 
multicentre trials will provide the answers. 
This paucity of existing evidence translates into clinical practice.  Pulmonary 
disease was the most powerful independent predictor of β-blocker underutilisation in 
the Euro Heart Failure Survey  (OR  0.35).
173  My  analysis from the Continuous 
Morbidity Recording scheme revealed  similar  odds  of  β-blocker prescribing in 
primary care (OR 0.30).  Whether the gap between patients with and without COPD 
is improving was previously unknown.  The results were disappointing.  Despite the 
overall improvement, the relative difference between those with and without COPD 
remained unchanged.  By 2004, only 18% of individuals with HF and COPD were 
prescribed β-blockers in the community.  A decade after landmark β-blocker trials, it 
is remarkable that the Quality and Outcomes Framework in the United Kingdom fails 
to incorporate β-blockade.  The inclusion of β-blocker targets in the framework for 
2009/10 will hopefully improve utilisation in those with concurrent COPD.  The 
subject certainly merits revisiting in future. 
The Achilles heel of β-blockade in HF with COPD is the lack of proven 
prognostic benefit.  The only contemporary evidence derives from the Val-HeFT 
trial.  Mortality in patients with HF and COPD was approximately 17% in those 
prescribed  β-blockers, as opposed to 31% in those without  β-blockade.
128  No 
statistical adjustment for baseline differences was performed.  The analyses from   172 
VALIANT and CHARM build on this report.  51% of patients with concurrent 
COPD in VALIANT received β-blockers, with an associated lower mortality (25% 
vs 35%, p<0.001).  No significant interaction was observed between COPD and β-
blocker use with respect to mortality.  β-blocker use was not adversely associated 
with any pre-specified outcome in patients with COPD, including non-cardiovascular 
mortality.  Likewise in CHARM, mortality was significantly lower in patients 
receiving β-blockers irrespective of concurrent bronchodilator therapy.  Although 
limited by patient numbers, formal testing revealed no significant interaction 
between bronchodilator use and the better survival associated with β-blockade.  Both 
analyses must be interpreted cautiously.  Recruitment bias and the absence  of 
pulmonary function data limit inference to patients with severe or reversible airflow 
obstruction.  Association must never be mistaken for causation.  Nevertheless, the 
findings support the use of β-blockers in patients with HF and COPD. 
The  short and long term effects  of  β-blockade contrast markedly: acute 
negative inotropy precedes improved left ventricular systolic function.  β-agonists 
exert the reverse pharmacologic effects of β-blockers.  It follows that acute positive 
inotropy may give way to longer term left ventricular systolic dysfunction.  Critical 
appraisal of existing evidence supports this theory.  β-agonists were associated with 
increased mortality and HF hospitalisation in two previous studies involving patients 
with HF.
248,249  However, the results were undermined by limited adjustment for 
severity of HF and confounding by indication. 
The analysis from CHARM in part addresses these shortcomings.  
Confounding by severity of HF was minimised by comprehensive adjustment 
incorporating HF signs, symptoms,  functional class and ejection fraction.    173 
Bronchodilator use was associated with increased all cause mortality, cardiovascular 
death, progressive pump failure, and HF hospitalisation.  The adverse prognostic 
implications were consistent in patients with reduced and preserved systolic function.  
Moreover, the magnitude of risk associated with bronchodilators was comparable to 
many recognised predictors of poor outcomes.
355 
The relationship between bronchodilators, pulmonary disease, and the 
syndrome of heart failure appears complex.  Elucidating the risk associated with 
specific bronchodilators will require large well characterised cohorts to provide 
sufficient statistical power to assess clinical endpoints.  Although bronchodilators are 
the cornerstone of symptomatic relief, the weight of evidence may eventually sway 
the balance of risk and benefit.  Only randomised controlled trials can conclusively 
prove or disprove the safety of bronchodilators in patients with HF.  In the meantime, 
physicians should prescribe bronchodilators only when clinically indicated, and be 
aware that bronchodilator use identifies a patient at increased risk of worsening heart 
failure and death. 
Given the range and magnitude of diagnostic and therapeutic problems, the 
prognosis of patients with HF and COPD has been remarkably overlooked until 
recently.
97,128,167,171  Both conditions are systemic disorders with overlapping 
pathophysiological processes.  Following an extensive literature review, I found that 
COPD was consistently an independent predictor of death and HF hospitalisation 
when reported in multivariable models.  In many models the prognostic significance 
approached or exceeded that of traditional factors.  However, the causes of increased 
mortality were uncertain.   174 
My analysis from VALIANT characterises the impact of COPD on outcomes 
in patients with MI complicated by HF or LVSD.  Atherosclerotic consequences of 
chronic systemic inflammation in COPD have been postulated.
139,333,334  COPD was 
an independent predictor of mortality, largely due to increased non-cardiovascular 
and sudden death.  Although the causes of sudden death are uncertain, numerous 
substrates for ventricular arrhythmias exist in patients with COPD.  The safety of β-
agonists in susceptible patients must again be questioned.  The proposed 
atherosclerotic effects of COPD appeared of limited clinical significance.  The 58% 
increased risk of atherosclerotic events was reduced by adjusting in multivariable 
analyses (HR 0.98 [0.77-1.23]).  The independent predictors of MI or stroke were all 
established cardiovascular risk factors or comorbidity.  This reinforces the 
importance of intensive treatment of existing cardiovascular risk factors and disease 
in such patients. 
In conclusion, this thesis has summarised and extended our understanding of 
heart failure with concurrent chronic obstructive pulmonary disease.  An array of 
diagnostic and therapeutic dilemmas have been exposed which confront practicing 
physicians on a daily basis.  The right answers require the right questions.  Hopefully 
I have posed the right questions and contributed towards finding the right answers.  
Only large randomised controlled trials will solve the quandary of β-blockers and β-
agonists.  Justification for these trials evolves from observational data and smaller 
prospective studies such as my own.  In the meantime, I hope the evidence presented 
in this thesis will stimulate physicians to re-evaluate the management of patients with 
HF and COPD. 
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